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The two known estrogen receptors, ERα and ERβ, are the products of different genes on separate 
chromosomes.  Of these, ERα has been the most extensively studied, and its expression in breast 
cancer determines the ER+ phenotype.  ERβ, on the other hand, was discovered only recently 
and its role in breast cancer pathology remains unclear.  ERβ inhibits E2-induced proliferation of 
T47D breast cancer cells in addition to decreasing the expression of cell cycle related genes.  
Clinical studies have shown a positive correlation between ERβ expression with disease-free 
survival and overall survival in breast cancer patients.  ERβ activation with a selective ERβ 
agonist could antagonize the stimulating activity of the ERα in breast cancer cells, and such an 
ERβ agonist could help overcome acquired resistance. Therefore, this work began a search for 
such agents.  
 
A one-pot hydrozirconation-transmetallation-aldimine addition sequence that leads to allylic 
amides, homoallylic amides and C-cyclopropylalkylamides was significantly accelerated by 
microwave technology and used for library preparation.  The conventional methodology 
provided a first generation discovery library.  A potentially antiestrogenic compound was 
identified in a transcriptional screening assay from this library, C-cyclopropylalkylamide 26a (O-
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ethyl-N-{2-[(1S*,2R*)-2-{(R*)[(diphenylphosphinoyl)amino](phenyl)methyl}cyclopropyl]-
ethyl}-N-[(4-methylphenyl)sulfonyl]carbamate; a.k.a. CK1-183). 
 
Following up on these findings and with the goal to expand the scope of the synthesis 
methodology, a second generation library of allylic amides and C-cyclopropylalkylamides was 
prepared.  The new library was screened in a fluorescence polarization based homogenous in 
vitro assay at ERα, and hits were further evaluated in cell-based assays.  Three new C-
cyclopropylalkylamides, 37c, 37a and 39c, were identified with improved potency over the lead 
agent 26a against 17β-estradiol (E2) stimulated MCF-7 cells.  
 
This second generation library was screened against both ERs.  The screening results served to 
build an SAR model of allylic amides and C-cyclopropylalkylamides at ERα and ERβ.   
A hit from the ERβ screen, C-cyclopropylalkylamide 37d (N-(R*)-(((1R*,2R*)-2-
butylcyclopropyl)-(4-(phenyl)phenyl)methyl)benzamide), contained a biphenyl core and served 
as a starting point for the design and synthesis of a third generation of C-cyclopropylalkylamide 
ER targeting agents.  
 
Biphenyl C-cyclopropylalkylamides represent novel structural scaffolds for design and synthesis 
of ERα and ERβ targeting agents and a novel avenue for selective estrogen receptor modulator 
(SERM) development.  
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1. INTRODUCTION 
 
Breast cancer is one of the leading causes of death in women in the USA.  According to the 
National Cancer Institute, the cumulative risk of an average woman in the United States to 
develop breast cancer in her lifetime is 1 in 8.1,2  Estrogens such as17β-estradiol (E2, 1; Figure 
1) are known to be both initiators and promoters of carcinogenesis.  Depleting secretion of 
estrogens via ovariectomy (surgical-, chemical- or radiation-induced) has been the most effective 
treatment of hormone-responsive breast cancer.  Estrogens act as mitogens in breast cancer via 
the estrogen receptor (ER).  Antiestrogens primarily function through competing with 
endogenous estrogens for binding to the ER and thus preventing the estrogens' action in breast 
cancer.   
HO
OH
A B
C D
            1
17β-Estradiol (E2)
O
N
            2
Tamoxifen (TAM)
S
HO
OHO
O
N
            3
Raloxifene (RAL)  
Figure 1. Model ligands for ERs. 
 
The most prescribed antiestrogen therapeutic agent for treating breast cancer is tamoxifen 
(Nolvadex®) (TAM, 2; Figure 1).  For the last 20 years, tamoxifen has been the therapy of 
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choice for all stages of ER positive breast cancer and in 1998 FDA approved it as 
chemoprevention agent in women at high risk of developing breast cancer.3,4   
 
1.1. Estrogen Receptors in Breast Cancer 
 
The steroid hormone E2 (1) is a key regulator of growth, differentiation, and function of male 
and female reproductive tissues, mammary gland, and the skeletal, cardiovascular and nervous 
systems.  The predominant biological effects of E2 are mediated through two distinct 
intracellular receptors, ERα and ERβ.  Although ER signaling is required for normal mammary 
gland development, it has been hypothesized that aberrant signaling could lead to abnormal 
cellular proliferation and survival, potentially participating in the development and progression 
of breast cancer.5  There is direct evidence that estrogen has mitogenic effects in breast cancer.  
Estrogen directly increases the number of cells transiting the cell cycle in cell culture. This effect 
is blocked by known antiestrogens.6 ERα expression in breast cancer determines the ER positive 
(ER+) phenotype.  However, the role of ERβ in breast cancer pathology remains unclear.  
 
 
1.1.1. Estrogen Receptor Mechanism of Action 
 
ERα and ERβ are type I nuclear receptors and transcriptional factors.  Both receptors belong to 
the family of nuclear hormone receptors and have similar functional domains: an N-terminal 
domain (NTD), a central DNA-binding domain (DBD) and a C-terminal, ligand-binding domain 
(LBD).2,7  The DBD mediates interaction with target genes.  In the absence of a ligand, ER 
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monomers are associated with a heat shock protein (HSP90).  Upon ligand binding, the HSP90 
and ER dissociate.  Concomitantly, ERs undergo a conformational change, resulting in 
recruitment of a large coactivator complex.  Depending on the conformation of the ligand-bound 
ER and the precise composition of this coactivator complex, the ER is then free to bind to 
specific estrogen response elements (EREs) in the genome, resulting in the regulation of specific 
genes (Figure 2). 
 
Figure 2. Transcriptional regulation of ER target genes. 
 
The N-termini of both ERα and ERβ are targets for phosphorylation by the mitogen-activated 
protein kinase (MAPK) pathway.2  The LBD and NTD contain two separate activation functions 
(AFs) (Figure 3).  The LBD activation function (AF-2) contacts NR boxes within the coactivator 
p160 molecule, and the NTD activation function (AF-1) binds to the p160 C-terminus and 
CBP/p300.  Depending on cellular and promoter context, coactivator binding exclusively to AF-
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1 leads to either partial activation or no activation of the ER.8  N-Terminal domains of both 
receptors interact with the coactivator GRIP-1, but the ERβ does so much more weakly than the 
ERα.  In contrast to ERα, ERβ appears to have diminished AF-1 activity while, at the same time, 
it possesses a fully functional AF-2.8  This interaction is necessary for transcriptional activity of 
both receptors.   
 
Figure 3.  Structural domains of the human ERα and ERβ.8 
 
The coactivator complexes enhance the transcription by chromatin remodeling.2  Full activation 
generally requires that coactivators bind simultaneously to both AF-1 and AF-2.8  The 70-80 
amino acid long DBD forms two zinc binding motifs that are involved in target gene promoter 
recognition, ERE binding and ER dimerization.  Side chains of four amino acids on the 
recognition helix (called the p-box) of each monomer make direct and indirect hydrogen bonds 
to ERE nucleotides.2  
 
The most studied drug discovery target on the ER is the LBD.  This domain is multifunctional.  
The LBD mediates ligand binding, receptor dimerization, interaction with chaperone and 
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coregulator proteins, nuclear translocation and transcription activation.9  The AF2 in the LBD 
constitutes the ligand-dependent activation function.  Upon agonist binding to LBD, helix 12 
(H12) of the ER dramatically changes its position in space and closes the ligand binding cavity, a 
structural change that is crucial for AF2 recruitment of coactivators.  Helices 1, 2, 3, 4 and 5 
form a shallow hydrophobic pocket that can recognize the LxxLL motif (NR-box) on coactivator 
proteins.  Thus, it is named the coactivator-binding domain (CBD) and is necessary for 
transcriptional activity of ERs.  Coactivators bind to the AF2 surface via the amino acid motif 
LxxLL in which the leucine residues dock into the hydrophobic cleft.  Binding specificity is 
aided by oppositely charged amino acids at either end of the ER hydrophobic cleft that form a 
charge clamp with the LxxLL peptide backbone.6  Coactivators then participate in the chromatin 
remodeling and recruitment of basal transcription factors leading to activation of target gene 
transcription and downstream stimulatory effects of the ER ligand interaction.  The role of each 
ER receptor in breast cancer pathology and their drug targeting are discussed in more detail in 
the following sections.  
 
 
1.1.2. Estrogen Receptor Alpha 
 
Only a small percentage of the cells in the normal breast express ERα (15-17%), and these are 
not the same normal breast cells as those that are proliferating.  Expression of this receptor was 
found to be much higher in invasive breast cancer and ductal carcinoma in situ (30–75%).5  The 
presence of ERα in breast cancer tissue is usually correlated with better prognosis and is the key 
determining factor for indicating endocrine therapy.2,10  ER-mediated estrogen signaling is 
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known to involve cross-talk with other signaling pathways, such as MAPK and growth factors.  
The biological effects of E2 through the ERα are mediated through four distinct but 
interconnected pathways: (1) classical ligand-dependent, leading to an up- or down-regulation 
of target gene transcription and subsequent tissue responses; (2) ligand-independent, through 
interaction with kinase pathways activated by growth factors that lead to phosphorylation of ER; 
(3) ERE-independent, ligand-ER complexes alter transcription of genes containing alternative 
response elements such as AP-1; and (4) cell-surface (nongenomic) signaling, activation of a 
membrane-associated form of ER linked to intracellular signal transduction pathways that 
generate rapid tissue responses.11  
 
The classical ligand-dependent pathway of ERα is the most studied and has been used to develop 
clinically-used antiestrogens for breast cancer treatment.  As stated above, there are two 
activation domains in the ERα, AF-1 and AF-2 that act synergistically to recruit various 
coactivator proteins to the DNA/ER complex.  Depending on the cellular and promoter context, 
coactivator binding exclusively to AF-1 leads to either partial activation or no activation of ERα.  
However, the full activation generally requires that coactivators bind simultaneously to both AF-
1 and AF-2.8  It was recently proposed that ERα corepressors play an important role in breast 
cancer pathophysiology by controlling the magnitude of the estrogen response, mediating 
antiestrogen inhibition of ERα, repressing DNA-bound ERα in the absence of the ligand, and 
conferring active repression of ERα-downregulated genes.12 
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1.1.3. Estrogen Receptor Beta 
 
ERβ was discovered only recently,13 whereas the first description of ERα came 50 years ago.  
ERβ mechanisms in breast cancer pathology remain unclear.  Ström et al.14 have recently shown 
that ERβ inhibits E2-induced proliferation of T47D breast cancer cells, in addition to decreasing 
the expression of cell cycle related genes.  Clinical studies have shown a positive correlation 
between ERβ expression with disease-free survival and overall survival in breast cancer 
patients.15  Furthermore, ERβ expression has been inversely correlated with HER2 expression.16  
It has been shown that ERβ is the more abundant ER in the normal breast, and examination of the 
ductal epithelium of ERβ –/– mice suggests that it is a prodifferentiative factor.8  Overall, the 
role of ERβ is currently suggested to be antiproliferative in breast cancer.  
 
 
1.1.4. Structural versus Functional Difference Between ER Subtypes 
 
ERα and ERβ share great homology in their DBD (97%), but only 56% homology in their 
LBDs.17  Only 20-25 residues are in close contact with bound ligands and that region is almost 
identical in the two receptors.  Studies using point mutations and chimeric constructs identified 
two key differing residues: Leu384 in ERα vs. Met336 in ERβ, and Met421 in ERα vs. Ile373 in 
ERβ.17  However, subtype-specific ligands have recently been developed to assist in our 
understanding of the biology and interactions of these receptors.  The subtype-specific ligands 
will be discussed in greater detail later in the text. 
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The X-ray crystallographically determined structure of ERβ-LBD bound by the isoflavone 
genistein (GEN, 6) and the natural ligand E2 shows that ERβMet336 lies above the ligand and 
delineates part of the pre-formed pocket on the β-face of the cavity.  ERβIle 373 lies on the α  
face, right below the D ring of E2.  Therefore, Pike et al.38 suggested that the change of the 
weakly polar methionine from the α- to the β-face of the cavity enables ERβ to accommodate 
more polar substituents at the distal end of the cavity.  It has also been suggested that ERβ is 
easier to antagonize than ERα because the agonist position of H12 in ERβ is more unstable than 
in ERα.38  This feature is important for selective ERβ agonist design, and could explain why 
most of the ERβ-selective agents are generally more rigid and smaller in size than those that are 
selective for ERα.  
 
 
1.2. Selective Estrogen Receptor Modulators (SERMs) 
 
TAM 2 was prepared in the early 1960’s as a potential antifertility agent.  It was not until the 
early 1970s that TAM was suggested as an antiestrogenic agent for the treatment of breast 
cancer.  The term “selective estrogen receptor modulators” (SERMs) came into the scientific 
literature after the finding that TAM exerts mixed effects in humans in that it is antiestrogenic in 
the breast but estrogenic in the uterus and bone. 
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1.2.1. Tamoxifen and Raloxifene as Model SERMs 
 
The ligand binding cavity in ERα is completely partitioned from the external environment and 
occupies a relatively large portion of the LBD's hydrophobic core.  When a typical agonist such 
as the hormone E2 binds the ERα, it interacts with the binding cavity through a combination of 
specific hydrogen bonds and hydrophobic interactions.  The phenolic hydroxyl of the A-ring of 
E2 situates between H3 and H6 and makes direct hydrogen bonds to the carboxylate of 
ERαGlu353, the guanidinium group of ERαArg394, and a highly ordered water molecule.  The 
17β hydroxyl of the D-ring makes a single hydrogen bond with ERαHis524 in H11.  The 
remainder of the molecule participates in a number of hydrophobic contacts.18  The antagonist 
raloxifene (RAL, 3) binds to the same site and its phenolic moieties form hydrogen bonds with 
ERαGlu353, ERαArg394 and ERαGlu353.  In addition, its nitrogen in the piperidine ring forms 
a hydrogen bond with the carboxyl group of ERαAsp351, resulting in the displacement of H12 
and the protrusion of the 11A side chain of raloxifene from the pocket between H3 and H11.  
This helix H12 displacement is found to be a general feature of both steroidal and non-steroidal 
antiestrogens that possess a bulky side-chain substitutent.18  At the molecular level there is a 
clear difference between the binding modes of an agonist and an antagonist.  However, the 
molecular interaction on its own fails to fully explain the complexity of the selective ER 
modulator pharmacology.  TAM (2) and RAL (3) were originally considered antagonists, and are 
in certain species, but they truly represent model SERMs in humans. They are agonists in some 
tissues (bone, liver, and the cardiovascular system), antagonists in other tissues (brain and 
breast), and mixed agonists/antagonists in the uterus, with TAM having greater uterine-
stimulatory activity than RAL.19   
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1.2.2. Molecular Basis for SERM Tissue Selectivity 
 
Whether a compound will act as an agonist or antagonist or as a mixed agonist/antagonist in the 
target tissue depends upon its structure, the conformational change in the receptor LBD upon 
ligand binding, the promoters of the target genes and the coregulator proteins present in the cells 
comprising the tissue.19  Hall et al.20 have shown that the sequence of the ERE in the promoter of 
the target gene influences the structure of the ER and coregulator recruitment.  Coregulator 
proteins, on the other hand, actively stabilize the ER-ligand complex.  Different classes of 
coactivator proteins combine with ER bound by estrogen agonists of different structure to elicit 
varying degrees of receptor stabilization, and antagonists and coactivator binding inhibitors 
disfavor the costabilized conformation.21  
 
In the development of new antiestrogens for breast cancer, it is crucial to understand the diverse 
mechanisms of antagonism at ERs.  Active antagonists, when complexed with ER, can cause the 
ER to bind to DNA and recruit corepressors so that the complex is transcriptionally inactive.  
Passive antagonists cause the ligand-bound ER to simply not bind to DNA because of several 
possible reasons: the HSP90 does not dissociate; dimer formation is inhibited; and/or 
translocation to the nucleus is prevented.  There are also direct and indirect antagonists.  When 
H12 is sterically pushed by the ligand side chain (most antagonists that have a bulky side chain 
exert their action in this way), coactivator recruitment is blocked, resulting in transcriptional 
inactivation. In the case of indirect antagonists, the ligand-induced conformational change results 
in a situation where H12 is not pulled into agonist conformation or the hydrophobic cleft for 
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coactivator binding is distorted.8  The endpoint of antagonist binding is, regardless of the exact 
mechanism, inhibition of transcription of ER-regulated genes.  
 
1.3. Estrogen Receptor Subtype Selective Agents  
 
Several groups have developed subtype selective ligands for the ERs (reviewed in Ref. 22), 
which allow study of the pharmacology of ERs.  Here, only a few selective agents, those used in 
the present work as control agents in biological assays and/or guides for the design of new ER 
targeting agents, will be discussed.  The Katzenellenbogen group has developed a compound 
called propylpyrazole–triol (PPT, 5; Figure 4), a triarylpyrazole that was found to be an 
approximately 1000-fold selective agonist at ERα over ERβ.23  They also developed a 100-fold 
selective ERβ agonist, diarylpropionitrile (DPN, 4; Figure 4).24   These two compounds have 
served as tools to uncover structural differences between the ligand binding pockets of the two 
receptors.17  Ab initio quantum chemical calculations of the interaction between a phenyl ring 
and the respective side chains of ERβMet336 and ERαLeu384 suggest that the side chain of 
ERβMet336 has a greater potential for interaction with the aromatic ring than the side chain of 
ERαLeu384.25  It was also suggested that GEN's 5-OH group has a repulsive interaction with 
ERαMet421 in ERα, which does not occur with the side chain of ERβIle373.39  Based on these 
findings, it is not a surprise that GEN (6) has been commonly used as a lead structure for the 
design of ERβ selective agents (Figure 5) and that it has guided the design and synthesis of 
numerous subtype selective agents. 
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Figure 4. Representative subtype selective agents.23,24 
  
ER subtype selectivity as a medicinal chemistry problem was attractive at first in order to design 
chemical tools to assist in the study of the complex biology of each receptor, and potentially their 
interplay.  However, subtype selective agents do have important clinical implications.  One of 
the recent successful examples is ERB-041 (7; Figure 5), developed by the Wyeth Corp.33  ERB-
041 is an orally available ERβ-selective agonist that has shown dramatic beneficial effects in 
rodent preclinical models for inflammatory bowel disease.26  Other positive attributes of ERB-
041 are that it is not uterotrophic, does not prevent bone loss nor weight gain after ovariectomy, 
is not mammotrophic and does not inhibit ovulation.26 
 
 
1.3.1. Pharmacophore Models for ER Subtype Selectivity 
 
Katzenellenbogen’s group32 developed a pharmacophore model for ERβ-selective agents by 
taking into an account the smaller size of the ERβ binding cavity, and the key differing residues 
ERαMet421 and ERαLeu384 vs. ERβIle373 and ERβMet336.  They began with their original 
pharmacophore model for ER targeting agents27 and modified it accordingly.  The size of the 
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ligand was reduced by removal of the third, typically aryl, substituent on the core.  One of the 
two phenol rings was fused to a heterocycle to reduce the size further.  They imposed other rules, 
including one stating that the introduced substituents should interact favorably with ERβIle373, 
or ERβMet336 and/or unfavorably with ERαMet421 and ERαLeu384.32  Their pharmacophore 
model fits relatively well with the structures of selective ERβ ligands developed by others 
(compounds 6, 7 and 10,28 9 and 12,29 8 and 13,30 11,31 15,32 5 and 14,33 17,34 18,35 1936) shown 
in Figure 5.  Interestingly, a virtual screening approach utilizing direct receptor-based molecular 
docking and indirect ligand-based pharmacophore mining approaches, focusing the search for 
plant-based ERβ-selective ligands, gave phytoestrogens structurally similar to genistein as hits 
with over 100-fold selectivity for ERβ.  Also, it was evident that ligands relatively larger in size 
were preferably selective for ERα.37  
 
 
1.3.2. Estrogen Receptor Beta Selective Agents – SAR and Applications 
 
The phytoestrogen GEN was one of the first agents discovered to be selective (30-40 fold) for 
ERβ.  GEN has been cocrystalized with ERβ LBD and from the crystal structure only a few 
features indicate that its interaction with ERβ might be more favorable than its interaction with 
ERα.38  It has been suggested that the stabilizing the van der Waals interaction of the isoflavone 
ring with the side chain of ERβMet336 contributes to genistein's selectivity.38  Ab initio quantum 
chemical calculations of the interaction between a phenyl ring and the respective side chains of 
ERβMet336 and ERαLeu384 suggest that the side chain of ERβMet336 has a greater potential 
for interaction with the aromatic ring than does the side chain of ERαLeu384.39   
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Figure 5.  ERβ selective ligands.25-33  
Selectivity for ERβ over ERα in binding assays is presented as the number below each structure. Data is taken from 
literature references 25-33.  
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It was also suggested that the 5-OH group on GEN has repulsive interactions with the side chain 
of ERαMet421, interactions not present in with the side chain of ERβIle373.39  Based on these 
findings, it is not a surprise that GEN was commonly used as a lead structure for the design of 
ERβ selective agents.  Figure 5 shows a select but structurally diverse set of compounds that are 
selective to various degrees for ERβ in order to illustrate the more general SAR of these agents.  
Biphenyl-containing compounds 9 and 13 were recently developed by Wyeth Corp. research 
groups.28  The phenolic A ring from estradiol was preserved to guarantee the binding affinity of 
these agents, and an oxime was used to mimic the D ring of estradiol.   
 
Varying the substitution on the biphenyl core gave various levels of selectivity: biphenyl 
hydroxime 13 was only 11-fold selective, but by introducing a methyl group and changing the 
position of the fluorine substituent to give biphenyl oxime 9, selectivity was improved to >43-
fold.  The majority of ERβ selective ligands have two phenolic groups separated by ~9-12 Å, and 
distance and positioning of OH groups can increase or decrease selectivity.  High selectivity and 
high binding potency agents (e.g., compounds 7, 11, 12 and 15) have two phenol rings connected 
through a five-membered heterocyclic ring (oxazole, pyrazole, furan), with the distance between 
the OH groups averaging 11.5Å.  The structure of the heterocycle seems not to affect the potency 
or selectivity as long as the ligand size and distance between OH groups remains constant.  Less 
selective agents usually have a larger distance between the OH groups.40  Vinyl, cyano and 
halogen substituents, in the majority of cases, are more selective for ERβ by either promoting the 
favorable soft-soft interaction with ERβMet336 or by inducing unfavorable interactions with 
ERαMet421 (reviewed in Ref. 22). 
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The role that ERβ selective agents could play in breast cancer pharmacotherapy is yet to be 
determined.  A proposed model for possible advantages of these agents towards targeting SERM-
resistant cancer is discussed later in section 4.2.  Synthetic and screening efforts in the present 
work were oriented towards discovering new scaffolds for ER targeting agents and for designing 
agents with features that potentially could target both ERα and ERβ. 
 
1.4. Synthetic Methods for Allylic Amides, Homoallylic Amides and C-Cyclopropylalkyl 
Amides 
 
1.4.1. Conventional Synthetic Methods and Discovery Library Synthesis 
 
Wipf et al.41,42,43 recently reported a new method for the synthesis of homoallylic amides, allylic 
amides and C-cyclopropylalkylamides.  The methodology provided a 67-member discovery 
library (Table 1).  The library members were prepared using a novel three-component aldimine 
addition reaction.  By controlling the solvent and order of addition of the reagents, C- 
cyclopropylalkylamides (26), allylic amides (27) or homoallylic amides (28) can be prepared 
from readily available starting materials, aldehydes (22) and alkynes (24).  The general synthesis 
is presented in Error! Reference source not found..  The synthetic sequence begins with the 
hydrozirconation44 of alkynes (24) with the Schwartz reagent (Cp2ZrHCl), followed by in situ 
Zr-Zn transmetallation.45  The resulting alkenylzinc species (25) readily adds to N-
diphenylphosphinoylimines (23)46 to provide the allylic amides (27).  Addition of diiodimethane 
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(CH2I2) to the reaction mixture, once all N-diphenylphosphinoylimines (23) are consumed, 
affords C-cyclopropylamides (26) through a Simmons-Smith type cyclopropanation.47 
R1 H
O
Ph2P(O)NH2
TiCl4, TEA, CH2Cl2 R1 N
P
Ph
O
Ph
22 23
H R4
24
1. Cp2ZrHCl
2. Me2Zn
MeZn
25
1. 23
2. CH2I2
23
1. CH2I2
2. 23
R1 R4
NHP(O)Ph2
R1 R4
NHP(O)Ph2
R1
R4
NHP(O)Ph2
26
27
28
R4
 
Scheme 1. Synthesis of the discovery library of C-cyclopropylalkylamides (26), allylic amides (27) and homoallylic 
amides (28).   
 
Simply by changing the order of addition of reagents and solvents, diversity was introduced into cyclopropane (26) 
and alkene (27, 28) scaffolds.  
 
In contrast, addition of CH2I2 and N-diphenylphosphinoylimines (23) simultaneously to the 
alkenylzinc (4) afforded exclusively the homoallylic amides (28).42  The obtained 67-member 
discovery library was screened in transcriptional cell based assays for agonism and antagonism 
at ERα.48  The discovery library screening data and detailed biological evaluation of the lead 
structure, part of the present work, are presented and discussed in detail in the Results section 
(2.1).  Furthermore, the synthetic methods were tested under microwave conditions, and this new 
methodology will also be described.  
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Table 1. Structures of the 67-member discovery library 
 
 
 
 
 
 
C-Cyclopropylalkylamides* C1-C2 R R1 R2 R3 R4 
26a (CK1183) anti P(O)Ph2 Ph H H CH2CH2N(Ts)CO2Et 
26b anti P(O)Ph2 3-OMe-Ph H H C4H9 
26c anti P(O)Ph2 2-OMe-Ph H H C4H9 
26d anti P(O)Ph2 4-Cl-Ph H H C4H9 
26e anti P(O)Ph2 Ph H H CH2CH2OH 
26f anti P(O)Ph2 Ph H H CH2CH2CO2Si(iPr)3 
26g anti P(O)Ph2 Ph H H CO2Me 
26h anti P(O)Ph2 Ph H H CH=CH2 
26i anti P(O)Ph2 Ph H H CH2CH2OSi(tBu)Ph2 
26j anti P(O)Ph2 Ph H H C4H9 
26k syn P(O)Ph2 Ph H H C4H9 
26l anti P(O)Ph2 PhCC H H C4H9 
26m anti CO2CH2Ph Ph H H CO2Me 
26n anti CO2CH2Ph Ph H H C(O)NHiPr 
26o syn CO2CH2Ph Ph H Me C(O)NHiPr 
26p syn P(O)Ph2 Ph H Me C4H9 
26q anti P(O)Ph2 Ph Et H Et 
26r anti P(O)Ph2 Ph Me H CH=CH2 
R1 R4
R3
R2
NHR
1
2
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26s anti Ts Ph H H C4H9 
26t syn Ts Ph H H C4H9 
26u anti CO2CH2Ph Ph Me H C(O)NHiPr 
26v anti Ts PhCH2CH2 H H C4H9 
26w anti C(O)Ph Ph H H C4H9 
26x anti C(O)Ph-4-NO2 Ph H H C4H9 
* Diastereomerically pure 
 
 
 
 
C-Cyclopropylalkylamino acids* R R1 R2 
26-1a CO2CH2Ph Ph (S)-NHCH(Me)Ph 
26-1b CO2CH2Ph Ph NHPh-4-Br 
26-1c CO2CH2Ph Ph l-Ph-OMe 
26-1d C(O)Ph-4-Br Ph OMe 
* Enantiomerically pure 
 
 
 
C-Cyclopropylalkylamino acids* R R1 R2 
26-2a CO2CH2Ph Ph l-Ph-OMe 
* Enantiomerically pure 
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C-Cyclopropylalkylamides R R1 R2 R3 R4 
26-3a P(O)Ph2 Ph H Me C4H9 
26-3b C(O)Ph-3,5-diNO2 Ph H Me C4H9 
26-3c C(O)Ph Ph H Me C4H9 
26-3d P(O)Ph2 Ph Me H H 
 
 
 
 
 
C-Cyclopropylalkylamides R R1 R2 R3 R4 
26-4a C(O)Ph-3,5-(NO2)2 Ph-4-CO2Me H Me C6H13 
26-4b P(O)Ph2 Ph H Me CH2CH2OH 
26-4c P(O)Ph2 Ph-4-CO2Me H Me C6H13 
 
 
 
Allylic amides R R1 R2 R3 R4 
27a P(O)Ph2 Ph H H CH2CH2N(Ts)CO2Et 
27b P(O)Ph2 (E)-PhCH=C(CH3) H H C4H9 
27c P(O)Ph2 Ph H H C4H9 
27d P(O)Ph2 Ph H H CH2CH2OSi(tBu)Ph2 
27e P(O)Ph2 Ph H H CH2CH2CO2Si(iPr)3 
27f P(O)Ph2 (E)-PhCH=CH H H C4H9 
R1 R4
R3NHR
R2
R1 R4
R3
R2
NHR
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27g P(O)Ph2 4-CO2Me-Ph H H C4H9 
27h P(O)Ph2 3-OMe-Ph H H C4H9 
27i P(O)Ph2 2-OMe-Ph H H C4H9 
27j P(O)Ph2 4-NO2-Ph H H C4H9 
27k P(O)Ph2 3-NO2-Ph H H C4H9 
27l P(O)Ph2 4-Cl-Ph H H C4H9 
27m P(O)Ph2 PhCC H H C4H9 
27n Ts Ph H H C4H9 
27o Ts PhCH2CH2 H H C4H9 
27p P(O)Ph2 Ph H Me C4H9 
27q P(O)Ph2 Ph Me H H 
27r P(O)Ph2 Ph Et H Et 
27s P(O)Ph2 4-CO2Me-Ph Si(CH3)3 H (E)-CH=CHC6H13 
27a1 P(O)Ph2 Ph H H CH2CH2N(Ts)CO2Et 
 
 
 
 
 
Homoallylic 
amides* 
C1-C2 R R1 R2 R3 R4 R5 
28a anti P(O)Ph2 Ph CH2CH2OSi(tBu)Ph2 H H H 
28b  P(O)Ph2 Ph Me Me H Me 
28c anti P(O)Ph2 4-CO2Me-Ph CH2CH2OSi(tBu)Ph2 H H H 
28d syn P(O)Ph2 4-OMe-Ph C4H9 H H H 
28e syn P(O)Ph2 Ph C4H9 H H H 
R1
R5
R4NHR
R2 R3
1
2
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28f syn Ts Ph C4H9 H H H 
28g syn Ts Ph CH2CH2OSi(tBu)Ph2 H H H 
28h syn P(O)Ph2 Ph Et H Et H 
28i anti P(O)Ph2 Ph Et H Et H 
28j  P(O)Ph2 Ph H H Me H 
28k syn 3,5-(NO2)2-PhC(O) Ph C4H9 H H H 
* Diastereomerically pure 
 
 
Propargylic amides R R1 R2 
28-1a P(O)Ph2 Ph C4H9 
 
 
1.4.2. Microwave Chemistry 
  
Microwaves have been used for heating food since the late 1950’s.  However, their use for 
heating and accelerating reactions in synthetic organic chemistry came about at a much later 
date, 1986.49  In the late 1980's and early 1990's, domestic microwaves were used for 
microwave-assisted organic synthesis (MAOS).  This approach met with many problems with 
temperature and pressure control that resulted in poor reproducibility.  However, it became 
increasingly evident that microwave presented advantages over conventional heating.50  
Microwave irradiation is electromagnetic irradiation in the frequency range of 0.3 to 300 GHz.  
All domestic microwaves and all microwave reactors for chemical synthesis operate at a 
frequency of 2.45 GHz (which corresponds to a wavelength of 12.24 cm) to avoid interference 
NHR
R1
R2
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with telecommunication and cellular phone frequencies.  The energy of the microwave photon in 
this frequency region (0.0016 eV) is too low to break chemical bonds and is also lower than the 
energy of Brownean motion.  Therefore, microwaves cannot induce chemical reactions.50  
Microwave-supported synthesis takes advantage of highly efficient dielectric heating.  
Microwave heating is highly dependent on the ability of the irradiated material to absorb 
microwave energy and convert it to heat.  The conduction of heat is different than in 
conventional heating.  Simply put, microwave heating can be visualized as heating from “inside 
out” and conventional heating from “outside in”.  Modern microwave reactors provide a 
homogenous distribution of the microwaves through the reaction vessel and therefore a very high 
efficiency of microwave heating is achieved.  These features of microwave heating generally 
result in an increased reaction rate and fewer byproducts for many synthetic organic reactions, in 
particular those that use solvents and/or reactants that have a high dielectric constant.  In some 
cases, it is enough that reactive intermediates have a sufficient dipole moment, increasing the 
ability of the entire reaction mixture to absorb microwave energy and thus increase the reaction 
rate.  Many reactions that take hours, even days with conventional heating may proceed in only 
min. in a microwave.  Reasons behind this increased rate lie in the superheating that microwaves 
produce in a closed vessel, with an increased pressure (PV = nRT).  Incorporation of a 
microwave system significantly accelerated the hydrozirconation–transmetallation–aldimine 
addition sequence and served as a more efficient platform for library synthesis, as described 
below (section 1.4.3).  The development of key protocols for these microwave based syntheses is 
discussed in the results (section 2.1.5.1).   
 
 
                                                                                                                                
24 
1.4.3. Synthesis of the Second Generation Library of Allylic Amides and C-
Cyclopropylalkylamides Using Microwave 
 
Extensions of the recently reported microwave methodology51 were used in library syntheses.  
The University of Pittsburgh Center for Chemical Methodologies & Library Development 
(CMLD, http://ccc.chem.pitt.edu/UPCMLD/index.html) prepared a 20-membered library of 
allylic and C-cyclopropylalkylamides from three alkynes and seven phosphinoylimines using 
microwave acceleration followed by serial chromatographic purification.  Subsequent 
functionalization of this library with ten different acyl chlorides, seven carbamoyl chlorides, and 
nine sulfonyl chlorides resulted in the synthesis of a 100-membered focused library of allylic and 
C-cyclopropylalkylamides for this second generation library.  All microwave reactions in the 
library were performed on a Personal Chemistry Emrys Optimizer.  Experimental details of the 
second generation library synthesis are reported elsewhere,52  Scheme 2. The design of the 
second generation library is discussed in detail in section 2.1.6.1.  
 
In brief, the library synthesis involved the following steps.  Diverse alkynes, internal and 
terminal, unfunctionalized or with various functionalities, were submitted to hydrozirocation 
reaction conditions in a microwave.  In a typical case, a suspension of the Schwartz reagent in 
toluene was treated with alkyne at 100 oC, 300W for 1 minute and provided a clear yellow 
solution of alkenyl zirconocene.  The mixture was then cooled to -78 oC, and treated with a 
solution of dimethylzinc. 
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Scheme 2. Second generation library microwave supported synthesis.   
 
After warming to 0 oC, the resulting zinc intermediate was treated with the aldimine in a 
microwave at 100 oC, 150W for 2 min.  The desired phosphinoyl-protected allylic amide was 
obtained after aqueous quench.  After removal of the amine protecting group under acidic 
conditions, the free amine salts were further functionalized by N-acylation, N-carbamoylation, 
and N-sulfonation, providing allylic amide second generation library members.52  Without 
purification, the crude phosphinoyl allylic amides were submitted to Simmons-Smith type 
cyclopropanation conditions in the presence of diiodomethane at 60 oC, 300W for 30 min. in the 
microwave. The deprotection and further functionalization were performed the same way as for 
allylic amides, providing C-cyclopropylalkylamide library members.52 
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Seventy allylic amides and C-cyclopropylalkylamides with purities exceeding 85% (as 
determined by C-18 reverse-phase HPLC with monitoring at 220 nm) were tested for their 
effects on on ERα52 and ERβ (Table 6, section 2.1.7).  The novel ER targeting agents identified 
from these screens, their biological evaluation and their SAR are discussed in greater detail in 
section 2.1.6. 
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2. RESULTS AND DISCUSSION 
 
2.1. New ER Targeting Agents from the Discovery Library of Allylic Amides, 
Homoallylic Amides and C-Cyclopropylalkylamides 
 
Antiestrogens primarily function by competing with endogenous estrogens for binding to the ER. 
In the case of SERMs, binding to the ER can produce estrogenic and antiestrogenic responses 
depending on tissue type and the specific chemical structure of the compound.  SERM resistance 
is one of the major problems in current hormonal therapy of breast cancers.  Therefore, there is a 
growing need for the design and synthesis of structurally novel antiestrogens in the hope to 
overcome these problems.  Many of the discovery library (Table 1, section 1.4.1) components 
contained a combination of a di- or triaryl ring system with a central electron-rich (e.g., olefin) 
moiety.  This is a structural feature common for some estrogens and many antiestrogens.  The 
initial goal was to find novel structural scaffolds with antiestrogenic properties and no 
stimulatory effects on ERα. 
 
 
2.1.1. Discovery Library Screening at ERα 
 
The purpose of the initial screen of the discovery library was to determine if library members 
held potential for agonism or antagonism of ERα at a classical ERE.  All library members were 
tested for ligand-dependent transcriptional activity of ERα using a transient transfection 
assay.53,54  ER naïve HEK293 cells were co-transfected with three plasmids containing genes for 
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CMV promoter-driven ERα, the reporter ERE-tk-Luc, and standard CMV-β-galactosidase (β-
Gal) for transfection efficiency control using DOTAP liposomes as the transfection reagent.  In 
this system, ERα and β-Gal are constitutively expressed, and compounds that cause the ERα to 
adopt an agonist-bound conformation cause binding of the receptor to the ERE and transcription 
of luciferase, providing a readout of ligand-dependent ERα transcriptional activation that can be 
standardized against β-Gal expression.  Library members and TAM were screened at 10 µM.  E2 
(10 nM) was used as the positive control.  Figure 6 shows the compound-induced fold induction  
 
 
Figure 6. Screen of the discovery library for ERα agonists at classical ERE.  
ER naïve HEK293 cells were transfected with CMV promoter-driven human ERα, an ERE-tk-Luc reporter and a 
CMV-β-gal transfection control using DOTAP liposomes.  E2 and TAM were used as positive controls.  Library 
compounds and TAM were tested at 10 µM and E2 at 10 nM.  Data represents fold of induction (mean ±SD, N=3).  
This screen in search for agonists was optimized and performed by Dr. Ying Mu.48 
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Figure 7. Structures of lead C-cyclopropylalkylamide 26a (CK1-183) and control agents (40, 41 and 42). 
 
of luciferase activity compared to the activity in cells treated only with vehicle (DMSO, 0.1%).   
As expected, TAM showed modest estrogenic activity in this assay.  In contrast, none of the 
library compounds promoted ER transcription. 
 
To search for ERα antagonists, the same experimental setup was used, but the compounds were 
tested for antagonism of E2-induced luciferase transcription.  From the 67-member discovery 
library, thirteen compounds, structurally representative of all three subgroups (three homoallylic 
amides, three allylic amides and seven C-cyclopropylalkylamides), were tested as potential 
antagonists.  The transiently transfected HEK293 cells were co-incubated with E2 (10 nM) and 
with the candidate antagonists at both 10 µM and 1 µM concentrations.  (Z)-l,l-Dichloro-2,3-
diphenyl-2-[4-[2-(dimethylamino)ethoxy]phenyl]cyclopropane 42 (BDRM23)55 and TAM 
(Figure 7), known ERα antagonists, were used at 10 µM and 1 µM as positive controls (Figure 
6). The synthetic precursor alkyne 40 (1 and 10 µM) was used as a negative control.   
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Two compounds, the allylic amide 27b, (E)-N-[1-(1-Methyl-2-phenylvinyl)hept-2-enyl]-P,P-
diphenylphosphinamide, (Table 1) and the C-cycloproplyalkylamide 26a (CK1-183), O-ethyl-N-
{2-[(1S*,2R*)-2-{(R*)-[(diphenylphosphinoyl)amino](phenyl)methyl}cyclopropyl]ethyl}-N-[(4-
methylphenyl)sulfonyl]carbamate (Figure 7), significantly inhibited E2-induced transcription at 
the ERE at 1 and 10 µM (Figure 8).   
 
Figure 8.  Test for potential ERα antagonism in the transcriptional assay. 
Library compounds, seven C-cyclopropylalkylamides (26a (CK1-183), 26d, 26m, 26o, 26r, 26t, 26y), three allylic 
amides (27a, 27b, 27i), three homoallylic amides (28a, 28b, 28i), and TAM and 42 were tested at 10 µM (hatched 
bars) and 1 µM (black bars) in the presence of E2 at 10 nM. Data represents fold of induction (mean ± SD, N=3) and 
stimulation control E2 (N=9). 
 
Preliminary tests for inhibition of E2-induced proliferation of MCF-7 cells showed compound 
27b to be inactive at the concentrations used (Table 2), whereas C-cyclopropylalkylamide 26a 
(CK1-183), the second-most active antagonist in the transcriptional screen, inhibited MCF-7 cell 
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proliferation in these initial tests.  Therefore, 26a (CK1-183) was evaluated in more detail for 
antagonistic activity in cell-based and protein-ligand displacement assays. 
 
2.1.2. C-Cyclopropylalkylamide 26a (CK1-183) as a New ERα Partial Antagonist 
2.1.2.1. C-Cyclopropylalkylamide 26a (CK1-183) Inhibits Transcriptional Activity of 
ERα 
 
 
The C-cyclopropylalkylamide 26a (CK1-183) was further examined for concentration-dependent 
inhibition of the E2-induced transcriptional activation of ERα.  Transfected HEK293 cells were 
stimulated with E2 (1 nM) in the presence of a range of concentrations (3.2 nM - 50 μM) of 
compound 26a (CK1-183) or TAM (Table 2).   
 
 
Figure 9. C-Cyclopropylalkylamide 26a (CK1-183) inhibits E2 induced transcriptional activation of ERα. 
The separated enantiomers, 26a (CK1-183-ent1) (▲) and 26a (CK1-183-ent2) (▼), and the racemate (■) of C-
cyclopropylalkylamide 26a (CK1-183) show indistinguishable activities.  Data represents normalized luciferase 
counts to β-Gal read out used as an internal standard (means ± SD, N = 3).  
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IC50 values were estimated from concentration-dependence curves that best fit the data obtained 
as an average from at least two transfections done in triplicate (Figure 9).   
Compound 26a (CK1-183) antagonized the effects of E2 in a concentration-dependent manner, 
yielding an IC50 of 11 + 2 µM. In this assay, TAM gave an IC50 of 4.9 + 2.0 µM.  Compound 26a 
(CK1-183) failed to induce transcription at ERE as compared to TAM and E2 (Figure 6).  These 
findings indicated that 26a (CK1-183) is likely to be a full or partial antagonist.  
 
 
2.1.2.2. C-Cyclopropylalkylamide 26a (CK1-183) Inhibits E2 Stimulated Proliferation of 
MCF-7 Cells 
 
 
 
Figure 10. C-Cyclopropylalkylamide 26a (CK1-183) inhibits E2 induced MCF-7 proliferation. 
Compound 26a (CK1-183) (▲) and its enantiomers, 26a-ent1 (▼) and 26a-ent2 (♦) inhibit E2 (1 nM) induced 
proliferation of MCF-7 cells in a concentration dependent manner (Figure 10).  TAM (■) and alkyne 8 (●), the 
synthetic precursor for 26a (CK1-183) (Figure 7), were used as positive and negative controls, respectively.  Data 
represents percent growth inhibition (mean ±SD, N=4). 
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Compound 26a (CK1-183) was further evaluated for antiestrogenic action in an E2-stimulated 
MCF-7 cell proliferation assay.  It inhibited the E2 stimulated growth of MCF-7 cells in a 
concentration-dependent manner.  
 
 
2.1.2.3. C-Cyclopropylalkylamide 26a (CK1-183) is a Modest Competitor on ERα 
 
Compound 26a (CK1-183) was tested for its ability to displace a fluorescent E2 derivative from 
the ERα.  Recombinant human ERα was complexed with fluorescently labeled estradiol (ES2) 
and then treated with test agents.  After 2 h, the fluorescence polarization was measured. ES2 
bound to ERα protein gave high fluorescence polarization.  In this assay, the presence of a 
displacing ligand causes a decrease in the fluorescence polarization.  Concentration dependence 
curves were constructed and IC50s were calculated from the best-fit curves for the controls E2 (5 
± 4nM) and TAM (28 ± 20 nM).  Although compound 26a (CK1-183) showed a concentration-
dependent displacement of ES2 in this in vitro assay, its IC50 value was above the highest 
concentration tested (> 10 μM), leading to the conclusion that 26a (CK1-183) is at best a modest 
E2 competitor at the ERα (Figure 11). 
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Figure 11. C-Cyclopropylalkylamide 26a (CK1-183) tested in ERα competition assay 
Compound 26a (CK1-183) (▼) (IC50 > 10μM) shows low potency in an in vitro ERα competition assay (Panvera) 
as compared to E2 (■) (IC50 5 ± 4 nM) and TAM (▲) (IC50 28 ± 20 nM).  Data (mP) represents fluorescence 
polarization (mean±SD, N=3), mP = 1000x(S–GxP)/(S+GxP), where S and P are the background-subtracted 
intensity measurements for the parallel and perpendicular components, and G is a constant of the instrument.   The 
one site competition method in GraphPad Prism 4 software was used for constructing dose-response curves and 
calculating IC50s. 
 
2.1.2.4. C-Cyclopropylalkylamide 26a (CK1-183) Has No Effect on ERα Negative Breast 
Cancer Cells 
 
 
The unusual structure of 26a (CK1-183) as compared to a variety of known antiestrogens 
stimulated further evaluation of the specificity of 26a (CK1-183) in ER-negative MDA-MB231 
human breast cancer cells.  The growth inhibitory properties of 26a (CK1-183) were ER-
dependent, as it had no effect on the proliferation of MDA-MB231 cells.  C-
Cyclopropylalkylamide 26a (CK1-183) did not demonstrate any antiproliferative effects on these 
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cells even at high micromolar concentrations (Table 2). Colchicine was used as a positive 
control.48 
Table 2. Fifty percent inhibitory concentrations of compounds examined for E2-induced luciferase activity 
and MCF-7 cell proliferation, and for E2-independent MDA-MB231 cell proliferation. 
Compound ERα/ERE-tk-Luc 
IC50 (µM) 
MCF-7 
GI50 (µM) 
MDA-MB231 
GI50 (µM) e 
TAM 4.9 ± 2.0 a 3.9 ± 2.3b >50 e 
Colchicine - - 0.082 ± 0.009 e 
26a 11 ± 2 a 12 ± 4 c >50 e 
26a-ent1 13 ± 4 a 8.8 ± 2.1 b >50 e 
26a-ent2 23 ± 7 a 13 ± 0 b >50 e 
27a - 15 ± 0 d - 
27b - >20 d - 
28a - 13 ± 0 d - 
28b - 16 ±1 d - 
40 - >20 d - 
42 - 12 ± 0 d - 
Values given are means + SD. The range of concentrations used was 3.2 nM - 50 µM. aN = 6. bN = 8. cN=20.dN = 
4.eN = 8. 
 
In conclusion, a new structural class of ERα modulating agent was identified from a library 
screen of 67 homoallylic amides, allylic amides, and C-cyclopropylalkylamides (this is the 
discovery library described in section 1.4.1).  Constructs containing CMV promoter-driven ERα 
and the estrogen-regulated element of the Xenopus vitellogenin A2 gene inserted into the tk-
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luciferase plasmid were transiently transfected into mammalian cells.  ERα antagonists were 
identified by their ability to antagonize 17β-estradiol (E2)-induced transcription in transfected 
cells.  One compound, C-cyclopropylalkylamide 26a (CK1183),42,48 was shown to inhibit E2-
induced proliferation of ER-positive MCF-7 human breast cancer cell lines while having no 
effect on ER-negative MDA-MB231 human breast cancer cells.  This compound served as a lead 
for a second generation library (described in section 1.4.3) synthesis towards new ER targeting 
agents.52  Preliminary SAR around C-cyclopropylalkylamide 26a (CK1-183) as a lead is 
dicussed in the next section.  
 
 
2.1.3. Synthetic Efforts Based on C-Cyclopropylalkylamide 26a (CK1-183) as a Lead 
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Scheme 3. C-Cyclopropylalkylamide analogue synthesis.  
R1=H, R2=tBu (45a, 46a, 48a); R1=Me, R2=tBu (45b, 46b, 48b); R1=Cl, R2=Et (45c, 46c, 48c) 
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In order to better understand the structure-activity relationships within the first generation 
discovery library, the synthesis of a number of analogues based on systematic modification of 
the sulfonylcarbamate moiety of 26a (CK1-183) was undertaken (Scheme 3).  Synthetic 
protocols for the synthesis of C-cyclopropylalkylamides were developed previously in the Wipf 
group and will be discussed in detail in the experimental section.  
 
Briefly, sulfonylisocyanates 44a-c (44a R1=H, 44b R1=Me, 44c R1=Cl), commercially available 
or easily obtained from corresponding sulfonylamides 43a-c, were converted to 
sulfonylcarbamates 45a-c in moderate to high yields (42-98%). The Mitsunobu protocol56,57 
gave the highly functionalized alkynes 46a-c in moderate to high yields (47-97%), which were 
submitted to one pot hydrozirconation–transmetallation–aldmine (47) addition–cyclopropanation 
give C-cyclopropylalkylamides 48a-c (Scheme 3).  Synthesis of the library of analogues of 26a 
(CK1-183) proved to be problematic.  Alkyne precursors that were highly functionalized (46a-c) 
provided poor yields (20-30%) of C-cyclopropylalkylamides 48a-c.  Unfortunately, only three 
analogues were obtained in purity (> 90%) sufficient for testing in biological assays (Figure 12).  
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Figure 12. Analogues of C-cyclopropylalkylamide 26a (CK1-183) biologically tested. 
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New methodology was needed for more efficient focused library syntheses.  In addition, more 
elaborate changes in the lead structure were necessary to increase the chances of obtaining new 
compounds with improved cell potency.   
 
The newly developed microwave-supported methodology for the synthesis of allylic amides and 
C-cyclopropylalkylamides will be discussed in more detail in section 2.1.5. 
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2.1.4. SAR of C-Cyclopropylalkylamides from Discovery Library 
2.1.4.1. SAR from Cell-Based Assays 
 
To investigate the importance of the sulfonylcarbamate moiety of 26a (CK1-183), a synthetic 
precursor of this compound, alkyne 40 (Figure 7), and C-cyclopropylalkylamide 41 were tested 
in the MCF-7 antiproliferative assay and the transcriptional assays.  Alkyne 40 was tested in 
order to evaluate any biological activity arising from the sulfonylcarbamate portion of 26a (CK1-
183), and compound 41 to test the contribution from the bulky lipophilic phosphinoyl group.  
Interest in the effect of  the sulfonylcarbamate moiety of these compounds was stimulated by a 
recent report on ER targeting agents that contain sulfonamide moieties58 and the results of an 
antagonist screen (Figure 8) where structural analogues of 26a (CK1-183) lacking the 
sulfonylcarbamate had no antagonistic activity.  
 
Figure 13. Lead compound 26a (CK1-183) and control compounds 40 and 41, tested for inhibition of E2 
induced transcriptional activation of ERα at classical ERE.   
Data represents the % inhibition calculated from the means of normalized luciferase counts (N=3). Luciferase counts 
were normalized by β–Gal counts used as an internal standard and cotransfected with the receptor and the reporter.   
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Alkyne 40 demonstrated poor-to-moderate MCF-7 growth inhibition (Figure 7) and almost no 
activity in the transcriptional assay (Figure 13).  Compound 41, representing the phosphinoyl 
bulky lipophilic portion of 26a (CK1-183), showed similar low activity in altering the growth of 
MCF-7 cells and no inhibitory activity on E2-induced transcriptional activation of the ERα at a 
classical ERE (Figure 13).  These findings suggested that the 26a (CK1-183) structure as a whole 
was necessary for biological activity.  
 
Molecular docking studies of 26a (CK1-183) using the CAChe suite of algorithms with a model 
of the ERα LBD were performed.  Docking studies (for details, see section 2.1.4.2) using the 
model of the LBD when bound by raloxifene indicated that the sulfonylcarbamate portion of the 
molecule binds deep inside the ligand binding pocket of  the ERα-LBD while the phosphinoyl 
group lies outside the pocket.   
 
In order to test the importance of the sulfonylcarbamate moiety, three structurally close 
analogues of 26a (48a-c) were synthesized (Figure 12).  It was expected that small modifications 
in sulfonylcarbamate portion of 26a (CK1-183) would induce changes in the antagonistic 
activity.  The introduced changes did not significantly affect the MCF-7 antiproliferative activity, 
yielding IC50 values of 14.7 μM (48a), 20.2 μM (48b) and 17.8 μM (48c).  These results 
indicated that the proposed model with the sulfonylcarbamate portion binding deep inside the 
ligand binding pocket was not sufficient to explain the antagonistic activity of 26a (CK1-183) 
and its close analogues (48a, 48b and 48c).  Attention was then directed towards the phosphinoyl 
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group and its positioning as a cap to the binding pocket (Figure 15), interfering with helix 12 
movement as discussed in section 2.1.4.2.   
 
Since biological activity is often due to a single enantiomer in a racemate, the enantiomers of 
26a (CK1-183) (26a-ent1 and 26a-ent2) were separated by chiral HPLC and tested in parallel 
with racemic 26a (CK1-183) in the transcriptional assay.  Interestingly, no difference was 
observed between the activities of the enantiomers of 26a (CK1-183), both being equipotent to 
the racemate (Figure 9).  The activities of the enantiomers and the racemate were also compared 
in the MCF-7 antiproliferative assay (Figure 10).  Again, the enantiomers and the racemate of 
26a (CK1-183) were not statistically different in their inhibition of E2-induced growth of this 
ER-positive cell line.   
 
 
2.1.4.2. Docking studies 
 
Molecular docking studies using the CAChe suite of algorithms with a model of the ERα LBD 
were conducted to compare the binding mode of both enantiomers of 26a (CK1-183), as well as 
raloxifene (Figure 14).  The crystal stucture of human ERα-LBD in complex with RAL 
(1ERR)38 was downloaded from the Protein Data Bank web page.  RAL was used as a standard 
to test the docking system used.  RAL was redocked into the pocket in the 1ERR crystal structure 
by holding the residues of the protein fixed and allowing the ligand to be flexible.  The 
orientation and hydrogen bonding of the redocked complex were close to that in the crystal 
structure (Figure 14).  The lead structure 26a (CK1-183) was superimposed on RAL in the ER 
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binding pocket, the model of RAL was removed, and the model of 26a (CK1-183) was docked 
into the pocket by holding the protein rigid and the ligand flexible.  Docking studies indicated 
that the phosphinoyl group of 26a (CK1-183) may serve as a cap to the binding pocket (Figure 
15), interfering with helix 12 movement, while the remainder of the structure of 26a (CK1-183) 
binds deeper into the raloxifene binding cleft and may interact with residues at helices H3 (A350, 
D351), H6 (W383, R394) and H11 (L525, L536), suggesting a partial or full antagonist binding 
mode.  The docking energy (a.k.a. score) was –74.4 kcal/mole (Figure 15), comparable to the 
score obtained for RAL, –104.4 kcal/mole (Figure 14).   
 
Figure 14. Raloxifene docked into ERα-LBD using BioMedCAChe. 
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The scores and the orientation in the pocket indicate the possible interaction of 26a (CK1-183) 
being at best comparable to that of RAL.  The observation that the phosphinoyl system lies 
essentially outside of the ligand binding pocket in the molecular docking exercises helps to 
explain the absence of enantiomer specificity for this compound.  Taken together, the modeling 
and the results of the biological evaluation of the individual enantiomers of 26a (CK1-183) and 
its close analogues (48a, 48b and 48c) indicated that the interaction of this compound with the 
ER ligand binding pocket is likely to be goverened solely by hydrophobic interactions.   
 
 
Figure 15. C-Cyclopropylalkylamide 26a (CK1-183) docked into the ERα-LBD raloxifene binding pocket 
using BioMedCAChe. 
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Therefore, it is understandable that the results obtained in the MCF-7 cells, were quite similar 
regardless of the changes to the sulfonylcarbamate moiety or the different spatial orientation of 
the enantiomers.   
 
Overall, the unusual structure of 26a (CK1-183), its ability to antagonize E2 in the cell-based 
assays and its modest ability to displace E2 in the binding pocket suggested new avenues for 
SERM design. 
    
The lead structure 26a (CK1-183) suffered from a lack of drug-like properties, high ClogP (7.6) 
and high molecular weight (616.7) as opposed to a preferable ClogP value < 5 and a molecular 
weight < 500, found in most drugs and drug like molecules.59  A lack of drug-likeness of 26a 
(CK1-183) and results presented above in the biological assays and molecular docking studies 
indicated that the following steps were necessary in order to optimize the potency of this 
compound: (1) remove the large and hydrophobic phosphinoyl group and introduce smaller and 
more functionalized aromatic substituents on the nitrogen; (2) replace the sulfonylcarbamate 
with smaller size moieties in order to test whether this portion of the molecule is crucial for 
biological activity; and (3) introduce substituents that would promote hydrogen bonding with key 
residues in the pocket.  These concepts were addressed in the second generation library design.  
It was important to elaborate further on the replacement of the sulfonyl carbamate and the 
phosphinoyl group that initially appeared to be necessary for the action of 26a (CK1-183) in 
cells. When small changes were introduced, such as changing the acyl substituent and changing 
the para substitution on the phenyl ring of the sulfonylcarbamate, the MCF-7 activity failed to 
improve. 
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A second generation library52 of allylic amides and C–cyclopropylalkyl amides was designed to 
explore the chemical space around 26a (CK1-183) and identify new ER agents with improved 
cell potency (see Introduction 1.4.3.).  Biological evaluation of the second generation library and 
its SAR are discussed in detail in upcoming sections (2.1.6, 2.1.7). 
 
 
2.1.5. Microwave Supported Synthesis 
 
Initial synthesis of the library of analogues of 26a (CK1-183) proved to be problematic and 
provided only three analogues in relatively poor yields (20-30%), discussed in section 2.1.3. This 
result initiated a search for alternative and more efficient synthetic protocols. In consideration of 
the polarity and dipole moments of the reactants in the one-pot sequence of hydrozirconation-
transmetallation-aldimine addition, it was proposed that microwave heating could improve the 
reaction times and yields.  Therefore, the hydrozirconation and aldimine addition steps were 
tested in a microwave reactor.  
 
Microwave heating has been increasingly used in organometallic chemistry.  Heck and 
Sonogashira couplings are a few of the Pd(0)-catalyzed reactions that have been performed under 
microwave conditions with high yields and high selectivity.50  Palladium chemistry is the most 
explored  microwave-accelerated reaction involving metals.  Zirconium chemistry was yet to be 
explored in the microwave.  
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Table 3. Hydrozirconation in toluene in the microwave – flash heat mode.  
OTBDPS
 Entry                         Alkyne                      Tmax  (oC)          Power (W)        Conversion
150 300 >99%
100 300 >99%
100 150 >99%
80 300 ~ 50%
1
2
3
4
C4H9
5
6
7
8
100   30 >99%
 80  75 >99%
 80  50   90%
80 30 ~ 90%
150 300 >99%
100 300 >99%
9
10
49
50
51
C3H7C3H7
 
*For a detailed explanation of the microwave conditions, see text. 
  
The original protocol for the “one-pot” hydrozirconation-transmetallation-aldimine addition41 
entailed a solvent switch from dichloromethane to toluene following the hydrozirconation step.  
The reason for this switch was that the hydrozirocation was much faster in dichloromethane and 
THF than in toluene.  To simplify this procedure, the efficiency of the hydrozirconation in 
toluene in a microwave was tested.  The reaction mixture was heated in the microwave reactor in 
“flash heat mode”.  This procedure entails fast heating the reaction mixture to high temperature 
followed by almost immediate cooling.  Under these condtions, the reaction mixture stays at high 
temperature less than one minute.  This allows the reaction to proceed and it is believed that the 
fast and immediate cooling prevents side reactions from taking place.  Under these conditions, 
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the hydrozirconation of the alkynes tested proceeded with greater than 99% conversion as 
determined by GC-FID (Table 3).  The total reaction time required for full conversion was 1-2 
min in the “flash heat mode”.51  The next step of this “one pot” protocol was the transmetallation 
of the hydrozirconation products with dimethylzinc at –78 oC.  After the transmetallation was 
completed, an aldimine was added and the aldimine addition reaction was optimized in the 
microwave.  Initially, the aldimine addition was tested at lower temperatures (60 oC) for 15–30 
min..  This protocol gave similar or lower yields to those provided by the conventional heating 
and the reaction products were less pure. The optimized protocol involved fast heating at higher 
temperatures followed by fast cooling.  Representative examples shown in Table 4 are discussed 
in detail in the next section.  
 
2.1.5.1. Hydrozirconation – Transmetallation – Aldimine Addition 
 
Further improvement in the synthesis of allylic amides was observed when the aldimine addition 
was carried out using the microwave’s flash heating mode (Scheme 4).51  This methodology 
proved to be highly efficient and time saving.  The methodology worked well for internal 
alkynes and terminal alkynes.51  Representative examples of this process are provided in Table 4.  
Electron withdrawing groups on the phenyl ring of the aldimine as in 54 provided the highest 
yields with both terminal and symmetric internal alkynes (Table 4, entries 1, 4, 6 and 8). 
 
Electronically less activated aldimines showed decreased addition efficiencies in the microwave, 
resulting in lower yield (e.g. entry 2) when terminal alkynes were used.  However, the aldimine 
addition improved when internal alkynes were used (entries 3 and 5).   
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Table 4. Hydrozirconation and aldimine addition in a microwave – flash heat mode.  
 
Entry       Alkyne                Aldimine                         Allylic amide                              Microwave       Conventional
C3H7C3H7
C4H9 95%
N P
O
Ph
Ph
O
MeO
HN P
O
Ph
Ph
O
MeO
C4H9
Ph
HN
C3H7
P
O
Ph
Ph
C3H7
62%
Ph
HN
C4H9
P
O
Ph
Ph
Ph N P
O
Ph
Ph 43%
C2H5 Ph
HN
C2H5
P
O
Ph
Ph
78%
C2H5
C2H5
1
2
3
4
72%
N/A
84%
76%
5
6
7
74%
HN P
O
Ph
Ph
O
MeO
C3H7
C3H7
N/A
Ph
HN P
O
Ph
Ph
OTBDPS OTBDPS
64% 73%
HN P
O
Ph
Ph
O
MeO
80% N/AN
O
Ts
O N
O
O
Ts
50
50
52
51
51
49
53
54
47
47
47
54
47
54
HN P
O
Ph
Ph
O
MeO
C2H5
C2H5
74% N/A5452
8
55
56
57
58
59
60
61
62  
* The examples for the conventional method were published previously.41 
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C4H9
1. Cp2Zr(H)Cl, toluene
    μW 80 oC, 75 W, 45 sec.
2. Me2Zn, toluene, -78 oC - 0 oC, 5 min
3.                        
   toluene,  μW 100 oC, 150 W, 40 sec.
N
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O
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H3CO
O
HN
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50
54
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95%  
Scheme 4. Allylic amide synthesis in a microwave.  
 
The conventional method for the hydrozirconation–transmetallation–aldimine addition required 
an inert atmosphere (dry nitrogen or argon gas).  The microwave protocol under closed vessel 
conditions proceeded without any need for an inert atmosphere. This finding is in accord with 
published results for microwave-assisted reactions of transition metals.50  It is believed that the 
rate increase by the more efficient heating allows the desired reaction to proceed at a rate much 
faster than oxygen- and moisture-initiated side reactions.   
 
This was the first reported example of hydrozirconation and aldimine addition reactions 
performed in the microwave.51  An extension of this methodology was used to prepare a second 
generation library of allylic and C-cyclopropylalkylamides (second generation library) as 
described in the introduction (1.4.3). 
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2.1.6. Biological Evaluation of the Second Generation Library 
2.1.6.1. Design of the Second Generation Library 
 
 
The second generation library (Scheme 2, Table 6) was designed and synthesized based on C-
cyclopropylalkylamide 26a (CK1-183) as a lead structure in order to explore in greater detail 
SAR on both receptors. The goal was to increase cell potency in this series against breast cancer 
cells.  The starting activity of the lead structure 26a (CK1-183) in the high micromolar range and 
the failure to improve on its activity with initially explored changes on the sufonylamide (see 
section 2.1.4.1) suggested more radical changes were needed. The unusual structure of 26a 
(CK1-183) as compared to the well defined pharmacophore model for ER targeting agents27 
provided an opportunity to explore novel scaffolds for ER targeting agents.  Interest in the effect 
of the sulfonylcarbamate moiety of these compounds was stimulated by a recent report on ER 
targeting agents containing sulfonamide moieties.58  The first three analogues (48a, 48b and 48c) 
of 26a (CK1-183) (Figure 12) with changes in the sulfonamide failed to improve or change the 
activity as compared to the lead.  Therefore, the sulfonamide was conserved but its positioning 
was varied in the design of the second generation library. Some derivatives (compounds 36a-
36m and 39a-39c, Table 6) were synthesized with alternate substituents on the arylsulfonamide.   
It was anticipated that the sulfonamide, a common moiety in many drugs, would improve upon 
the drug like properties of the new agents.  The phenyl ring on 26a (CK1-183) was decorated 
with the following substituents: chloro, trifluoromethyl and methyl acetyl (see Table 6).  These 
substituents were introduced to increase solubility and/or promote binding to the ER ligand 
binding pocket via either hydrogen bonding (methyl acetyl and trifluoromethyl) or favorable 
                                                                                                                                
51 
hydrophobic or soft-soft interactions (chloro).  The series also included agents with the biphenyl 
core that were designed to promote interactions with the ERβ.   
 
In order to clarify the role of the cyclopropane ring in this series, the majority of the 
cyclopropane-containing library members had a matched counterpart that contained a double 
bond instead of the cyclopropane ring, with the rest of the structure remaining quite similar (see 
Table 6).  For the sake of ease of library synthesis and the fact that alkyne precursors containing 
the sulfonamide gave analogues with no improvement over 26a (CK1-183), the alkyne 
precursors in the second generation library synthesis were restricted to simple terminal alkynes 
(1-hexyne) and internal alkynes (3-hexyne, 4-octyne). The cyclohexylmethyl alkyne precursor 
was used to introduce bulk to the molecule and test the notion that the size of ER targeting agents 
can important in designing selective agents (for discussion, see section 1.3).  In this series, the 
main feature of a majority of ER targeting agents, the phenolic OH group, necessary for the 
hydrogen bonding with key residues on both ERs, was not introduced for two reasons.  First, the 
initial microwave-supported synthetic scheme,52 designed with a limited number of steps, could 
not support the additional steps needed for the introduction of protected OH groups.  Second, the 
initial lead structure did not contain a hydroxyl group and was hypothesized to act on ER 
transcription and breast cancer cell proliferation through novel mechanisms,48 leading the SAR 
explorations toward new structural changes as compared to classical pharmacophore models.  It 
was an open possibility that 26a (CK1-183) could act on an alternative site, such as coregulator 
binding domain.  However, to be able to test this hypothesis, a compound or with a lower IC50 
value was needed.  The second generation library design had two goals: (1) to explore the novel 
structural scaffolds for targeting ERs; and (2) to increase the cell potency of the lead structure.  
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2.1.6.2. Second Generation Library Tests in vitro and in Cells 
 
 
Seventy high-purity (>85% by HPLC using UV monitoring at 210 nm) library members 
(presented in Table 6) were screened for their ability to compete with fluorescently labeled 17β-
estradiol for binding to human ERα.  The MCF-7 proliferation assay was used for the 
reevaluation of hits from the second generation library in the ERα competitor assay (Table 5).  
 
Figure 16. Results of screening the second generation library with the ERα  fluorescence polarization baased 
displacement assay (Panvera).     
When fluorescently labeled E2 was complexed with recombinant ERα, slow tubling of the labeled E2 resulted in 
high fluorescent polarization.  In the presence of a test compound, the labeled E2 was displaced and the polarization 
value decreased.  Displacement % was calculated from the obtained difference in fluorescence polarization value 
and plotted for each compound in three tested concentrations (0.2, 1 and 5 μM). Data represents the means ± SD 
(N=2). 
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Figure 17. Hits from Screening the Second Generation Library at the ERα. 
 
Compounds that showed >50% displacement and concentration dependence were identified as 
hits.  The order of appearance of data points in Figure 15 corresponds to the library members and 
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the structural information listed in Table 6.  The data represents the percent of displacement 
(%I), calculated based on the following formula: 
 
 % I = ((mP0 – mP)/(mP0 – mP100)) x 100 
 
where mP0 is the mP value for 0% competition as referred to high polarization of fluorescently 
labeled estradiol complexed to ERα (ER/ES2 complex); mP100 is the mP value for 100% 
competition, as referred to the low polarization in the presence of E2 (1 µM); and mP is the 
fluorescence polarization observed in the presence of test compounds. The fluorescence 
polarization (mP) values are calculated using the following formula:  
 
mP = mP = 1000 x (S–G x P) / (S + G x P)  
 
where S and P are the background-subtracted fluorescence intensity measurements for the 
parallel and perpendicular components, and G is a constant of the instrument.    
The MCF-7 proliferation assay was used for the reevaluation of those agents that were identified 
from ERα competitor assay.  The second generation allylic amide and C-cyclopropylalkylamide 
library in vitro screening at ERα gave 11 hits (Figure 17).   
 
Out of these hits, three compounds (37a, 37c and 39a; Figure 17) showed improvement in cell 
potency over the original lead structure 26a (CK1-183) (GI50: 12.0 ± 4.0 μM) as tested in MCF-
7 cells, identified from the discovery library with GI50 values bellow 10 μM (Table 5 and Figure 
17).  In addition to these three compounds, compound 35b showed a low micromolar value for 
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GI50 value in MCF-7 cells, but in a counterassay showed inhibitory effect on the growth of the 
MDA-MB231 ER negative cell line, and therefore was excluded from further study.  
 
Figure 18. Inhibition of E2-induced proliferation of MCF-7 cells.  
Data represents percent growth inhibition (%GI) versus concentration (Log M) of each agent (mean± SD, N = 4).   
MCF-7 cells were stimulated with E2 (10 nM) and treated with decreasing concentrations of test compounds for six 
days.  Cell density was evaluated by a colorimetric MTS assay and data represents percent growth inhibition (%GI). 
Shown are means ± SD (N = 4).   
 
Table 5. Hits from the testing of the second generation library in MCF-7 cells 
Compound ERαa 
% displacement at 
0.2, 1 and 5 µM 
MCF-7b 
GI50 (µM) 
RAL 67 74 90 0.6 ± 0.0 
33a 55 65 79 13.0 ± 9.3 
35a 53 67 99 32.5 ± 1.0 
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35b 69 84 110 3.5 ± 0.5 
36a 56 76 108 ND 
36c 61 92 98 ND 
36d 63 86 90 ND 
37a 64 84 89 3.7 ± 2.8 
37b 72 77 80 12.5 ±  2.0 
37c 63 65 91 2.7 ± 0.8 
39a 52 74 91 > 50.0 
39c 58 70 88 5.7 ± 2.0 
 
aData represents % of displacement from fluorescent polarization assay for test compounds at each test 
concentration. Shown are the means ± SD (N = 2); bMCF-7 cells were stimulated with E2 (10 nM) and treated with 
decreasing concentrations of test compounds (50 μM – 3.2 nM) for six days.  At day seven, the cell density was 
evaluated by a colorimetric MTS assay and data represents percent growth inhibition (%GI). Shown are means ± SD 
(N = 4).   
 
The structures of the three new C-cyclopropylalkylamides 37a, 37c and 39c are markedly 
different from the initial lead 26a (CK1-183).  The cyclopropane ring and a phenyl ring were 
present in all lead structures.  Surprisingly, C-cyclopropylalkylamides 37a, 37c and 39c have 
neither the phosphinoyl group nor the sulfonylcarbamate moiety present in the lead compound 
26a (CK1-183).  However, the cyclopropane ring was present and appeared to be important for 
activity in cells.   The hits from fluorescence polarization-based displacement assay on ERα 
when retested in MCF-7 cells, and those compounds that contained a cyclopropane (37a, 37c and 
39c) showed significant activity (Table 5).  With the exception of compound 35b, other members 
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that contained a double bond instead of a cyclopropane were markedly less active, for example 
compound 35a (Table 5).  The l,l-dichloro-2,2,3-triarylcyclopropanes (DTACs) were developed 
by Day et al. as pure antiestrogens lacking the uterotrophic effect of tamoxifen,55 and the 
dichlorocyclopropyl analogue of tamoxifen, (Z)-l,l-dichloro-2,3-diphenyl-2-[4-[2-
(dimethylamino)ethoxy]phenyl]cyclopropane (42)55 was used as a control antiestrogen in the cell 
based assays.  It appears that neither the double bond nor the cyclopropane moiety in the second 
generation library were critical for the activity in fluorescence polarization-based assays.  Based 
on the limited data available the exact role of the cyclopropane ring remains unclear.   
 
 
2.1.6.3. Screening of the Second Generation Library on ERβ 
 
Seventy high-purity second generation library members (>85% by HPLC at 210nm UV) listed in 
Table 6 were screened for their ability to compete with fluorescently labeled 17β-estradiol for 
binding to human ERβ under the same conditions as on ERα (see experimental section 5.2.5).   
The results clearly showed that the ERα is much more tolerant to diverse substitutions in this 
series than is the ERβ (see Figure 16 and Figure 19).  Therefore, the criteria for hits at the ERα 
and ERβ were adjusted accordingly.  In the screen on the ERα, compounds that gave >50% 
displacement at the lowest concentration tested (0.2 µM) and showed concentration dependence 
over all three concentrations tested (0.2, 1 and 5 µM) were considered hits and were further 
evaluated in cells (Figure 17).   
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Figure 19. Results of screening the second generation library in the ERβ  competitior assay (Panvera).  
When fluorescently labeled E2 was complexed with ER, slow tubling of the labeled E2 resulted in high fluorescent 
polarization.  In the presence of a test compound, the labeled E2 was displaced and the polarization value decreased. 
Displacement % was calculated from the obtained difference in fluorescence polarization value and plotted for each 
compound in three tested concentrations (0.2, 1 and 5 μM).  Data represents the means ± SD (N=2).  
 
When the second generation library was screened for ERβ displacement, the efficiency of 
displacement was significantly lower for the entire series, and only those compounds that gave 
close to 50% displacement were considered as hits.  As a result, only one compound, biphenyl C-
cyclopropylalkylamide 37d (CC1-243), fulfilled these criteria and was further evaluated.    
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For the purpose of clearer representation, the screening data on both estrogen receptors for all 
tested second generation library members, with included structures and substitution patterns, is 
presented in Table 6.  
Table 6. Activities of C-cyclopropylalkylamides from the second generation library in fluorescence 
polarization displacement-based screen assays at ERα and ERβ.   
 
 
  
R1 
 
R2 
 
Ar 
ERα 
% displacement at 
0.2, 1 and 5 µM 
ERβ 
% displacement at 
0.2, 1 and 5 µM 
32a n-C3H7 n-C3H7 p-ClC6H4 5      30 -44 2 -1 -5 
 
 
  
R1 
 
R2 
 
Ar 
ERα 
% displacement at 
0.2, 1 and 5 µM 
ERβ 
% displacement at 
0.2, 1 and 5 µM 
33a n-C3H7 n-C3H7 p-CF3C6H4 55 65 79 8 16 27 
33b n-C3H7 n-C3H7 p-PhC6H4 46 11 -77 19 -10 -25 
33c n-C3H7 n-C3H7 Ph 47 25 72 6 9 14 
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R1 
 
R2 
 
Ar 
 
R3 
ERα 
% displacement at 
0.2, 1 and 5 µM 
ERβ 
% displacement at 
0.2, 1 and 5 µM 
34a n-C3H7 n-C3H7 (p-CO2Me)C6H4 Ph 0 52 78 1 28 11 
34b n-C3H7 n-C3H7 (p-CO2Me)C6H4 2-thiophene 48 73 86 5 13 31 
34c n-C3H7 n-C3H7 p-CF3C6H4 2-thiophene 43 31 73 9 12 19 
34d n-C3H7 n-C3H7 p-CF3C6H4 CH2CH2Ph 56 31 67 8 13 17 
34e n-C3H7 n-C3H7 p-CF3C6H4 p-CF3C6H4 -7 32 61 10 5 5 
34f n-C3H7 n-C3H7 Ph Ph 51 56 82 8 6 17 
34g n-C3H7 n-C3H7 Ph p-CF3C6H4 47 59 68 10 11 16 
34h n-C3H7 n-C3H7 (p-CO2Me)C6H4 2-furanyl 36 58 76 -4 -4 15 
34i n-C3H7 n-C3H7 (p-CO2Me)C6H4 t-Bu 27 42 63 1 -4 10 
34kj n-C3H7 n-C3H7 (p-CO2Me)C6H4 p-PhC6H4 27 25 27 -1 -3 4 
34k H n-C4H9 Ph Ph 58 70 67 2 3 9 
34l H n-C4H9 Ph CH2CH2Ph -33 35 46 0 2 8 
34m H n-C4H9 Ph tBu -67 13 13 -10 -12 -4 
34n H n-C4H9 Ph Ph-Ph 18 5 -4 -8 -9 -10 
34o H n-C4H9 Ph p-CF3C6H4 -61 21 27 -8 -7 3 
34p H n-C4H9 Ph (p-CO2Me)C6H4 21 24 37 -9 -7 5 
34r H n-C4H9 Ph 2-furanyl -111 29 41 -3 -2 6 
34s H n-C4H9 Ph 2-thiophene 67 40 54 -1 -3 8 
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34t n-C3H7 n-C3H7 (p-CO2Me)C6H4 (p-CO2Me)C6H4 -14 24 38 -13 -3 8 
34u n-C3H7 n-C3H7 (p-CO2Me)C6H4 CH2Ph 3 22 48 -11 -2 13 
34v c-C6H11 Me p-PhC6H4 p-CF3C6H4 29 20 1 -7 -6 -3 
34w c-C6H11 Me p-PhC6H4 3-pyridyl 32 44 48 -8 -4 6 
 
 
  
R1 
 
R2 
 
Ar 
 
R4 
ERα 
% displacement at 
0.2, 1 and 5 µM 
ERβ 
% displacement at 
0.2, 1 and 5 µM 
35a n-C3H7 n-C3H7 (p-CO2Me)C6H4 iBu 53 67 99 9 13 35 
35b n-C3H7 n-C3H7 Ph CH2CH(CH3)2 69 84 110 -4 3 22 
35c H n-C4H9 Ph o-ClC6H4 68 68 73 11 7 7 
 
 
  
R1 
 
R2 
 
Ar 
 
R5 
ERα 
% displacement at 
0.2, 1 and 5 µM 
ERβ 
% displacement at 
0.2, 1 and 5 µM 
36a n-C3H7 n-C3H7 (p-CO2Me)C6H4 rac-
camphorsulfonyl 
56 76 108 22 16 37 
36b n-C3H7 n-C3H7 (p-CO2Me)C6H4 8-quinoline 54 111 54 7 24 42 
36c n-C3H7 n-C3H7 (p-CO2Me)C6H4 o-ClC6H4 61 92 98 15 32 40 
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36d n-C3H7 n-C3H7 (p-CO2Me)C6H4 p-CF3C6H4 63 86 90 15 29 43 
36e n-C3H7 n-C3H7 p-CF3C6H4 Ph 70 66 102 13 10 30 
36f n-C3H7 n-C3H7 p-PhC6H4 8-quinolinyl 56 28 67 14 11 13 
36g n-C3H7 n-C3H7 p-PhC6H4 p-CF3C6H4 72 14 46 7 8 7 
36h n-C3H7 n-C3H7 Ph p-ClC6H4 42 61 95 6 13 42 
36i n-C3H7 n-C3H7 Ph p-CF3C6H4 47 74 90 -1 10 30 
36j n-C3H7 n-C3H7 Ph Me 48 39 56 -3 -4 17 
36l n-C3H7 n-C3H7 (p-CO2Me)C6H4 2-thiophene 39 33 92 5 8 32 
36m n-C3H7 n-C3H7 (p-CO2Me)C6H4 p-PhC6H4 -69 47 54 6 12 16 
 
 
  
R1 
 
R2 
 
Ar 
 
R3 
ERα 
% displacement at 
0.2, 1 and 5 µM 
ERβ 
% displacement at 
0.2, 1 and 5 µM 
37a  n-C4H9 H (p-CO2Me)C6H4 2-furanyl 64 84 89 8 2 15 
37b  n-C4H9 H Ph Ph 72 77 80 -4 2 9 
37c  n-C4H9 H Ph 2-furanyl 63 65 91 8 7 20 
37d  n-C4H9 H p-PhC6H4 Ph 56 58 33 26 31 46 
37e  n-C4H9 H p-PhC6H4 CH2Ph 47 33 28 2 8 14 
37f  n-C4H9 H p-PhC6H4 2-furanyl 58 57 54 -2 0 13 
37g  n-C4H9 H p-PhC6H4 p-PhC6H4 52 42 -6 0 6 4 
37h n-C4H9 H p-CF3C6H4 2-thiophene 50 58 79 8 14 13 
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37i  n-C4H9 H (p-CO2Me)C6H4 Ph 54 54 75 -3 -2 6 
37j  n-C4H9 H p-PhC6H4 2-thiophene 58 54 37 -1 8 5 
37k n-C4H9 H p-PhC6H4 3-pyridyl 64 63 53 2 2 10 
37l n-C4H9 H p-CF3C6H4 Ph 45 47 58 13 6 13 
37m n-C4H9 H p-CF3C6H4 tBu 40 39 56 -2 -4 7 
37n n-C4H9 H (p-CO2Me)C6H4 p-CF3C6H4 20 45 45 -2 1 15 
37o  c-C6H11 Me p-PhC6H4 2-thiophene 15 7 3 0 -3 0 
37p c-C6H11 Me p-PhC6H4 Ph 4 -7 1 -5 -2 -1 
37q c-C6H11 Me p-PhC6H4 CH2Ph -17 -22 18 -13 -10 -9 
37r c-C6H11 Me (p-CO2Me)C6H4 Ph 46 53 42 -3 2 7 
37s c-C6H11 Me (p-CO2Me)C6H4 2-furanyl 49 58 97 -4 -1 28 
37t n-C3H7 n-C3H7 p-ClC6H4 2-furanyl 26 39 73 -2 5 25 
37u c-C6H11 Me p-ClC6H4 tBu 17 23 37 -11 -11 4 
37v c-C6H11 Me p-ClC6H4 p-PhC6H4 35 11 -13 -10 -4 11 
37w n-C4H9 H o-CF3C6H4 Ph 32 33 48 -9 1 13 
37x n-C4H9 H o-CF3C6H4 2-thiophene 38 52 68 10 15 22 
37y n-C4H9 H o-CF3C6H4 2-furanyl 6 15 57 0 2 22 
 
 
  
R1 
 
R2 
 
Ar 
 
R4 
ERα 
% displacement at 
0.2, 1 and 5 µM 
ERβ 
% displacement at 
0.2, 1 and 5 µM 
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38a n-C3H7 n-C3H7 p-PhC6H4 CH2Ph 7 17 -6 -8 -6 -5 
 
 
  
R1 
 
R2 
 
Ar 
 
R5 
ERα 
% displacement at 
0.2, 1 and 5 µM 
ERβ 
% displacement at 
0.2, 1 and 5 µM 
39a  n-C4H9 H p-PhC6H4 8-quinolinyl 52 74 91 28 18 22 
39b  c-C6H11 Me p-PhC6H4 8-quinolinyl 52 52 41 -5 -4 2 
39c  n-C3H7 n-C3H7 p-PhC6H4 8-quinolinyl 58 70 88 15 17 29 
 
 
 
2.1.7. SAR of the Second Generation Library on ERα and ERβ 
 
Evaluation of the screening data gave preliminary SAR for the second generation library on both 
receptors.  Compound 37d showed the highest displacement efficiency in the ERβ screen and it 
did not satisfy the criteria for being a hit on the ERα (see Table 6). However, the highest 
displacement valaue on ERβ did not pass 50% for any tested agent. Therefore, it was rather 
difficult to choose hits that had potential for further development to target ERβ based only on the 
screening results.  Instead, the selection criteria were modified to include known structural 
features that were shown earlier to promote ERβ binding.36  Screening results on ERα were used 
as co-selection criteria.   
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Figure 20. Preliminary SAR presented on compound 37d (CC1-243) from ER screens of the second 
generation library. 
 
The biphenyl core (site A) was shown to be beneficial for the selective targeting of ERβ.36  
Young et al. used GEN as a lead structure in the search for new ERβ selective ligands.  The 
phenolic group in GEN was acting as an A ring mimic in estradiol and was preserved as the key 
pharmacophore element.  Young et al.  chose the biphenyl core in order to simplify the 
chromenone moiety in GEN.36  In addition, the biphenyl was a synthetically easily accessible 
core through Suzuki couplings and a large number of substituted phenyl precursors was readily 
available.  4’-Hydroxy-biphenyl-carbaldehyde oxime derivatives were synthesized with varied 
substituents. 36  It was shown that placing fluorine and/or chlorine on the biphenyl core, while 
keeping the phenol OH group, provided selective agents for ERβ, with more then 10 fold 
(compound 13), and up to 40-fold in some cases (compound 9), increased binding affinity for the 
receptor (Figure 5).  
 
The biphenyl core was present in the following second generation library members, allylic 
amides (33b, 34v, 34w, 36f, 36g and 36m) and C-cyclopropylalkylamides (37d, 37e, 37f, 37g, 
37i, 37j, 37k, 37o, 37p, 39a, 39b and 39c) (Table 6).  Biphenyl C-cyclopropylalkylamide 37d 
(CC1-243) was selected as the lead since it was the most efficient agent as measured by the 
percent of displacement of E2 at ERβ (Table 6) and also failed to meet the hit criteria on ERα.  
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Figure 20 ilustrates sites on 37d used in the SAR discussions.  Based on the screening data on 
both receptors, the initial SAR model is discussed below.  
 
Only one biphenyl core-containing library member 39a satisfied the criteria for hit selection in 
the screen on ERα (Table 6).  However, this compound failed to inhibit estradiol-stimulated 
growth of MCF-7 cells (GI50 > 50 μM; Table 5).  Replacement of the biphenyl with smaller a 
substituted aryl ring, p-chlorophenyl in 39c, preserved the displacement activity on ERα and the 
cell based activity was recovered (GI50 = 5.7 ± 2.0 μM, Table 5).  This result indicated the 
biphenyl core was less tolerated on ERα if combined with larger substituents on the nitrogen 
(39a).  Therefore the possibilities were opened for the search for ERβ selective agents from this 
series.  In addition, based on the screening results, when the biphenyl present in 37d was 
replaced with a phenyl ring while the remaining structure was kept constant (37b), the activity at 
ERβ dropped to insignificant levels (<10% displacement) while the activity on ERα slightly 
improved (Table 6).  Changes in site B (Figure 20) also led to similar detrimental consequences 
in displacement efficiency on ERβ.  A phenylamide was the best tolerated moiety for activity at 
the ERβ (37b), while other rings were much better tolerated by the ERα.  When the simple 
phenylamide on compound 37d was replaced by a biphenylamide moiety (compound 37g), a 
complete loss of activity at the ERβ resulted.  It was concluded that only one biphenyl core was 
necessary and that increasing the size of the ligand is detrimental for the activity on ERβ.  When 
the size of the alkyl chain (site C) was increased to cyclohexyl (compound 37p) while keeping 
the rest of the molecule 37d unchanged, the activity at both receptors was lost.  Therefore, site C 
was kept unchanged in the further synthetic elaborations.  
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Sites A and B were chosen for further elaboration. The synthesis was guided around the biphenyl 
core and the amide linkage.  The earlier results of discovery library screening suggested that a 
cyclopropane ring is important for the cell based activity.  The screening data on both receptors 
gave some indication that this was still holding true. When the activity of biphenyl-C-
cyclopropylalkylamide 37d was compared to that of compounds with the biphenyl core and 
lacking the cyclopropane ring (36f, 36g and 36m), the activity on both receptors was reduced 
(Table 6).  However, these comparisons were not sufficient to give a final determining 
conclusion, simply for the lack of pure analogue of 37d where only the cyclopropane ring was 
replaced by a double bond.  The most significant indication for the importance of the 
cyclopropane ring lies in the finding that majority of active library members on both receptors 
did contain a cyclopropane ring.  
 
In conclusion, the second generation library was tested in biochemical assays in vitro and in 
human breast cancer cells with the goal of finding ERα antagonists with improved properties 
over the lead structure 26a (CK1-183) identified from the first generation library (section 2.1).  
The library was also tested in the hopes of finding new scaffolds for ERβ targeting agents.  The 
second generation library was screened at ERα and ERβ using a fluorescence polarization-based 
homogenous displacement assay (adapted from kits purchased from Panvera).60  The collected 
displacement data was used to develop an SAR model (2.1.7) that served towards the design and 
synthesis of agents with further improved activity and modest selectivity for ERβ (see section 
2.2.2 for details). 
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The second generation library gave three new ER tarageting agents (37a, 37c and 39c) with cell 
activity in the lower micromolar range, supporting the hypothesis that C-cyclopropylalkylamides 
are novel ER targeting scaffolds.  However, the second generation library failed to give 
compounds with potencies in the submicromolar range both in vitro and in cells.  The library was 
designed with the lack of the classical ER pharmacophore – a phenolic ring – that would drive 
the agent into the pocket and form crucial hydrogen bonds as does the estradiol A ring with Glu 
ERα353/ERβGlu305 and ERαArg394/ERβArg346.  This lack of classical pharmacophore 
features was addressed in the follow up, limited size series of biphenyl C-cyclopropylalkylamide 
analogues.  
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2.2. Biphenyl C-Cyclopropylalkylamide Analogues of 37d (CC1-243)   
 
Based on the initial SAR from the fluorescence polarization based screening on ERα and ERβ 
and the published SAR of biphenyl agents selective for ERβ36, six analogues of compound 37d 
(CC1-243) were designed and synthesized (69a, 70b-d, 71 and 72; Figure 21).  Attempts were 
made to improve the in vitro and cellular potency, and preferably selectively target ERβ. 
 
The biphenyl core was supplied with a key phenolic 4’-OH group to promote hydrogen bonding 
with ERβGlu305 (ERαGlu353) and ERβArg346 (ERαArg394).  A fluorine substituent was 
chosen based on published SAR for known biphenyl agents36 because this one substituent was 
able to provide the selectivity over a non-substituted biphenyl 11-fold (compound 13, Figure 5). 
Although, additional substitutions did provide higher selectivity, 36 at this stage of the biphenyl-
C-cyclopropylalkylamide design, fluorine was considered enough to support the proof of 
principle and test the importance of the biphenyl core in the C-cyclopropylalkylamide series.  
The alkyl chain was kept simple and small in order not to compromise already existing activity 
on ERβ (see detailed SAR discussions in section 2.1.7).  The phenylamide was changed into a 
smaller acetylamide or simply removed.  These changes were designed to further decrease the 
size of the C-cyclopropylalkylamide ligand and therefore, hopefully, improve selectivity for 
ERβ.  
 
Six analogues of biphenyl C-cyclopropylalkylamide 37d (CC1-243) were synthesized (Figure 
21), and tested in a fluorescence polarization-based assays on both ERs as well as for inhibition 
                                                                                                                                
70 
of E2-induced proliferation of MCF-7 breast cancer cells.  The final goal of the design was to 
develop a dual agent, agonist on ERβ and antagonist (or inactive) on ERα.  Preliminary synthetic 
efforts and biological evaluation are presented, and the rationale behind the dual agent design 
and its potential use are discussed in the future directions section.  Analogues 69a, 70b-d, 71 and 
72 were therefore synthesized and tested.  The synthesis and biological evaluation of these third 
generation C-cyclopropylalkylamides are presented in the following sections.  
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Scheme 5. Synthesis of biphenyl oxime 13. 
 
2-Fluoro-4'-hydroxybiphenyl-4-carbaldehyde oxime (13)36 was synthesized to serve as a positive 
control and as a representative compound containing the biphenyl core known to target ERs.  
The originally reported synthetic approach36 for this compound was modified, resulting in an 
improved yield (42%).  The palladium catalyst trans-(Cy2NH)2Pd-(OAc)2 (DAPCy) was recently 
developed by Boykin et al.61 for Suzuki couplings62 in dioxane at room temperature.  The 
catalyst63 was easily prepared as yellow crystals from palladium (II) acetate and 
dicyclohexylamine in dioxane at room temperature.  As reported, the catalyst was stable at room 
temperature and under no protection from air for up to four months.  Suzuki coupling using 
DAPCy gave the desired biphenyl aldehyde 65a in 70% yield.  The aryl methyl ether was 
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removed by a standard procedure using BBr3 at low temperature and the resulting deprotected 
aldehyde, after simple basic aqueous work up, was submitted to the next step without further 
purification.  Oxime 13 was formed in 42% yield over two steps by treating the aldehyde 66 with 
hydroxyloxime hydrochloride36 in methanol at room temperature (Scheme 5).  
 
 
 
 
2.2.1. Synthesis of Biphenyl C-Cyclopropylalkylamides 
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Scheme 6. Synthesis of phosphinoyl protected biphenyl C-cyclopropylalkylamide precursors.  
R1=Me (63a), R1=OBn (63b); R2=F (64a), R2=H (64b); R1=Me, R2=F (65a, 67a, 68a); R1=Bn, R2=F (65b, 67b, 
68b); R1=Bn, R2=H (65c, 67c, 68c). 
 
Suzuki coupling of commercially available benzyl- or methyl-protected 4-
hydroxybenzeneboronic acid (63a) to 4-bromobenzaldehyde (64a) using the DAPCy catalyst 
developed by Boykin61,63 provided biphenyl aldehydes in good to excellent yields (65-88%).  
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Imine formation using titanium (IV) chloride as the Lewis acid catalyst initially gave 
phosphinoylimine 67a in poor to moderate yields (30-47%).52  Changing the work up to a fast 
filtration over a pad of silica gel and washing with ethyl acetate significantly improved the yields 
(80%) of the phosphinoylimines 67b-c.64   
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Scheme 7. CC1-243 analogues derived from a common precursor. 
 
One-pot hydrozirconation-transmetallation-aldimine addition in dichloromethane in the 
microwave (100 oC, 300 W, 10 min) immediately followed by cyclopropanation in the presence 
of excess of diiodomethane at room temperature (16-20 h) gave the phosphinoyl-protected 
biphenyl C-cyclopropylalkylamides 68a-c in moderate yields (43-66%), (Scheme 6).  Acidic 
deprotection followed by acylation gave the final product 69a (61%) or benzyl-protected 
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compounds 69b-d (22-75%).  Benzyl ethers were easily removed by hydrogenolysis under 1 atm 
of H2 in the presence of palladium hydroxide on carbon (Scheme 7). 
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Scheme 8. Synthesis of the lead structure 37d (CC1-243). 
 
The synthetic schemes (Scheme 7 and Figure 21) presented above allowed for diversification in 
two ways.  Substituents on the biphenyl core were attainable by changing the substitution on aryl 
boronic acid and aryl bromide coupling partners.  The amide linkage also allowed for 
diversification by changing the acylation coupling partner, as done previously in the synthesis of 
the second generation library.  After the acidic deprotection step, the amine salt could be coupled 
without further purification in the presence of DMAP with diverse acyl chlorides, carbamoyl 
chlorides and sulfonyl chlorides.52   
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Figure 21. Structures of biologically tested biphenyl C-cyclopropylalkylamides (37d, 69a, 70b-d, 71, 72) and 
control oxime (13). 
 
In this initial exploration around lead structure 37d (CC1-243), only six analogues were made, 
one at a time.  For deprotection and acylation steps, reactions were performed in parallel using a 
Bradley Greenhouse and purified individually by column chromatography.  The lead compound 
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37d (CC1-243) was resynthesized following the literature procedure with small modifications,52 
Scheme 8.  The cyclopropanation step that provides the phosphinoyl-protected biphenyl C-
cyclopropylalkylamide 75 was performed in the presence of a large excess of diiodimethane (10 
eq) and the reaction mixture was kept at room temperature overnight to give the product in 36% 
yield.  Deprotection and acylation gave the final product 37d in 40% yield. Biological evaluation 
of the biphenyl C-cycopropylalkylamides, shown in Figure 21, as ER targeting agents and 
preliminary SAR is discussed in greater detail below. 
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2.2.2. Evaluation of Biphenyl C-Cyclopropylalkylamides for in vitro Binding to the ERα 
and ERβ 
 
Biphenyl C-cyclopropylalkylamide 37d (CC1-243), the hit found in the second generation 
library screen on ERβ ligand displacement assays (2.1.6.3), was only modestly active at the ERs, 
with the highest concentration tested (25 µM) giving only 50% displacement of fluorescent 
estradiol on both proteins (data not shown).  This was attributed to the lack of a key phenolic OH 
to orient the ligand into the binding pocket of the ERs, necessary for key hydrogen bonding with 
ERβGlu 305 (ERαGlu353) and ERβArg346 (ERαArg394), the compound's high ClogP value 
(7.6) and its poor water solubility.  Six analogues were synthesized to improve on its activity.  
Aryl substituents, such as 4’-OH, 4’-OMe and 2-fluoro groups of the biphenyl core, were 
introduced and the amine substituent was changed from phenyl to smaller or larger groups or left 
unprotected (Figure 21).  The biological evaluation of these analogues is discussed below in 
detail.  
 
Biphenyl C-cyclopropylalkylamides (69a, 70b-d, 71, 72) and the control compound 3-fluoro-4'-
hydroxybiphenyl-4-carbaldehyde oxime (13) were tested in a commercial assay (Panvera) 
adapted to 384-well plate format for their ability to displace a fluorescent E2 derivative (ES2) 
complexed with ERα (Figure 22) and ERβ (Figure 23).  The recombinant human ERs were 
incubated with ES2 and then treated with test agents.  After 1-2 h, the fluorescence polarization 
was measured. ES2 bound to ER protein gave a high fluorescence polarization.  In this assay, the 
presence of a displacing ligand causes a decrease in the fluorescence polarization.   
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Figure 22.  Biphenyl C-cyclopropylalkylamides tested in a displacement assay on ERα 
 
Figure 23.  Biphenyl C-cyclopropylalkylamides tested in a displacement assay on ERβ 
The displacement assays were performed with ligands present in the concentration range of 1.6 nM – 25 μM.  
Concentration-dependence curves on both receptors were constructed from the one site competition best-fit curves 
using Graph Pad Prism 4 software. The data is presented as mean % displacement ± SD, (N=2). 
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The data shown in Figure 22 and Figure 23 is representative of experiments run in duplicate, 
from a minimum of two separate experiments.  The data is presented as percent displacement 
(%I) ± SD.  The estimated one site competition IC50 values are presented in Table 7.  E2, RAL 
and GEN were used as standards in each run.  The known biphenyl oxime 13 was used as a 
positive control and gave comparable IC50 values to those found previously in radioactive ligand 
binding assays.36  
Table 7. Biphenyl C-cyclopropylalkylamides tested in displacement assays on ERs. 
 
Compound ERα IC50 (nM) ERβ IC50 (nM) ERβ/ ERα 
E2 1.0 1.0 1 
RAL 13.1 12.5 1 
GEN 403 13 31 
13 888.1 43.5 20 
69a >25000 >25000 NA 
70b 4300 2200 2 
70c >25000 >25000 NA 
70d >25000 22700 NA 
71 >25000 >25000 NA 
72 >25000 6700 >4 
The displacement assays were performed with test compounds present in the concentration range of 1.6 nM – 25 μM 
and controls (E2, RAL and GEN) present in the range 0.16 nM – 5 μM.  Concentration-dependence curves on both 
receptors were constructed and IC50 values were calculated from the one site competition best-fit curves using Graph 
Pad Prism 4 software. The selectivity ratios were caluculated by dividing the IC50 value on ERα by the IC50 value on 
ERβ.  
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2.2.3. Docking studies 
 
Docking studies using the CAChe suite of algorithms were performed with a molecular model of 
the ERβ LBD obtained from X-ray crystallographic coordinates and were conducted to compare 
the binding mode of biphenyl C-cyclopropylalkylamide 72, with biphenyl oxime 13.  The 
coordinates for the binding pocket from structural studies of human ERβ-LBD in complex with 
GEN (1QKM)65  were downloaded from the Protein Data Bank.  GEN was used first as a 
standard to validate the docking system.  GEN was redocked into the pocket by holding the 
residues of the protein fixed and allowing the ligand to be flexible.  The orientation and 
hydrogen bonding were close to that in the crystal structure (data not shown).  The biphenyl 
oxime structure 1336 was superimposed on that of GEN in the ERβ-LBD binding pocket, the 
model of GEN was removed, and oxime 13 was then docked into the pocket by holding the 
protein rigid and the ligand flexible. Figure 24 shows the binding energy (–46.7 kcal/mole) for 
this interaction.  The ligand adopted similar orientation to that of GEN in the pocket.  The 
phenolic OH of 13 formed a hydrogen bond with Glu474 and the oxime OH formed a hydrogen 
bond with His475, the same residues with which GEN forms hydrogen bonds (Figure 24).  
 
An analogue of compound 37d (CC1-243), the free amine 72, was superimposed on the model of 
docked biphenyl oxime 13 and then after removal of the oxime ligand the model of the ligand 
was docked under the same conditions outlined above.  Interestingly, the alkyl chain of 72 slid 
deep into the back wall of the pocket and formed favorable hydrophobic interactions with the 
side chain of Met336 (Figure 25).   
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Figure 24. Biphenyl oxime 13 docked into the GEN binding pocket of ERβ-LBD (BioMedCAChe). 
 
This finding indicated the possibility that compound 72 might be selective for ERβ.  The docking 
exercise also showed compound 72 orients in the GEN pocket in the same way as the tested 
oxime, including a hydrogen bond with Glu475.  However, the prediction did not hold true as the 
behavior of compound 72 in the displacement assays was poor.  It was anticipated that removal 
of the bulky phenyl ring on the amide would promote more favorable binding to both receptors.  
This assumption was comfirmed in the molecular docking exercises.  In the displacement assays, 
however, compound 72 did not interact with ERα to displace the fluorescently labeled estradiol, 
even at the highest concentrations used (>2 µM).  Compound 72 showed competitive activity on 
ERβ (6.7 µM).  This was a disappointing result considering the activity of this compound in 
                                                                                                                                
81 
MCF-7 cells, discussed in the next section.  The encouraging finding was the selectivity for ERβ 
in this assay, even though it was at best very modest.  
 
Figure 25. Biphenyl C-cyclopropylalkylamine 72 docked into GEN binding pocket of ERβ-LBD 
(BioMedCAChe). 
 
 
2.2.4. Biphenyl C-cyclopropylalkylamides Tested on Breast Cancer Cells 
 
A new model for simultaneous targeting both ERs in breast cancer is proposed and discussed in 
detail in section 4.2.  The above described biphenyl C-cyclopropylalkylamides were tested for 
inhibition of estradiol-induced proliferation of MCF-7 human breast cancer cells in order to 
identify potential antiestrogens.  Three analogues of compound 37d (CC1-243) were shown to 
inhibit E2 induced proliferation of MCF-7 cells.  Data presented in Figure 2666 are means + SD 
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(N = 4).  Statistical Graph Pad 4 software was used to estimate GI50 values from non-linear best 
curve fit (p=0.9 > 0.05): RAL (65.4 nM), 13 (20.9 μM), 70b (500 nM), 70c (13.5 μM) and 72 
(400 nM) and.  The MCF-7 cell based evaluation was performed by Miranda Sarachine.   
 
 
Figure 26. Biphenyl C-cyclopropylalkylamides tested for inhibition of E2 stimulated growth of breast cancer 
cells.66 
 
RAL was used as a positive control.  The MCF-7 antiproliferative assay is usually the first-used 
cell-based test in search for ERα antagonists.  The biphenyl oxime 13 had a high GI50 value 
(20.9 µM), not a surprise considering that this compound was designed as an agonist for both 
receptors.36    The desired compound should compete with estradiol at ERβ with good selectivity 
and yet act as an antagonist, or be inactive, on ERα.  However, the MCF-7 antiproliferative 
assay is an indirect measure of ERα antagonism and was used here only as a first cell-based test 
of these agents.  Surprisingly, two compounds, 70b and 72 showed GI50 values in the 
submicromolar range, inhibiting estradiol-induced MCF-7 proliferation.  However, this is not 
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sufficient evidence to declare these compounds as antiestrogens.  Compound 70b was found to 
interact with both receptors in vitro in the fluorescence polarization-based displacement assay 
(Table 7).  However, the IC50 values of this compound were significantly higher in the 
fluorescence polarization assay as compared to its GI50 determined in MCF-7 cells, indicating 
that the compound likely exerted its cell growth-inhibitory actions by a mechanism that did not 
involve the ERα.  In addition, the second-most active analogue in MCF-7 cells, compound 72, 
showed no interaction with ERα in the fluorescence polarization-based assay and only a modest 
interaction with ERβ.  
 
 
2.2.5. SAR of Biphenyl C-Cyclopropylalkylamides on ERα and ERβ 
 
The biphenyl core36 has recently been extensively explored for the selective targeting of ERβ. 
Biphenyl oxime 13 was used as a model agent.  In the fluorescence polarization-based 
displacement assays, this compound showed 20-fold selectivity for ERβ.  The attempt was made 
to develop agents that would selectively target ERβ as agonists and at the same time act as 
antagonists on ERα.  It was disappointing to find that the biphenyl C-cyclopropylalkylamides 
synthesized had modest to poor activity in the ER displacement assays.  One compound, 70b, 
had low micromolar activity, which was achieved by simple modification of the original hit 
CC1-234 through introduction of one phenol group and one aryl fluorine.  When the phenol was 
masked as a methyl ether (compound 69a), the activity at both receptors was lost, indicating that 
the phenolic OH was critical for ER binding.  When the benzamide in 70b was replaced by the 
bulky and lipophilic phosphinoyl group, the activity was also lost, showing that the size was 
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important.  It was suspected that by changing the benzamide to an acetamide (compound 70d), 
activity at both ERs in the displacement assays would be improved simply by the decreased size 
of the agent.  Unfortunately, the change from benzamide to acetamide resulted in complete loss 
of activity on both receptors, yielding a compound with IC50 values of >25 µM (Table 7).  
 
From the published literature on agents that have been found to be selective for ERβ, it can be 
noted that the most potent and most selective agents are small in size and have low ClogP values 
(2-4.5 on average).  In an effort to further decrease the size and the ClogP value of our 
analogues, the amide on the biphenyl C-cyclopropylalkylamide was replaced by a free primary 
amine and analogue 72 was synthesized.  It was anticipated that this compound would have good 
potency at the ERβ and show selectivity.  This compound did not interact with ERα in such a 
way that was measurable by the competition with fluorescently labeled estradiol, and it competed 
with labeled estradiol on the ERβ only modestly with an IC50 of 6.7 µM.  However, this 
compound showed significant inhibitory activity against MCF-7 cell growth.  This inhibitory 
activity of 72 is likely derived from either an active metabolite of the aliphatic primary amine, or 
from activation through alternative pathways that would lead to cell growth inhibition without 
binding to the ERs.  It is possible that this agent could bind to the ER, but in a way that would 
not interfere with the interaction of labeled estradiol.  It might also interact with the coactivator 
binding domain of the ER, resulting in the inhibition of MCF-7 cell growth by preventing the 
transcriptional activation of ERα through interference with coactivator recruitment.  The 
fluorescence polarization-based displacement assay used is unable to detect this kind of possible 
interaction of test agents with the ERs.  A recent report suggests that bi- and terphenyls can 
provide a backbone that mimics a peptide alpha helix and inhibit the interaction of ERs with 
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coregulators. 67  This report proposed their use to block coactivator recruitment and therefore 
inhibit breast cancer cell proliferation.  In this vein, future studies could explore the agents 
presented here for their ability to target the coregulator binding domain.  The fact that 
introduction of the OH to the biphenyl core did not result in significant improvement of the 
biological activity, as well as the presence of an aliphatic alkyl chain on the compounds, could 
support the notion that the coregulator binding site is an alternative target for the binding of these 
agents.  This hypothetical mechanism of action can be tested in future explorations of the 
biological activity of this series.  Briefly, one possible in vitro test for the coregulator binding 
agents on ERs is proposed in the future directions section.  
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3. CONCLUSIONS 
 
The work presented here resulted in the identification of new scaffolds from libraries of allylic 
amides, C-cyclopropylalkylamides and homoallylic amides for targeting ERs.  Cell-based 
screening for agonists and antagonist in transcriptional activation assays of the ERα at a classical 
ERE identified one new antagonist, C-cyclopropylalkylamide 26a (CK1-183).48  C-
Cyclopropylalkylamide 3a was characterized as an antagonist on ERα when it was found to 
inhibit E2-induced ERE-tk-Luc transcription (IC50 = 11 ± 2 μM) and MCF-7 (GI50 = 12 ± 4 μM) 
cell proliferation in a concentration-dependent manner (Figure 9 and Figure 10, respectively).  
To further confirm this finding, antiproliferative activity of 26a (CK1-183) against the ER-
negative MDA-MB231 human breast cell line was examined, 26a (CK1-183) was found to be 
inactive (GI50 > 50 μM, Table 2).  However, this compound was able to displace fluorescently 
labeled estradiol at ERα to modest extent.  Furthermore, biological activities of the individual 
enantiomers of compound 26a (CK1-183) were not statistically different (Figure 9 and Figure 
10).48  Molecular docking studies using the CAChe suite of algorithms indicated that the 
phosphinoyl group of 26a (CK1-183) capped the binding pocket and probably in that way 
interfered with helix 12 movement, while the remainder of 26a (CK1-183)'s, sulfonyl-carbamate 
moiety bound deeper into the raloxifene binding cleft and interacted with residues at helices H3, 
H6 and H11, suggesting a partial or full antagonist binding mode.   
 
Overall, the unusual structure of 26a (CK1-183), its ability to antagonize E2 in the cell-based 
assays, and its modest ability to displace E2 in the binding pocket suggested new avenues for 
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SERM design.  C-cyclopropylalkylamide 26a (CK1-183) served as the lead structure for further 
synthetic efforts.  An initial set of modifications targeted the N-acyl segment of 26a (CK1-183), 
but these changes led to no improvement in the antiproliferative activity in MCF-7 cells.  This 
was a disappointing result, but it did show that changes in the phosphinoyl group protected 
portion of the molecule were necessary for two reasons: (a) to increase drug like properties and 
(b) to explore in greater detail SAR around the C-cyclopropylalkylamide core.   
 
A second generation library of allylic amides and C-cyclopropylalkylamides was designed as a 
focused library around 26a (CK1-183) as a lead structure to explore the SAR.52  Initial goal of 
this library synthesis was to find more potent ERα antagonists in breast cancer cells.  However, 
the library was tested at both receptors and it was interesting to find hits on both ERs.  Initial 
screening on ERα identified three compounds 37c, 37a and 39c that had somewhat improved 
activities in MCF-7 cells as compared to lead structure 26a (CK1-183) (Figure 17).  The GI50 
values of the hits were in low micromolar range, see section 2.2.4.  It was very important to 
finAa key finding was that that these new compounds had significantly smaller aromatic portions 
compared to the large phosphinoyl group of 26a (CK1-183), and the sulfonamide group was 
present only in one of them (39c).  In addition, all three contained a simple alkyl chain on the 
cyclopropane ring.  Most importantly, all compounds that showed significant activity at ERα 
from the second generation library were C-cyclopropylalkylamides, whereas analogues with a 
double bond instead of the cyclopropane showed no activity in breast cancer cells.  The 
cyclopropane ring appeared to be important for interaction with both ERs.   
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When the second generation library was screened in flurescence polarization displacement assay 
on ERβ, biphenyl C-cyclopropylalkylamide 37d was identified as a hit.  This compound was also 
interesting due to the fact it contained the biphenyl core, explored previously by the Wyeth 
research group and found to be important for ERβ selectivity.35,36  Six analogues of compound 
37d were synthesized and tested in displacement assays and for inhibition of E2 induced 
proliferation of breast cancer cells.  The most promising compound in this limited size series was 
70b.  Biphenyl C–cyclopropylalkylamide 70b showed two fold selectivity for ERβ in 
displacement assays, but with IC50 values on both receptors were in the low micromolar range 
(Table 7).  Surprisingly, this compound showed submicromolar activity in inhibiting estradiol 
induced MCF-7 cell proliferation.  This finding suggested alternative mechanisms for how this 
compound might act as an antiestrogen and further studies are needed.  An even larger surprise 
were the assay results of compound 72. This compound was an analogue of 70b that lacked the 
phenylamide and contained instead a free amine.  When docked into the GEN binding pocket of 
ERβ, compound 72 showed interaction with key amino acids through hydrogen bonding.  The 
alkyl chain on the cyclopropane was oriented deeper into the pocket and showed promising 
hydrophobic interactions with Met336.  These findings from modeling studies were suggesting 
higher potency and selectivity of this compound over the lead 37d.  Disappointingly, compound 
72 did not show any activity in the displacement assay on ERα, and very modest activity on 
ERβ.  However, in MCF-7 cells this compound was most active inhibitor of cell proliferation of 
all libraries compounds tested in this work.  The IC50 value of 72 at 400nM in MCF-7 cells 
suggested was very encouraging finding; however, a plethora of alternative mechanisms than 
direct antagonism on ERα is possible, some of which are discussed in section 4.   
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In summary, a new class of antiestrogens was discovered.  The selectivity of novel SERMs and 
the selectivity of these compounds for ER subtypes was investigated and addressed.  The goal 
was to improve the potency and subtype selectivity by using the uniqueness of C-
cyclopropyalkylamides as ER targeting agents.  Novel biphenyl structures for targeting ERs were 
discovered, opening new avenues for SERM design and targeting both estrogen receptors.   
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4. FUTURE DIRECTIONS 
 
4.1. Role of ERβ in Breast Cancer 
 
The relationship between tamoxifen resistance and ERβ expression and function is not clear.  
However, a limited size study in breast cancer patients’ samples suggests that low levels of ERβ 
expression predict tamoxifen resistance.68  In a more detailed clinical study, ERβ and coregulator 
expression were correlated with tamoxifen resistance.69  These studies point out that ERβ may 
play a significant role in breast cancer.  Whether that role could be targeted for SERM design 
with improved pharmacological profile over tamoxifen remains an open question.  
 
 
4.2. Hypothesized Model for Targeting ERβ in SERM Resistant Cancer 
 
Clinically, tamoxifen has been used as a therapy of choice not only for its effectiveness in 
stopping breast cancer proliferation and increasing survival of patients, but for its relatively mild 
side effects compared to other chemotherapy.  The major problem with tamoxifen use in breast 
cancer therapy is the development of resistance.  When tamoxifen therapy is continued beyond 
five years, tamoxifen becomes more likely to promote a clonal selection of metastatic breast 
cancer resistant to tamoxifen.  De novo resistance is usually attributed to the loss or absence of 
estrogen receptor.1  Acquired resistance develops in approximately 50% of ER+ patients that 
initially respond to tamoxifen therapy and leads to disease progression and death.  In acquired 
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tamoxifen resistance two different but closely related phenotypes are known: tamoxifen 
unresponsiveness and tamoxifen stimulation of breast cancer proliferation.  In many instances 
when aromatase inhibitors are given as secondary endocrine therapy after tamoxifen failure, 
patients respond well.  This is not a surprise since acquired tamoxifen resistance usually is not 
attributable to estrogen receptor loss and patients are still considered ER+.  As an antiestrogen, 
tamoxifen can affect the negative feedback in the pituitary-ovarian axis and that can result in 
increased circulatory levels of estrogens and compromise tamoxifen effectiveness.70  This 
mechanism in resistance development can be applied to all antiestrogens, but what makes 
tamoxifen specifically interesting is its switch in pharmacological action from an antagonist at 
the ERα to an agonist on a cellular level.  It has been shown that MCF-7 breast cancer cells, 
upon prolonged treatment with tamoxifen are likely to begin to proliferate.71  This in vitro 
finding correlates with the clinical data and presents MCF-7 tamoxifen resistant cells as a good 
model to study acquired tamoxifen resistance.  The mechanism of a tamoxifen antagonist – 
agonist switch in breast cancer is not clear.  Breast cancer cells T47D that are dependent on 
estradiol for proliferation continued to grow in the presence of tamoxifen when PKA was 
activated.  It has been proposed that phosphorylation of Ser305 on ERα by protein kinase A 
(PKA) induced Tamoxifen to switch from an antagonist to agonist.  It was found that this 
phosphorylation in the hinge region prevents bound tamoxifen to perturb ERα and alter 
coactivator recruitment, therefore allowing tamoxifen to bind as an agonist and lead to ERα-
dependent transactivation.72  Additional mechanisms were proposed to lead to tamoxifen 
resistance.  Osborne et al. 73 have shown that in patients with breast tumors HER2/neu positive 
and high levels of AIB1 (amplified in breast cancer 1) protein correlate with a poor outcome of 
tamoxifen therapy.  They proposed using AIB1 and HER2/neu expression as potential markers to 
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predict tamoxifen therapy efficacy.  Osborne et al. also proposed that high expression levels of 
AIB1 would promote tamoxifen agonism.  Whether AIB1 is upregulated in tamoxifen–
stimulated tumors is not known.  Furthermore, AIB1 activation through phosphorylation could 
be another possible pathway that increases the AIB1 stimulation of ERα transcriptional 
activation.  
 
It is evident that there are several mechanisms that could lead to ERα transcriptional activation 
in the presence of an antagonist, such as tamoxifen, in SERM resistant cells.  The proposed 
model suggests taking advantage of ERβ inhibitory action on ERα, and also that ERβ targeting 
with an agonist is not stimulatory in breast cancer cells.  The model is shown in 
 Figure 27.  ERβ agonistic/ERα antagonistic agents are envisioned as being able to activate ERβ, 
leading to indirect inhibition of ERα and at the same time antagonize ERα.  The result would be 
double inactivation of ERα transcriptional activation and inhibition of tamoxifen-stimulated 
breast cancer progression.   
 
 Figure 27. Hypothesized ideal SERM that targets both ERs. 
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Agents with these highly advantageous properties are currently not available.  In addition, 
screening in vitro test for the desired type of agents is not available and its design is briefly 
discussed bellow.  
 
I propose here an assay that would at the same time test agents for displacement on both ERs and 
coregulator binding intereference.  The assay would entail dual color fluorescence polarization.  
Fluorescence polarization (FP) assays can be used to directly measure the interaction between a 
protein (not labeled) and a labeled ligand or peptide. The literature gives a precedent for using 
dual color fluorescence polarization in genotyping assays.74 To the best of my knowledge, dual 
color fluorescence polarization has not been used for testing nuclear receptor-targeting agents. In 
the new assay, simultaneously recombinant human ERα or ERβ would employ fluorescently 
labeled estradiol (E2-FITC, green) and a labeled coactivator peptide (LXXLL-Rhodamine, red). 
In a recent study, the coactivator-derived peptide 685EKHKILERLLKDS697 was shown to be 
recruited by agonist-bound ERα, ERβ and TR,75 making it a good candidate for the dual color 
FP assay. In the assay, FP will be measured in the green and red channels. When agonist is 
added, the expected result is low green polarization (displaced E2-FITC) and high red 
polarization (receptor-recruited peptide); when antagonist is added, low polarization will occur in 
both channels (displacement of E2 and no peptide recruitment); when a coregulator domain 
binding competitor is added, high polarization in the green (no displacement of E2) channel and 
low polarization in the red (displacement of the labeled coregulator peptide) channel will occur. 
The assay and the agents as described above are believed to open a new avenue for SERM 
discovery and design. 
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5. EXPERIMENTAL SECTION 
 
5.1. Chemistry 
 
5.1.1. General Experimental Procedures 
 
All reactions were performed in flame dried round bottom flasks under a nitrogen atmosphere 
unless indicated otherwise.  Microwave irradiation was performed in microwave vessels (10 mL 
tubes) in either a CEM Discoverer or an Emrys Optimizer (Biotage) microwave reactor as 
indicated.  Solvents were dried by distillation: CH2Cl2 and Et3N were distilled over CaH2; THF 
was distilled over sodium benzophenone ketyl; toluene was purified by filtration through 
activated alumina; EtOAc and hexanes were distilled prior use.  Anhydrous ether and dioxane 
were purchased from Aldrich Chemical Co. and used without further purification.  1-Hexyne, 3-
butyn-1-ol, 3-hexyne, 3-octyne, 4-benzyloxybenzeneboronic acid, 4-bromo-2-
fluorobenzaldehyde, 4-bromobenzaldehyde, 4-chlorobenzenesulfonylamide, 4-methoxy-
benzeneboronic acid, 4-methylbenzenesulfonylisocyanate, BBr3 (1 M solution in hexanes), 
benzaldehyde, benzenesulfonylisocyanate, biphenyl-4-carbaldehyde, chlorosulfonylisocyanate, 
Cp2ZrCl2, Dabco®, dicyclohexylamine, diisopropyl azodicarboxylate (DIAD), 
diphenylphosphine chloride, diiodomethane, isopropanol, Me2Zn (2 M in toluene), methyl 4-
formylbenzoate, palladium (II) acetate, TBAF, TBDPSCl, tert-butanol, TiCl4 and 
triphenylphosphine were purchased from Aldrich, Acros, TCI or Lancaster Synthesis.  Reactions 
were monitored by TLC analysis (EM Science pre-coated silica gel 60 F254 plates, 250 µm 
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thickness) and visualized with a 254 nm UV light, by staining with PAA solution (2.5 mL of p-
anisaldehyde, 2 mL of AcOH, and 3.5 mL of conc. H2SO4 in 100 mL of 19:1 EtOH/H2O) and/or 
staining with Vaughn’s reagent (4.8 g of (NH4)6Mo7O24•4 H2O and 0.2 g of Ce(SO4)2 in 100 mL 
of 3.5 N H2SO4).  All crude products were purified by flash chromatography on SiO2 (Merck, 
pore size 60 Å, particle size 200-400 mesh, for column chromatography) unless indicated 
otherwise.  Chromatography columns were packed dry and equilibrated with the appropriate 
solvent system as noted.  Melting points were determined using Laboratory Devices Mel-Temp 
II and Fisher-Jones Melting Point apparati.  Infrared spectra were determined on a Nicolet 
Avatar 360 FT-IR spectrometer.  1H and 13C NMR spectra were obtained on Bruker Avance 300 
and Varian Mercury 400 instruments at 300 and 75 MHz or 400 and 100 MHz, respectively, in 
CDCl3 unless otherwise noted.  Chemical shifts were reported in parts per million (ppm) using 
the residual solvent signal as an internal standard.76  1H NMR spectra are tabulated as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, qn = quintet, m = 
multiplet, b = broad), number of protons and coupling constant(s).  13C NMR spectra were 
acquired using a proton decoupled pulse sequence with a pulse sequence delay of 3 sec.  Low 
resolution and high resolution mass spectra (MS and HRMS, respectively) were obtained in 
positive ion mode by electron ionization (EI), electrospray ionization (ESI), or by matrix-assisted 
laser desorption ionization (MALDI) using either α-cyano-4-hydroxycinnamic acid or a 
germanium-doped polysilicate (NanoHorizons, Inc.) matrix with either a Micromass Autospec 
double focusing instrument or an Applied Biosystems 4700 MALDI-TOF/TOF-MS.  
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13  
2-Fluoro-4'-hydroxybiphenyl-4-carbaldehyde oxime (13)36 was prepared according to the 
literature procedure36 from the corresponding aldehyde (65a) with some modifications. 3-Fluoro-
4'-methoxybiphenyl-4-carbaldehyde 65a (0.05 g, 0.20 mmol) was dissolved in freshly distilled 
CH2Cl2 (5 mL) under a nitrogen atmosphere, cooled to –78 oC and treated dropwise with BBr3 
(1M in hexanes, 0.5 mL, 0.3 mmol).  The reaction mixture was left to stir at –78 oC for 2h, 
warmed to r.t., and stirred for an additional 3h.  The mixture was poured into an ice-cold 1 M 
solution of NaHCO3 (10 mL) and, while at 0oC, diluted with EtOAc (50 mL).  The solution was 
acidified at 0oC by dropwise treatment with conc. HCl.  The organic phase was separated, dried 
over Na2SO4, filtered and concentrated in vacuo.  The obtained aldehyde (66) was submitted to 
next step without further purification.  The residue was dissolved in absolute MeOH (2.5 mL). 
Hydroxylamine (0.4 mmol), pyridine (0.4 mmol) and 5Å molecular sieves (0.25 g) were added 
and the reaction heated to reflux in a sealed tube for 6 h.  The solvent was removed under high 
vacuo, and the residue dissolved in EtOAc, filtered and concentrated. Purification by preparative 
TLC (1:1 EtOAc/hexanes) afforded 13 (20 mg, 42%) as a colorless solid: 1H NMR (300MHz, 
DMSO-d6) δ 11.51 (s, 1 H), 9.68 (s, 1 H), 8.18 (s, 1 H), 7.72 (t, 1 H, J = 7.7 Hz), 7.55 (d, 2 H, J 
= 8.6 Hz), 7.46 (m, 2 H), 6.82 (d, 2 H, J = 8.6 Hz). The data matched the previously reported.36 
 
                                                                                                                                
97 
 
37d  
N-(R*)-(((1R*,2R*)-2-Butylcyclopropyl)-(4-(phenyl)phenyl)methyl)benzamide (37d)52 (12 
mg, 31%) was obtained from 75 following the literature procedure52 as a colorless solid: m.p. 
176.0-178.0 oC (EtOAc/hexanes);  IR (KBr) 3303, 2955, 2923, 2855, 1631, 1527, 1489, 1076, 
761, 694 cm-1; 1H NMR (300MHz, CDCl3) δ 7.82 (d, 2 H, J = 6.9 Hz), 7.58 (d, 4H, J = 6.9 Hz), 
7.50 (d, 4H, J = 9.2 Hz), 7.44 (t, 1 H, J = 6.1 Hz), 7.34 (t, 1 H,  7.2 Hz),   6.54 (d, 2 H, J = 7.8 
Hz), 4.71 (t, 1 H, J = 8.3 Hz), 1.44 – 1.28 (m, 5H), 1.22 (t, 1 H, J = 7.0 Hz), 1.07 – 0.98 (m, 2 
H), 0.86 (t, 3 H, J = 7.0 Hz), 0.66 (dt, 1 H, J = 8.3, 4.7 Hz), 0.50 (dt, 1 H, J =  7.9, 4.1 Hz); 13C 
NMR (75MHz, CDCl3) δ 166.9, 141.3, 141.1, 140.5, 134.9, 131.8, 129.0, 128.9, 127.54, 127.47, 
127.4, 127.3, 127.2, 57.3, 33.7, 32.2, 24.6, 22.7, 18.2, 14.3, 11.7; MS (APCI) 384 ([M+H]•+, 
100), 263 (30); MS (EI)  383 (M•+, 17), 105 (100), 77 (24); HRMS (EI) calcd for C27H29NO 
383.2249 found 383.2244. 
 
 41  
N-(R*)-(((1R*,2S*)-2-(2-Hydroxyethyl)cyclopropyl)(phenyl)methyl)-P,P-
diphenylphosphinamide (41) (135 mg, 87%) was prepared as described previously.77 1H NMR 
(300MHz, CDCl3) δ 7.90-7.79 (m, 4 H), 7.52-7.47 (m, 2 H), 7.45 – 7.38 (m, 4 H), 7.35 (app d, 2 
H, J = 9.0 Hz), 7.32 – 7.29 (m, 2 H),   4.68 (bs, 1 H), 3.86-3.73 (m, 3 H), 3.59-3.54 (m, 1 H), 
                                                                                                                                
98 
2.18-2.08 (m, 1 H), 1.71 (bs, 1 H), 1.06-0.98 (m, 1 H), 0.90 – 0.85 (m, 1 H), 0.82 – 0.71 (m, 1 
H), 0.38 (dt, 1 H, J = 9.6, 4.8 Hz), 0.33 (dt, 1 H, J = 8.4, 5.4 Hz). 
 
                                                                       45a  
O-tert-Butyl-N-phenylsulfonylcarbamate (45a).  General Procedure A:  A previously 
reported method42 was used with some modifications.  Dry THF (20 mL) and tert-butanol (2.1 
mL, 22 mmol) were mixed in a round bottom flask (50 mL) under an N2 atmosphere and cooled 
to 0 oC.  Benzenesulfonylisocyanate (2.0 g, 1.5 mL, 10 mmol) was added via syringe dropwise 
while stirring at 0 oC.   Stirring was continued until the reaction mixture reached r.t., 
approximately 1 h.  The solvent was removed in vacuo to afford 45a as colorless oil that, after 
crystallization from hexanes, gave a colorless solid (2.8 g, 98%).  m.p. 119-120 oC 
(hexanes/EtOAc); IR (KBr) 3242, 3000, 2981, 2934, 1721, 1476, 1344, 1249, 1145, 1089, 918, 
826, 737, 583; 1H NMR (300MHz) δ 8.02 (d, 2 H, J = 7.7 Hz), 7.65 (t, 1 H, J = 6.3 Hz), 7.57 (d, 
2 H, J = 7.8 Hz), 7.28 (s, 1 H), 1.38 (s, 9 H); 13C NMR δ 144.7, 129.6, 129.4, 128.1, 126.4, 84.0, 
27.8; MS (EI) 242 (M•+-15, 10), 202 (9), 141 (35), 137 (21), 94 (39), 77 (74), 57 (100); HRMS 
(EI) calcd for  C10H12NO4S+ (M-CH3)•+ 242.0482, found 242.0482. 
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                                                                       45b 
O-tert-Butyl-N-phenylsulfonylcarbamate (45b). General method A was used with minor 
modifications.  Dry THF (20 mL) and tert-butanol (1.9 mL, 20 mmol) were mixed in a round 
bottom flask (50 mL) under an N2 atmosphere and cooled to 0 oC.  4-
methylbenzenesulfonylisocyanate (2.0 g, 1.5 mL, 10 mmol) was added dropwise via syringe 
while stirring at 0 oC.   Stirring was continued until the temperature reached r.t. (1 h).  The 
solvent was removed by vacuo to afford 45b as colorless oil that, after crystallization from 
EtOAc/hexanes, gave a colorless solid (2.4 g, 88%).  m.p. 104-105 oC (hexanes/EtOAc); IR 
(KBr) 3358, 3262, 3001, 2979, 2930, 1750, 1597, 1477, 1186, 918, 835, 818, 740, 579; 1H NMR 
(300MHz) δ 7.88 (d, 2 H, J = 7.8 Hz), 7.32 (d, 2 H, J = 8.3 Hz), 2.44 (s, 3 H), 2.17 (s, 1 H), 1.37 
(s, 9 H); 13C NMR δ 144.7, 129.6, 129.4, 128.1, 126.4, 84.0, 27.8, 21.6; MS (EI) 256 (M•+-15, 7), 
216 (34), 212 (67), 197 (34), 155 (39), 108 (51), 91 (100)65 (42), 57 (87); HRMS (EI) calcd for 
C11H14NO4S+ (M-CH3)•+ 256.0638, found 256.0628. 
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45c  
O-Ethyl-N-(4-chlorophenyl)sulfonylcarbamate (45c). 4-Chlorobenzenesulfonylisocyanate was 
prepared in situ using a literature procedure.78 In brief, 4-Chlorobenzenesulfonylamide (2.0 g, 10 
mmol) was suspended in dry chlorobenzene (15 mL) in a round bottom flask (50 mL) equipped 
with a condenser, Dabco® (0.05 g, 0.50 mmol) was added and the reaction mixture was 
vigorously stirred for 10 min. at r.t.  Chlorosulfonylisocyanate (1.6 g, 11 mmol) was added and 
the mixture was heated to 100 oC for 2.5 h.  The reaction mixture was cooled to 0 oC and 
absolute EtOH was added in excess via syringe while stirring at 0 oC. The mixture was left to stir 
for 30 min. while warming up to r.t.  The solvent was removed by vacuo and the residue 
redissolved and purified by flash chromatography on SiO2 (gradient of 4:1 to 7:3 
hexanes/EtOAc) to afford 45c (1.2 g, 42%) as a colorless solid: m.p. 85-86 oC (hexanes/EtOAc); 
IR (KBr) 3225, 3097, 2989, 2909, 1752, 1586, 1445, 1353, 1233, 1161, 1085, 917, 839, 819, 
773, 619 cm-1;  1H NMR (300MHz) δ 7.99 (d, 2 H, J = 8.5 Hz), 7.52 (d, 2 H, J = 8.5 Hz), 4.15 
(quartet, 2 H, J = 7.1 Hz), 1.22 (t, 3 H, J = 7.1 Hz). 13C NMR δ 150.4, 140.9, 136.9, 130.0, 
129.5, 63.5, 14.2; MS (EI) 263 (M•+, 19), 199 (42), 175 (47), 128 (100), 111 (87), 75 (66); 
HRMS (EI) calcd for C9H10ClNO4S 263.0019, found 263.0018. 
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46a  
O-tert-Butyl-N-but-3-ynyl-N-phenylsulfonylcarbamate (46a). General Procedure B, 
Mitsunobu Reaction: A literature procedure56,57 was used with some modifications. O-tert-
butyl-benzenesulfonylcarbamate 45a (2.5 g, 10 mmol) and triphenylphosphine (2.5 g, 10 mmol), 
were dissolved in dry THF (20 mL) in a round bottom flask under an N2 atmosphere, treated with 
3-butyn-1-ol (0.5 mL, 6.7 mmol) and cooled to 0 oC (ice bath).  While stirring at 0 oC, 
diisopropyl azodicarboxylate (DIAD) (1.9 mL, 10 mmol) was added dropwise.  The reaction 
mixture was warmed to r.t. and stirring was continued for 2 h.  The solvent was removed by 
vacuo and the residue redissolved and purified by flash chromatography on SiO2 (9:1 
hexanes/EtOAc) to afford 46a (1.8 g, 62%) as a colorless solid:  m.p. 51.0-53.0 oC 
(hexanes/EtOAc); IR (KBr) 3288, 3062, 3002, 2983, 2940, 2920, 1724, 1452, 1294, 1089, 968, 
844, 746, 658 cm-1; 1H NMR (300MHz) δ  7.90 (d, 2 H, J = 7.3 Hz), 7.57 (t, 2 H, J = 7.2 Hz), 
7.50 (t, 2 H, J = 7.7 Hz), 4.00 (t, 2 H, J = 7.3 Hz), 2.65 (td, 2 H, J = 5.2, 2.5, Hz), 2.01 (t, 1 H, J 
= 2.5 Hz),  1.30(s, 9H); 13C NMR (75MHz) δ 150.7, 140.2, 133.4, 128.8, 127.8, 84.8, 80.4, 70.6, 
45.2, 27.8, 20.1; MS (EI) 253 (17), 170 (70), 141 (44), 94 (17), 77 (51), 57 (100); HRMS (EI) 
calcd for C11H11NO4S 253.0409 (M-C4H8)•+, found 253.0412. 
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46b  
O-tert-Butyl-N-but-3-ynyl-N-(4-methylphenyl)sulfonylcarbamate (46b): According to the 
general procedure B, O-tert-Butyl-4-methylbenzenesulfonylcarbamate 45b (2.2 g, 8.1 mmol), 
triphenylphosphine (2.1 g, 8.1 mmol), 3-butyn-1-ol (0.4 mL, 5.4 mmol) and DIAD (1.6 mL, 8.1 
mmol), afforded 46b (1.2 g, 47%) as a colorless solid:  m.p. 72.0-73.5   oC (hexanes/EtOAc); IR 
(KBr) 3297, 2983, 1726, 1357, 1275, 1169, 722, 651, 577 cm-1; 1H NMR (300MHz) δ 7.78 (d, 2 
H, J = 8.3 Hz), 7.30 (d, 2 H, J = 8.1 Hz), 4.01 (t, 2 H, J = 4.6 Hz), 2.65 (t, d, 2 H, J = 4.9, 2.6 
Hz), 2.44 (s, 3 H), 2.02 (t, 1 H, 2.7 Hz), 1.34 (s, 9H); 13C NMR (75MHz) δ 150.9, 144.2, 137.3, 
129.4, 128.0, 84.7, 80.6, 70.6, 45.3, 28.0, 21.7, 20.1; MS (EI) 267 (9), 203 (25), 184 (74), 155 
(69), 108 (23), 91 (74), 65 (28), 57 (100); HRMS (EI) calcd for C12H13NO4S (M-C4H8)•+ 
267.0565, found 267.0571.  
 
46c  
O-Ethyl-N-but-3-ynyl-N-(4-chlorophenyl)sulfonylcarbamate (46c): According to the general 
procedure B, O-ethyl-4-chlorobenzenesulfonylcarbamate 45c (1.3 g, 4.9 mmol), 
triphenylphosphine (1.3 g, 4.9 mmol), 3-butyn-1-ol (0.25 mL, 3.3 mmol) and DIAD (1.0 mL, 4.9 
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mmol), afforded 46c (97 %) as a colorless solid:  m.p. 58.0-60.0 oC (hexanes/EtOAc); IR (KBr) 
3299, 3099, 2983, 2910, 1736, 1585, 1478, 1281, 1173, 1012, 970, 824, 765, 659 cm-1; 1H NMR 
(300MHz) δ 7.92 (d, 2 H, J = 8.7 Hz), 7.49 (d, 2 H, J = 8.7 Hz), 4.16 (q, 2 H, J = 7.1 Hz), 4.02 (t, 
2 H, J = 7.2 Hz), 2.66 (td, 2 H, J = 4.9, 2.6, Hz), 2.02 (t, 1 H, J = 2.6 Hz), 1.21 (t, 3 H, J = 7.1 
Hz); 13C NMR (75MHz) δ 152.0, 140.5, 138.0, 130.1, 129.2, 80.1, 70.9, 63.9, 45.5, 20.1, 14.2; 
MS (EI) (M•+, 315), 315 (21), 276 (21), 204 (58), 11 (87), 75(30); HRMS (EI) calcd for C13 
H14ClNO4S 315.0332, found 315.0339. 
 
47  
Diphenylphosphinylimino-methyl-benzene (47).  General Procedure C, imine synthesis: A 
literature procedure43 was used with some modifications.  In brief, TiCl4 (0.61 mL, 5.5 mmol) in 
a round bottom flask (100 mL) was diluted in freshly distilled CH2Cl2 (30 mL) under an argon 
atmosphere.  The solution was cooled to 0 oC and benzaldehyde (0.9 g, 8.7 mmol) was added 
neat, followed by Et3N (3.9 mL, 28 mmol).  Stirring was continued at 0 oC for 5 min. 
Diphenylphosphinamide (2.0 g, 9.2 mmol), prepared using literature procedure52,79 was added as 
a solid and the mixture was stirred at 0 oC for 15 min.  The mixture was warmed to r.t. and 
stirring was continued for 2 h.  The reaction mixture was poured into dry diethyl ether (200 mL) 
and stirred for 15 min at r.t. The resulting solution was filtered through a pad of Florisil/Celite 
(4:1) and the filtrate concentrated by vacuo.  The residue was chromatographed over deactivated 
SiO2 (9:1 EtOAc/hexane containing 1% v/v Et3N) to afford 54 (1.1 g, 32%) as a colorless solid 
                                                                                                                                
104 
 
48a  
O-Ethyl-N-2-((1R*,2R*)-2-((R*)-((diphenylphosphoryl)amino)(phenyl)methyl)-
cyclopropyl]-tert-butyl-N-phenylsulfonylcarbamate (48a). General Procedure D: A 
literature procedure42 for structurally similar compounds was used with some modifications.  In 
brief, Cp2ZrHCl (0.3 g, 1.2 mmol) was suspended in dichloromethane (freshly distilled, 2 mL) 
and immediately treated with alkyne 46a (0.4 g, 1.2 mmol), added as a solid.  The reaction 
mixture was stirred vigorously for 2 min. at r.t. and cooled to –78 oC and treated with Me2Zn, 
2M solution in toluene (0.6 mL, 1.2 mmol) and warmed up over 5 min. to 0 oC. Aldimine 47 (0.1 
g, 1.2 mmol) was added as a solid, and the reaction vessel was transferred to an oil bath and 
heated at reflux for 4 h.  Reaction was quenched with NH4Cl aqueous solution, diluted with 
EtOAc and separated organic layer filtered through a pad of Florisil/Celite (4:1), dried over 
MgSO4 and concentrated in vacuo.  The resulting residue was purified by flash chromatography 
(EtOAc/hexanes 9:1, 1% Et3N) to afford 48a (25 mg, 10%) as a colorless solid: m.p. 166.0-168.0 
oC (EtOAc/hexanes); IR (KBr) 3189, 3060, 2980, 2930, 1727, 1439, 1356, 1291, 1154, 1089, 
724, 699, 581 cm-1; 1H NMR (300MHz, (CD3)2CO) δ 7.93 – 7.91 (m, 5 H), 7.79 – 7.72 (m, 4 H), 
7.47 – 7.41 (m, 6 H), 7.35 – 7.30 (m, 4 H),  7.27 (app d, 1 H, J = 7.8 Hz), 5.17 (t, 1 H, J  = 10.2 
Hz), 3.92 (tdt, 1 H, J = 15.9, 9.6, 5.7 Hz), 3.55 (app q, 1 H, J = 8.7 Hz), 1.71 – 1.57 (m, 2 H), 
1.27 (s, 9 H), 1.23 – 1.08 (m, 2 H), 0.96 – 0.93 (m, 1 H), 0.53 (dt, 1 H, J = 9.3, 4.8Hz), 0.33 (dt, 
1 H, J = 8.4, 5.0Hz); 13C NMR (100 MHz, CDCl3) δ 150.9, 140.6, 133.2, 132.6, 132.5, 132.1, 
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132.05, 132.01, 131.8, 128.8, 128.7, 128.6, 128.5, 128.4, 127.8, 127.3, 127.0, 84.3, 58.8, 47.0, 
34.3, 28.0, 26.7, 16.3, 10.6; HRMS (MALDI) calcd for C35H40N2O5PS 631.2396 [M+H]+, found 
631.2256. 
 
48b  
O-Ethyl-N-2-((1R*,2R*)-2-((R*)-((diphenylphosphoryl)amino)(phenyl)methyl)-
cyclopropyl]-tert-butyl-N-(4methylphenyl)sulfonylcarbamate (48b).  According to the 
general procedure D, Cp2ZrHCl (0.3 g, 1.0 mmol), alkyne 46b (0.3 g, 1.0 mmol), aldimine 47 
(0.1 g, 0.3 mmol) and Me2Zn (2 M in toluene, 0.5 mL, 1.0 mmol) afforded 48b (19 mg, 9%) as a 
colorless solid: m.p. 78.0-79.0 oC (EtOAc/hexanes); IR (KBr) 3192, 3060, 2980, 2928, 1727, 
1438, 1355, 1155, 724, 700, 578 cm-1; 1H NMR (300MHz, (CD3)2CO) δ 7.93 – 7.87 (m, 2 H), 
7.80 – 7.72 (m, 4H), 7.47 – 7.40 (m, 8H), 7.35 – 7.22 (m, 6H), 3.92 (tdt, 1 H, J = 15.9, 9.6, 5.7 
Hz), 3.55 (app q, 1 H, J = 9.3 Hz), 2.41 (s, 3 H), 1.66 – 1.55 (m, 2 H), 1.27 (s, 9H), 1.25 – 1.11 
(m, 2 H), 0.94 – 0.88 (m, 1 H), 0.51 (dt, 1 H, J = 8.2, 4.1Hz), 0.31 (dt, 1 H, J = 8.1, 3.9Hz); 13C 
NMR (100 MHz, CDCl3) δ 151.1, 144.2, 137.5, 132.7, 132.6, 132.2, 132.1, 132.08, 131.9, 129.4, 
128.8, 128.7, 128.6, 128.5, 128.0, 127.4, 127.1, 84.2, 66.1, 58.8, 47.1, 34.4, 28.1, 26.7, 21.8, 
16.4, 15.5, 10.6; HRMS (MALDI) calcd for C36H42N2O5PS 645.2552 [M+H]+, found 645.3829. 
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48c  
O-Ethyl-N-2-((1R*,2R*)-2-((R*)-((diphenylphosphoryl)amino)(phenyl)methyl)-
cyclopropyl)-ethyl-N-(4-chlorophenyl)sulfonylcarbamate (48c).  According to the general 
procedure D, with some modifications (CH2I2 was added and the reaction mixture was stirred at 
r.t. for additional 2.5h), Cp2ZrHCl (0.3 g, 1.0 mmol), alkyne  46c (0.4 g, 1.0 mmol), aldimine 47 
(0.1 g, 0.3 mmol), Me2Zn (2 M in toluene, 0.5 mL, 1.0 mmol) and CH2I2 (0.1 mL, 1.7 mmol) 
afforded 48c (46 mg, 23%) as a colorless solid: m.p. 125.0-126.0 oC (EtOAc/hexanes);  IR (KBr) 
3342, 3188, 3059, 2991, 1733, 1439, 1371, 1275, 1180, 1090, 1014, 759, 699, 572, 539 cm-1; 1H 
NMR (300MHz, CDCl3) δ 7.94 – 7.88 (m, 2 H), 7.85 (d, 2 H, J = 8.7 Hz), 7.51 – 7.41 (m, 7H), 
7.36 – 7.23 (m, 7H), 3.92 (q, 2 H, J = 7.2 Hz), 3.88 (t, 1 H, J = 7.5 Hz), 3.73 (t, 1 H, J = 7.5 Hz),  
2.51 (broad s, 1 H),  1.81 – 1.68 (m, 1 H), 1.56 – 1.46 (m, 1 H), 0.80 – 0.75 (m, 1 H), 0.42 (dt, 1 
H, J = 9.6, 4.8Hz), 0.35 (dt, 1 H, J = 8.4, 5.1 Hz); 13C NMR (75MHz, CDCl3) δ 152.0, 142.8, 
140.0, 138.0, 132.4, 132.3, 131.9, 131.8, 129.7, 128.9, 128.6, 128.4, 128.4, 128.2, 127.2, 126.7, 
63.4, 59.0, 47.2, 34.1, 26.6, 16.3, 14.0, 10.5; MS (API-ES) 637 ([M+H]•, 100);  MS (EI) 636 
(M•+, 35), 306 (73), 201 (100), 156 (35); HRMS (EI) calcd for C33H34ClN2O5PS 636.1615 found  
636.1655. 
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53-1 
Sulfonylcarbamate Synthesis. O-Isopropyl-N-(4-methylphenyl)sulfonylcarbamate (53-1). 
According to the general procedure A, methylbenzenesulfonylisocyanate (1.9 g, 1.5 mL, 10 
mmol) and isopropanol (1.5 mL, 20 mmol) afforded 53-1 as colorless oil that, after 
crystallization from hexanes, gave a colorless solid (2.8 g, quant.): m.p. 76.0-78.0 oC 
(hexanes/EtOAc); IR (KBr) 3271, 2984, 1747, 1597, 1437, 1340, 1238, 1167, 1091, 892, 817, 
660 cm-1; 1H NMR (300MHz) δ 7.92 (d, 2 H, J = 8.3 Hz), 7.77 (s, 1 H), 7.33 (d, 2 H, J = 8.2 Hz), 
4.87 (septet, 1 H, J = 6.33 Hz), 2.44 (s, 3 H), 1.19 (d, 6H, J = 6.3 Hz); 13C NMR δ 150.2, 145.1, 
135.8, 129.6, 128.5, 71.6, 21.8; MS (EI) 257 (M•+, 23), 242 (20), 230 (52), 215 (19), 193 (24), 
155 (47), 108 (100), 91 (90); HRMS (EI) calcd for C11H15NO4S 257.0722, found 257.0734. 
 
 53  
O-Isopropyl-N-but-3-ynyl-N-(4-methylphenyl)sulfonylcarbamate (53): According to the 
general procedure B, O-Isopropyl-4-methylbenzenesulfonylcarbamate 53-1 (2.6 g, 10.0 mmol), 
triphenylphosphine (2.6 g, 10 mmol), 3-butyn-1-ol (0.5 mL, 6.7 mmol) and DIAD (1.6 mL, 10 
mmol), afforded 53 (1.5 g, 72%) as a colorless solid:  m.p. 71.6-73.4 oC (hexanes/EtOAc); IR 
                                                                                                                                
108 
(KBr) 3308, 2988, 2934, 1731, 1597, 1357, 1170, 1089, 1102, 899, 811, 735 cm-1; 1H NMR 
(300MHz) δ 7.83 (d, 2 H, J = 8.3 Hz), 7.30 (d, 2 H, J = 8.4 Hz), 4.89 (septet, 1 H, J = 6.3 Hz), 
4.01 (t, 2 H, J = 7.3 Hz), 2.65 (td, 2 H, J = 7.6, 2.7 Hz), 2.43 (s, 3 H), 2.02 (t, 1 H, 2.6 Hz), 1.15 
(d, 6 H, J = 6.3 Hz); 13C NMR (75MHz) δ 151.9, 144.8, 137.2, 129.6, 129.3, 128.6, 80.6, 72.3, 
70.8, 45.5, 21.9, 21.6, 20.3, 16.4; MS (EI) 309 (M•+, 27), 287 (12), 270 (34), 245 (28), 206 (37), 
184 (100), 155 (74), 91 (46); HRMS (EI) calcd for C15H19NO4S 309.1035, found 309.1041. 
 
54  
Methyl 4-[(diphenylphosphinylimino)methyl]benzoate (54).  Acording to the general 
procedure C, methyl 4-formylbenzoate (1.4 g, 8.7 mmol), diphenylphosphinamide (2.0 g, 9.2 
mmol), TiCl4 (0.6 mL, 5.5 mmol) and Et3N (3.9 mL, 28 mmol), afforded 54 (1.1 g, 32%) as a 
colorless solid.  1H NMR (300MHz) δ 9.37 (d, 1 H, J = 30 Hz), 8.16 (d, 2 H,  J = 6.0 Hz), 8.06 
(d, 2 H, J = 6.0 Hz), 7.98-7.89 (m, 4H), 7.53-7.26 (m, 6H), 3.91 (s, 3 H).  
 
55  
(E)-Methyl 4-(1-((diphenylphosphinoyl)amino)hept-2-enyl)benzoate (55).51 Aldimine 
Addition in a Microwave. General Procedure E: According to the general procedure E, A 
suspension of Cp2ZrHCl (0.1 g, 0.4 mmol) in dry toluene (1.6 mL) was treated with 1-hexyne 
(0.05 mL, 0.4 mmol) and the mixture was heated in the CEM Discoverer microwave in flash heat 
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mode (80 oC, 75 W) for 40 sec.   The mixture was cooled to –78 oC, treated with Me2Zn (2 M in 
toluene, 0.2 mL, 0.4 mmol), warmed to 0 oC and aldimine 54 (0.1 g, 0.3 mmol) was added.  The 
mixture was heated in the microwave in flash heat mode (100 oC, 150 W) for 40 sec. then cooled 
to r.t.  The reaction was quenched by addition of 1M NH4Cl (0.5 mL) with vigorous stirring, then 
diluted with EtOAc (50 mL) and1M NaHCO3 (1 mL).  The organic layer was collected and the 
aqueous layer was extracted with EtOAc (2 x 50 mL).  The combined organic extracts were 
washed with H2O (2 x 10 mL) and a saturated aqueous NaCl solution (brine) (2 x 10 mL), dried 
(MgSO4, 2 g), filtered and concentrated by vacuo.  The residue was chromatographed over 
deactivated SiO2 (9:1 EtOAc/hexane containing 1% v/v Et3N) to afford 55 (110 mg, 95%) as a 
colorless solid: 1H NMR (300MHz, CDCl3) δ 7.99-7.93 (m, 2 H), 7.81 – 7.80 (m, 2 H), 7.46 – 
7.22 (m, 10H), 5.65 (dd, 1 H, J = 15.3, 6.1), 5.40 (dt, 1 H, J = 15.5, 6.6 Hz), 4.85 (td, 1 H, J = 
9.3, 6.0 Hz), 3.92 (s, 3 H), 3.29 (td, 1 H, J = 8.8, 5.6 Hz), 2.08 – 1.98 (m, 2 H),  1.30 – 1.26 (m, 
4H), 0.87 (t, 3 H, J = 6.9 Hz). 
 
56  
(E)-N-(1-Phenylhept-2-enyl)-P,P-diphenylphosphinamide (56).51 According to the general 
procedure E, Cp2ZrHCl (0.2 g, 0.8 mmol), 1-hexyne (0.1 mL, 0.8 mmol), aldimine 47 (0.2 g, 0.5 
mmol) and Me2Zn (2 M in toluene, 0.4 mL, 0.8 mmol) afforded 56 (84 mg, 43%) as a colorless 
solid: 1H NMR (300MHz, CDCl3) δ 7.95 (m, 2 H), 7.84 (m, 2 H), 7.48-7.26 (m, 11 H), 5.64 (dd, 
1 H, J = 9.1, 6.2 Hz), 5.53 (dd, 1 H, J = 15.4, 6.0), 4.81 (td, 1 H, J = 9.4, 6.2 Hz), 3.27 – 3.24 (m, 
1 H), 1.99 – 1.95 (m, 2 H),  1.31 – 1.24 (m, 4H), 0.90 – 0.85 (m, 3 H).  
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57  
(E)-N-(2-Ethyl-1-phenylpent-2-enyl)-P,P-diphenylphosphinamide (57). According to the 
general procedure E, Cp2ZrHCl (0.10 g, 0.4 mmol), 3-hexyne (0.05 mL, 0.4 mmol), aldimine 47 
(0.08 g, 0.25 mmol) and Me2Zn (2 M in toluene, 0.2 mL, 0.4 mmol) afforded  57 (75 mg, 77%) 
as a colorless solid:  NMR (300MHz, CDCl3) δ 7.95-7.85 (m, 4 H), 7.45-7.29 (m, 11 H), 5.53 (t, 
1 H, J = 14.3 Hz), 4.73 (t, 1 H, J = 10.7 Hz), 3.24 (td, 1 H, J = 10.0, 6.1 Hz), 2.16-2.04 (m, 3 H), 
1.78 – 1.68 (m, 1 H), 1.63 (s, 1 H), 1.03 (t, 3 H, J = 7.5 Hz), 0.70 (t, 3 H, J = 7.6 Hz). 
 
58  
(E)-Methyl 4-(1-diphenylphosphinoylamino-2-ethylbut-2-enyl)benzoate (58)51. According to 
the general procedure E, Cp2ZrHCl (0.2 g, 0.8 mmol), 3-hexyne (0.13 mL, 0.9 mmol), aldimine 
54 (0.19 g, 0.5 mmol) and Me2Zn (2 M in toluene, 0.4 mL, 0.8 mmol) afforded 58 (188 mg, 
74%) as a colorless solid:  m.p. 91.9-92.3 oC (EtOAc/hexanes);  IR (KBr) 3181, 2957, 2930, 
2869, 1722, 1610, 1436, 1281, 1185, 1107, 1123, 1019 cm-1; 1H NMR (300MHz, CDCl3) δ 7.97-
7.77 (m, 6 H), 7.50-7.35 (m, 8 H), 5.50 (t, 1 H, J = 7.2 Hz), 4.76 (t, 1 H, J = 10.6 Hz), 3.90 (s, 3 
H), 3.28 (dd, 1 H, J = 10.3, 6.3 Hz), 2.14-2.02 (m, 3 H), 1.74-1.71 (dq, 1 H, J = 14.5, 7.3 Hz), 
1.45 1.37 (m, 2 H), 1.17-1.09 (m, 2 H), 0.93 (t, 3 H, J = 7.3 Hz), 0.74 (t, 3 H, J = 7.3 Hz); 13C 
NMR (75MHz, CDCl3) δ 167.2, 148.3, 140.2, 140.2, 133.7, 133.6, 132.7, 132.6, 132.4, 132.3, 
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132.2, 131.9, 130.0, 129.3, 128.8, 128.6, 127.8, 59.5, 52.3, 31.4, 30.2, 23.2, 22.3, 14.5, 14.2; MS 
(EI) 475 (M•+, 59), 446 (16), 432 (14), 364 (63), 274 (45), 218 (53), 201 (100), 77 (48); HRMS 
(EI) calcd for C29H34NO3P 475.2276, found 475.2283. 
 
59  
(E)-N-(3-Propinyl-1-phenylhex-2-enyl)-P,P-diphenylphosphinamide (59). According to the 
general procedure E, Cp2ZrHCl (0.2 g, 0.8 mmol), 4-octyne (0.1 mL, 0.8 mmol), aldimine 47 
(0.2 g, 0.5 mmol) and Me2Zn (2 M in toluene, 0.4 mL, 0.8 mmol) afforded 59 (130 mg, 62%) as 
a colorless solid: m.p. 108.1-108.8 oC (EtOAc/hexanes); IR (KBr) 3187, 2956, 2928, 2868, 1436, 
1184, 1125, 1107, 748, 699 cm-1; 1H NMR (300MHz) δ 7.94-7.83 (m, 4H), 7.47-7.38 (m, 6H), 
7.37-7.24 (m, 5H), 5.60 (t, 1 H, J = 7.2 Hz), 4.72 (t, 1 H, J = 10.5 Hz), 3.23 (dd, 1 H, J = 9.9, 6.0 
Hz), 2.07 (dt, 3 H, J = 14.4, 7.2 Hz), 1.69 (dt, 1 H, J = 9.0, 6.5 Hz), 1.45 (dt, 2 H, J =14.7 ,7.4 
Hz), 1.14 – 1.06 (m, 2 H), 0.96 (t, 3 H, J = 7.3 Hz), 0.72 (t, 3 H, J = 7.2 Hz); 13C NMR (75MHz) 
142.7, 140.2, 133.7, 133.6, 132.4, 132.2, 132.0, 128.4, 128.2, 127.5, 127.4, 127.1, 59.4, 55.7, 
31.2, 29.9, 23.0, 22.0, 14.2, 14.0; MS (EI) 417(M•+, 28), 306 (43), 258 (35), 218 (82), 216 (93), 
201 (100); HRMS (EI) calcd for C27H32NOP 417.2222, found 417.2217.  
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60 
(E)-Methyl 4-((1-diphenylphosphinoyl)amino-2-propylhex-2-enyl)benzoate (60). 
According to the general procedure E, Cp2ZrHCl (0.2 g, 0.8 mmol), 4-octyne (0.1 mL, 0.9 
mmol), Me2Zn (2.0 M in toluene, 0.4 mL, 0.8 mmol) and aldimine 54 (0.2 g, 0.5 mmol), 
afforded 60 (180 mg, 74%) as a colorless solid: m.p. 91.9-92.3 °C (hexanes/EtOAc); IR (KBr) 
3181, 2957, 2930, 2869, 1722, 1610, 1436, 1281, 1185, 1107, 1123, 1019 cm-1; 1H NMR 
(300MHz) δ 7.97-7.77 (m, 6 H), 7.50-7.35 (m, 8 H), 5.50 (t, J = 7.2 Hz, 1 H), 4.76 (t, J = 10.6 
Hz, 1 H), 3.90 (s, 3 H), 3.28 (dd, J = 10.3, 6.3 Hz, 1 H), 2.14-2.02 (m, 3 H), 1.74-1.71 (dq, J = 
14.5, 7.3 Hz, 1 H), 1.45-1.37 (m, 2 H), 1.17-1.09 (m, 2 H), 0.93 (t, J = 7.3 Hz, 3 H), 0.74 (t, J = 
7.3 Hz, 3 H); 13C NMR (75MHz) δ 167.21, 148.28, 140.24, 140.18, 133.71, 133.61, 132.72, 
132.59, 132.41, 132.28, 132.16, 131.89, 130.02, 129.29, 128.77, 128.61, 128.78, 59.51, 52.29, 
31.40, 30.15, 23.23, 22.34, 14.46, 14.23; MS (EI) 475 (M•+,59), 446 (16), 432 (14), 364 (63), 274 
(45), 218 (53), 201 (100), 77 (48); HRMS (EI) calculated for C29H34NO3P 475.2276, found 
475.2283. 
 
61  
(E)-N-(5-((tert-Butyldiphenylsilyl)oxy))-1-phenylpent-2-enyl)-P,P-diphenylphosphinamide 
(61).51  According to the general procedure E, Cp2ZrHCl (0.1 g, 0.4 mmol), alkyne 49 (0.15 g, 
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0.8 mmol), aldimine 47 (0.75 g, 0.25 mmol) and Me2Zn (2 M in toluene, 0.19 mL, 0.38 mmol) 
afforded 61 (96 mg, 64%) as a colorless solid: 1H NMR (300MHz, CDCl3) δ 7.91-7.87 (m, 2 H), 
7.84 – 7.79 (m, 2 H), 7.63 (d, 4 H, J = 6.4 Hz), 7.45 – 7.23 (m, 17H), 5.73 (dd, 1 H, J = 15.4, 
6.0), 5.52 (dt, 1 H, J = 15.5, 6.5 Hz), 4.80 (td, 1 H, J = 9.4, 6.2 Hz), 3.63 (t, 2 H, J = 6.5 Hz), 
3.23 (t, 1 H, J = 6.4 Hz), 1.01 (s, 9 H).  
 
 62  
4-((1-Diphenylphosphinoylamino-5-(isopropoxycarbonyltosylamino))-pent-2-enyl)benzoic 
acid methyl ester (62).51  According to the general procedure E, Cp2ZrHCl (0.1 g, 0.4 mmol), 
alkyne 53 (0.1 g, 0.5 mmol), Me2Zn (0.2 mL, 0.4 mmol, 2.0M in toluene), and aldimine 54 (0.1 
g, 0.3 mmol), afforded 62 (140 mg, 80%) as a colorless solid: m.p. 62.8-64.8 oC 
(EtOAc/hexanes); IR (KBr) 3167, 3057, 2982, 2952, 1723, 1609, 1437, 1362, 1280, 1186, 1167, 
1107, 1122, 1087 cm-1; 1H NMR (300MHz) δ 7.97-7.89 (m, 4H), 7.83-7.74 (m, 4H), 7.51-7.26 
(m, 10H), 5.82 (dd, 1 H, J = 15.4, 5.5 Hz), 5.51 (td, 1 H, J = 14.2, 6.4 Hz), 4.85-4.79 (m, 2 H), 
3.91 (s, 3 H), 3.84 (t, 2 H, J = 7.0 Hz), 3.63 (td, 1 H, J = 7.1), 2.42 (s, 3 H), 1.27 (s, 1 H), 1.09 (d, 
6 H, J = 6.2), 0.97-0.86 (m, 1 H); 13C NMR (75MHz) δ 167.2, 152.0, 147.9, 147.8, 144.7, 137.4, 
135.0, 134.9, 132.6, 132.5, 132.4, 132.2, 132.1, 131.7, 130.1, 129.5, 129.4, 128.9, 128.8, 128.7, 
128.6, 128.5, 127.538, 127.540, 72.1, 56.5, 52.7, 46.7, 33.1, 21.9; MS (EI) 674 (M•+, 45), 473 
(48), 416 (28), 404 (52), 216 (87), 201 (100), 155 (40), 91 (65); HRMS (EI) calcd for 
C36H39N2O7PS 674.2216, found 674.2224.  
                                                                                                                                
114 
 
 
65a  
2-Fluoro-4'-methoxybiphenyl-4-carbaldehyde (65a). Suzuki coupling.62 General Procedure 
F: A literature procedure61 was used with some modifications.  DAPCy catalyst63 (0.02 g, 0.04 
mmol) was dissolved in a round bottom flask (50 mL) in dry dioxane (12 mL), under nitrogen 
atmosphere at r.t. 4-Bromo-2-fluorobenzaldehyde (0.4 g, 2.0 mmol) was added as solid, followed 
by 4-methoxybenzeneboronic acid (0.5 g, 3.0 mmol) and Cs2CO3 (1.3 g, 4.0 mmol), also added 
as solids. The reaction mixture was left to stir at r.t. under nitrogen atmosphere for 16 h.  The 
reaction was quenched by purring into deionized water (20 mL), and diluted with EtOAc (200 
mL).  The organic layer was dried over Na2SO4, filtered and concentrated in vacuo.  The residue 
was purified by flash chromatography (19:1 hexanes/EtOAc) to afford 65a (320 mg, 70%), after 
crystallization from CH2Cl2 and hexanes as a colorless solid. 1H NMR CDCl3 δ 10.36 (s, 1 H), 
7.91 (t, 1 H, J = 9 Hz), 7.57 (dt, 2 H, J = 12, 3 Hz), 7.46 (dd, 2 H, J = 9, 0.9 Hz), 7.35 (dd, 1 H, J 
= 12, 1.8 Hz), 7.00 (dt, 2 H, J = 12, 1.8 Hz), 3.94 (s, 3 H).  The data matched that previously 
reported.36 
 
65b  
4'-Benzyloxy-2-fluorobiphenyl-4-carbaldehyde (65b). According to the general procedure F, 
DAPCy (0.04 g, 0.04 mmol), 4-bromo-2-fluorobenzaldehyde (0.41 g, 2.0 mmol), 4-
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benzyloxybenzeneboronic acid (0.68 g, 3 mmol) and Cs2CO3 (1.3 g, 4.0 mmol) afforded 65b 
(330 mg, 88%) as a colorless solid: m.p. 124.0-125.0 oC (EtOAc/hexanes);  IR (KBr) 3448, 
1689, 1618, 1601, 1580, 1266, 1251, 1183, 1011, 833, 753 cm-1; 1H NMR (300MHz, CDCl3) δ 
10.35 (s, 1 H), 7.90 (t, 1 H, J = 8.4 Hz), 7.57 (d, 2 H, J = 8.4 Hz), 7.47-7.32 (m, 5H), 7.08 (d, 2 
H, J = 9.2 Hz), 5.13 (s, 2 H); 13C NMR (75MHz, CDCl3) δ 187.0, 165.3 (d, J = 192.3 Hz), 160.0, 
149.4 (d, J = 6.8 Hz), 136.8, 131.3, 129.4, 128.9, 128.7, 128.4, 127.7, 122.9, 122.4 (d, J = 5.8 
Hz), 115.7,  114.2 (d, J = 16.1 Hz), 70.4; MS (EI) 306 (M•+, 23),  307 (7), 215 (5), 157 (10), 159 
(8), 133 (8), 91 (100); HRMS (EI) calcd for C20H15FO2 306.1056, found 306.1049. 
 
65c  
4'-Benzyloxybiphenyl-4-carbaldehyde (65c)80 According to the general procedure F, DAPCy 
(0.04 g, 0.04 mmol), 4-bromobenzaldehyde (0.4 g, 2.0 mmol), 4-benzyloxybenzeneboronic acid 
(0.7 g, 3.0 mmol) and Cs2CO3 (1.3 g, 4.0 mmol) afforded 65c (290 mg, 50%) as a colorless solid: 
1H NMR (300MHz, CDCl3) δ 10.03 (s, 1 H), 7.93 (d, 2 H, J = 8.4 Hz), 7.71 (d, 2 H, J = 8.2 Hz), 
7.58 (d, 2 H, J = 8.8Hz), 7.48-7.34 (m, 5H), 7.08 (d, 2 H, J = 8.8 Hz), 5.13 (s, 2 H). 
 
67a  
N-(4-(4'Methyloxy-2’-fluorobiphenylmethylidene))-P,P-diphenylphosphinamide (67a). 
General Procedure G: A literature procedure52 was used with some modifications.  In brief, 
TiCl4 (0.1 mL, 0.8 mmol) was added dropwise into a solution of 4'-benzyloxybiphenyl-4-
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carbaldehyde (0.2 g, 1.0 mmol), diphenylphosphinamide (0.2 g, 1.0 mmol) and Et3N (0.4 mL, 
3.0 mmol)  in freshly distilled CH2Cl2 (50 mL), cooled to 0 oC.  Stirring was continued at 0 oC 
for 10 min.  The mixture was warmed to r.t. and stirring was continued for 20 h.  The mixture 
was concentrated.  The residue quickly filtered through SiO2 and eluted with EtOAc. Solvent 
was removed in vacuo to afford 67a (50 mg, 47%) as a colorless solid, m.p. 122.2-124.0oC 
(EtOAc/hexanes);  IR (KBr) 3032, 1739, 1604, 1204, 1127, 1108, 843, 807, 698, 564 cm-1; 1H 
NMR (300MHz, CDCl3) δ 9.65 (d, 1 H, J = 31.5 Hz), 8.46 (t, 1 H, J = 9.0 Hz), 8.13-8.08 (m, 
4H), 7.88 (d, 2 H, J = 9.0 Hz), 7.80 (d, 2 H, J = 9.0 Hz), 7.72 (d, 1 H, J = 1.8 Hz), 7.69-7.61 (m, 
6H, J = 9.0 Hz), 3.98 (s, 3 H); 13C NMR (75MHz, CDCl3) δ 160.4, 133.7, 132.0, 131.8, 131.7, 
131.6, 131.5, 131.0, 129.0, 128.5, 128.3, 128.3, 122.5, 114.5, 55.4; MS (EI) 429 (M•+, 34),  202 
(100), 77 (22); HRMS (EI) calcd for C26H21FNO2P 429.1294, found 429.1282. 
 
67b  
N-(4-(4'Benzyloxy-2’fluorobiphenyl-methylidene))-P,P-diphenylphosphinamide (67b). 
According to the general procedure G, 4'-benzyloxy-3-fluorobiphenyl-4-carbaldehyde (0.5 g, 1.6 
mmol), diphenylphosphinamide (0.4 g, 1.6 mmol), TiCl4 (0.1 mL, 1.3 mmol) and Et3N (1.3 mL, 
8.0 mmol),  afforded 67b (550 mg, 67%) as a colorless solid: m.p. 125-127 oC(EtOAc/hexanes);  
IR (KBr) 3034, 1604, 1436, 1253, 1202, 1126, 1024, 803, 731, 695 cm-1; 1H NMR (300MHz, 
CDCl3) δ 9.63 (d, 1 H, J = 31.8 Hz), 8.25 (t, 1 H, J = 7.5 Hz), 7.96 (dd, 2 H, J = 10.2, 2.7 Hz), 
7.57 (d, 4H, J = 8.4 Hz), 7.49-7.41 (m, 12 H), 7.08 (d, 2 H, J = 8.4 Hz), 5.13 (s, 2 H); 13C NMR 
(75MHz, CDCl3) δ 167.0, 164.3 (d, J = 256.7 Hz),  159.6, 148.4 (d, J  = 9.2 Hz), 136.6, 132.1, 
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131.8, 131.6, 131.5, 131.3, 129.0, 128.6 (d, J = 6.4 Hz), 128.4, 128.1, 127.4, 122.5, 115.5, 113.9 
(d, J = 20.1), 70.1; MS (EI) 505 (M•+, 17), 366 (20), 332 (64), 91 (100); HRMS (EI) calcd for 
C32H25FNO2P 505.1607, found 505.1589. 
 
67c  
N-(4-(4'Benzyloxy-biphenyl-methylidene))-P,P-diphenylphosphinamide (67c).       According 
to the general procedure G, TiCl4 (0.1 mL, 0.8 mmol), 4'-Benzyloxybiphenyl-4-carbaldehyde 
(0.3 g, 1.0 mmol), diphenylphosphinamide (0.2 g, 1.0 mmol) and Et3N (0.9 mL, 6.0 mmol) 
afforded 67c (383 mg, 79%) as a colorless solid: m.p. 184.0-185.0 oC (EtOAc/hexanes);  IR 
(KBr) 3448, 1621, 1599, 1438, 1202, 1189, 1124, 1107, 832, 819, 727 cm-1; 1H NMR (300MHz, 
CDCl3) δ 9.34 (d, 1 H, J = 32.0 Hz), 8.05 (d, 1 H, J = 7.6 Hz), 7.97 (td, 2 H, J = 10.3, 2.8 Hz), 
7.57 (d, 4H, J = 8.4 Hz), 7.49-7.41 (m, 12 H), 7.08 (d, 2 H, J = 8.4 Hz), 5.13 (s, 2 H); 13C NMR 
(75MHz, CDCl3) δ 159.1, 145.9, 136.6, 133.8, 132.4, 132.1, 131.7, 131.7, 131.6, 131.5, 130.7, 
128.6, 128.5, 128.3, 128.0, 127.4, 126.9, 115.3, 70.0; MS (EI) 487 (M•+, 13), 202 (41), 91 (100); 
HRMS (EI) calcd for C32H26NO2P 487.1701 found 487.1694. 
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68a  
N-(R*)-(((1R*,2R*)-2-Butylcyclopropyl)-(4’-methoxy-2-fluoro-4-(phenyl)phenyl)methyl)-
P,P-diphenylphosphinamide (68a). General procedure H: A literature procedure52 was used 
with modifications.  A suspension of Cp2ZrHCl (0.2 g, 0.6 mmol) in freshly distilled 
dichloromethane (2.0 mL) was treated with 1-hexyne (0.1 mL, 0.6 mmol) and the mixture was 
heated in the Emrys Optimizer (Biotage) microwave (80 oC,  300W) for 1 min.  The mixture was 
cooled to –78 oC, treated with Me2Zn (2 M in toluene, 0.3 mL, 0.6 mmol), warmed to 0 oC and 
aldimine 67a (0.1 g, 0.2 mmol) was added.  The mixture was heated in the microwave (100 oC, 
300 W) for 10 min. then cooled to r.t. and treated with diiodomethane (0.2 mL, 2.1 mmol) and 
left to stir at r.t. for 16 h.  The mixture was then cooled to 0 oC and quenched by addition of 
absolute methanol (0.5 mL) with vigorous stirring, and after 5 min. diluted with EtOAc (100 
mL).  The solution was filtered through a pad of Florisil and concentrated in vacuo.  The residue 
was chromatographed over SiO2 (EtOAc/hexane 1:1 – 3:1) to afford 68a (34 mg, 30% ) as a 
colorless solid, m.p. 168.0-170.5 oC (EtOAc/hexanes);  IR (KBr)  3201, 2925, 1609, 1492, 1436, 
1252, 1186, 816, 697, 540 cm-1; 1H NMR (300MHz, CDCl3) δ 7.92 – 7.85 (m, 2 H), 7.77 – 7.70 
(m, 2 H), 7.48 (app d, 2 H, J = 8.8 Hz), 7.48 – 7.38 (m, 4H), 7.33 – 7.27 (m, 2 H), 7.21 (dd, 1 H, 
J = 7.9, 1.7 Hz), 7.16 (d, 1 H, J = 1.8 Hz), (app dd, 1 H, J = 7.5, 5.1 Hz), 6.97 (app d, 2 H, J = 
8.8 Hz), 3.86 (s, 3 H), 3.62 (dd, 1 H, J = 9.6, 6.9 Hz), 1.35 – 1.25 (m, 6H), 1.17 – 1.11 (m, 2 H), 
0.88 (t, 3 H, J = 6.9 Hz), 0.80 – 0.74 (m, 2 H), 0.40 (app dt, 1 H, J = 9.1, 4.8 Hz), 0.23 (app dt, 1 
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H, J = 8.3, 5.1); NMR (75MHz, CDCl3) 13C δ 162.3, 159.5, 159.0, 132.4, 132.3, 131.9, 131.8, 
131.7, 131.5, 128.5, 128.3, 128.1, 127.9, 122.0, 114.3, 113.8, 113.5, 55.3, 55.1, 33.3, 31.7, 26.0, 
22.5, 19.1, 14.0, 10.6; HRMS (MALDI) calcd for C33H36FNO2P 528.2468 [M+H]+, found 
528.2267.  
  
68b  
N-(R*)-(((1R*,2R*)-2-Butylcyclopropyl)-(4’-benzyloxy-2-fluoro-4-(phenyl)phenyl)methyl)-
P,P-diphenylphosphinamide (68b). According to the general procedure H, Cp2ZrHCl (0.4 g, 
1.5 mmol), 1-hexyne (0.2 mL, 1.5 mmol), Me2Zn (2 M in toluene, 0.7 mL, 1.5 mmol), aldimine 
67b (0.3 g, 0.5 mmol) and diiodomethane (0.4 mL, 4.9 mmol), afforded 68b ( 200 mg, 68%) as a 
colorless solid: m.p. 171.8-173.0 oC (EtOAc/hexanes);  IR (KBr) 3164, 2955, 2923, 2855, 1609, 
1523, 1493, 1249, 1185, 1110, 1071, 822, 724, 695, 538 cm-1; 1H NMR (300MHz, CDCl3) δ 7.91 
(d, 1 H, J = 6.9 Hz), 7.87 (d, 1 H, J = 6.9 Hz), 7.77 (d, 1 H, J = 7.2 Hz), 7.73 (d, 1 H, J = 7.2 Hz), 
7.50 – 7.43 (m, 8H), 7.41 – 7.37 (m, 4H), 7.34 – 7.27 (m, 4H),  7.21 (app d, 1 H, J = 8.1 Hz), 
7.15 (app d, 1 H, J = 5,7 Hz), 7.12 (s, NH), 7.05 (app d, 1 H, J = 8.7 Hz), 5.12 (s, 2 H), 3.86 (dd, 
1 H, J = 18.3, 9.4 Hz), 3.62 (app t, 1 H, J = 6.9 Hz), 1.34 – 1.38 (m, 6H), 1.29 – 1.23 (m, 2 H), 
1.19 – 1.11 (m, 2 H), 0.88 (t, 3 H, J = 6.9 Hz), 0.81 – 0.75 (m, 1 H),  0.41 (app dt, 1 H, J = 9.0, 
4.5 Hz), 0.24 (app dt, 1 H, J = 8.4, 5.1); 13C NMR (75MHz, CDCl3) δ 162.1, 158.9, 158.6, 141.5, 
136.7, 133.9, 132.9, 132.3, 132.2, 131.8, 131.7, 131.5, 131.2, 128.5, 128.3, 127.9, 127.4, 122.0, 
115.1, 113.7, 113.4, 70.0, 55.0, 33.2, 26.0, 22.5, 19.1, 14.1, 10.5; MS (EI) 603 (M•+, 56), 546 
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(14), 532 (25), 506 (16), 402 (9), 256 (12), 201 (52), 91 (100), 77 (14); HRMS (qTOF) calcd for 
C39H40FNO2P 604.2815 [M+H]+, found 604.2815. 
 
68c  
N-(R*)-(((1R*,2R*)-2-Butylcyclopropyl)-(4’-benzyloxy-4-(phenyl)phenyl]methyl)-P,P-
diphenylphosphinamide (68c). According to the general procedure H, Cp2ZrHCl (0.3 g, 1.2 
mmol), 1-hexyne (0.1 mL, 1.2 mmol), Me2Zn (2 M in toluene, 0.6 mL, 1.2 mmol), aldimine  67c 
(0.2 g, 0.4 mmol) and diiodomethane (0.3 mL, 4.0 mmol), afforded 68c ( 100 mg, 40%) as a 
colorless solid: m.p. 154.0-156.0 oC (EtOAc/hexanes);  IR (KBr) 3448, 3179, 2953, 2923, 2856, 
1608, 1498, 1437, 1248, 1181, 1124, 1109, 817, 724, 695, 538 cm-1; 1H NMR (300MHz, CDCl3) 
δ 7.95 – 7.89 (m, 2 H), 7.78 – 7.72 (m, 2 H), 7.51 – 7.34 (m, 12 H), 7.27 (d, 2 H, J = 7.5 Hz), 
7.14 (d, 2 H, J = 8.7 Hz), 5.20 (s, 2 H), 3.90 – 3.87 (m, 1 H), 3.48 – 3.47 (m, 1 H), 1.32 – 1.27 
(m, 6H), 1.21 (t, 3 H, J = 7.1 Hz), 1.14 – 1.12 (m, 2 H), 0.97 – 0.95 (m, 2 H), 0.84 (m, 1 H), 0.41 
(app dt, 1 H, J = 9.0, 4.7 Hz), 0.25 (app dt, 1 H, J = 8.4, 4.9 Hz); 13C NMR (75MHz, CDCl3) δ 
158.2, 139.4, 136.9, 133.6, 132.4, 132.3, 132.0, 131.9, 131.7, 131.6, 128.5, 128.3, 128.1, 128.0, 
127.4, 127.2, 126.5, 115.1, 70.0, 33.2, 31.7, 26.8, 22.5, 19.0, 14.1; MS (EI) 585 (M•+, 15), 514 
(13), 501 (42), 384 (36), 201 (79), 91 (100); HRMS (qTOF) calcd for C39H40NO2P [M+H]+ 
586.2797, found 586.2875. 
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69a  
N-(R*)-(((1R*,2R*)-2-Butylcyclopropyl)-(4’-methoxy-2-fluoro-4-(phenyl)phenyl)methyl)-
benzamide (69a), (30 mg, 61%) was obtained from 68a following the literature procedure52 as a 
colorless solid: m.p. 158.0-160.5 oC (EtOAc/hexanes);  IR (KBr) 3288, 2954, 2921, 2856, 1736, 
1635, 1530, 1027, 818, 710, 695 cm-1; 1H NMR (300MHz, CDCl3) δ 7.80 (app d, 2 H, J = 6.9 
Hz), 7.53 – 7.41 (m, 6H), 7.36 (app t, 2 H, J = 7.8 Hz),  7.30 (d, 1 H, J = 1.8 Hz), 7.27 (app s, 1 
H), 7.23 – 7.22 (m, 1 H), 6.97 (d, 2 H, J = 8.7 Hz), 6.84 (d, 1 H, J = 8.1 Hz), 4.73 (t,  1 H, J = 8.4 
Hz), 3.85 (s, 3 H), 1.43-1.26 (m, 5 H), 1.24 – 1.09 (m, 1 H), 0.99– 0.90 (m, 1 H), 0.86 (t, 3 H, J = 
6.9 Hz), 0.59 (app dt, 1 H, J = 9.0, 4.8 Hz), 0.36 (app dt, 1 H, J = 9.0, 5.1); 13C NMR (75MHz, 
CDCl3) δ 166.4, 161.2 (d, J = 242.8 Hz), 142.0, 134.7, 132.1, 131.3, 129.4 (d, J = 6.8 Hz), 128.5, 
128.0, 126.9, 122.3, 114.3, 114.0 (d, J = 22.4 Hz), 55.3, 54.5, 33.3, 31.8, 24.0, 22.3, 18.5, 14.0, 
10.8; HRMS (MALDI) calcd for C28H30FNO2Na 454.2158 [M+Na]+, found 454.1686. 
 
69b  
N-(R*)-(((1R*,2R*)-2-Butylcyclopropyl)-(4’-benzyloxy-2-fluoro-4-(phenyl)phenyl)methyl)-
benzamide (69b), (35 mg, 57%) was obtained from 68b following the literature procedure52 as a 
colorless solid: m.p. 144.0-146.0 oC (EtOAc/hexanes);  IR (KBr) 3295, 2922, 1736, 1634, 1365, 
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1025, 822, 697 cm-1; 1H NMR (400MHz, CDCl3) δ 7.79 (app d, 2 H, J = 7.6 Hz), 7.51 – 7.26 (m, 
12 H), 7.03 (app d, 2 H, J = 8.0 Hz),  6.80 (d, 2 H, J = 7.6 Hz),  5.11 (s, 2 H), 4.73 (app t, 1 H, J 
= 8.8 Hz), 1.36 – 1.32 (m, 6H), 1.18– 1.13 (m, 1 H), 0.93 – 0.91 (m, 2 H), 0.86 (t, 3 H, J = 6.8 
Hz), 0.59 (app dt, 1 H, J = 9.6, 4.8 Hz), 0.36 (app dt, 1 H, J = 9.2, 5.1 Hz); 13C NMR (100 MHz, 
CDCl3) 166.9, 158.9, 137.0, 134.8, 131.732, 129.7, 129.6, 128.9, 128.8, 128.3, 127.7, 127.1, 
122.6, 115.4, 114.2 (d, J = 24.3 Hz), 70.3, 54.9, 33.6, 32.1, 29.9, 24.2, 22.7, 18.8, 14.3, 11.2; MS 
(EI) 507 (M•+, 21), 423 (17), 332 (16), 105 (100), 91 (84); HRMS (EI) calcd for C34H34FNO2 
507.2574 found 507.2591. 
 
69c  
N-(R*)-(((1R*,2R*)-2-Butylcyclopropyl)-(4’-benzyloxy-4-(phenyl)phenyl)methyl)benzamide 
(69c), (13 mg, 22%) was obtained from 68c following the literature procedure52 as a colorless 
solid: m.p. 141.0-143.5 oC (EtOAc/hexanes);  IR (KBr) 3293, 2954, 2919, 2855, 1630, 1499.5, 
1254, 1169, 1084 cm-1; 1H NMR (300MHz, CDCl3) δ 7.81 (d, 2 H, J = 7.3 Hz), 7.51 – 7.45 (m, 
8H), 7.41 (d, 2 H, J = 7.2 Hz), 7.37 – 7.33 (m, 2 H),  7.04 (d, 2 H, J = 8.4 Hz), 6.50 (d, 1 H, J = 
7.5 Hz), 5.11 (s, 2 H), 4.70 (app t, 1 H, J = 8.4 Hz), 1.43-1.31 (m, 8H), 1.03 – 0.95 (m, 2 H), 0.85 
(t, 3 H, J = 6.9 Hz), 0.64 (app dt, 1 H, J = 8.7, 5.1 Hz), 0.49 (app dt, 1 H, J = 9.3, 4.8); 
Insufficient amount of material to obtain 13C NMR;  MS (EI) 489 (M•+, 79), 405 (76), 368 (76), 
314 (93), 277 (74), 106 (85), 92 (72), 77 (100); HRMS (EI) calcd for C34H35NO2 489.2668 found 
489.2646. 
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69d  
N-(R*)-(((1R*,2R*)-2-Butylcyclopropyl)-(4’-benzyloxy-2-fluoro-4-
(phenyl)phenyl)methyl)acetamide (69d), (40 mg, 75%) was obtained from 68b following the 
literature procedure52 as a colorless solid: m.p. 186.0-188.0 oC (EtOAc/hexanes);  IR (KBr) 3293, 
2923, 1631, 1529, 1254, 1025, 825, 694 cm-1; 1H NMR (300MHz, CDCl3) δ 7.81 (app d, 2 H, J 
= 6.9 Hz), 7.54 – 7.44 (m, 10H), 7.41 (app d, 2 H, J = 6.9 Hz),  7.37 – 7.33 (m, 2 H), 7.04 (d, 2 
H, J = 8.7 Hz), 6.52 (d, 1 H, J = 7.8 Hz), 5.12 (s, 2 H), 4.71 (app t, 1 H, J = 8.4 Hz), 2.17 (s, 3 
H), 1.44 – 1.26 (m, 6H), 1.23 – 1.19 (m, 1 H), 1.06 – 0.95 (m, 2 H), 0.86 (t, 3 H, J = 6.6 Hz), 
0.64 (app dt, 1 H, J = 9.6, 4.8 Hz), 0.48 (app dt, 1 H, J = 9.2, 5.1 Hz); 13C NMR (75MHz, 
CDCl3) δ 166.6, 158.4, 140.5, 139.8, 137.0, 134.8, 133.7, 131.4, 128.5, 128.0, 127.9, 127.4, 
127.1, 126.9, 126.8, 115.2, 70.1, 57.0, 33.4, 31.8, 30.8, 24.4, 22.4, 17.9, 14.0, 11.4; HRMS 
(MALDI) calcd for C29H33FNO2 446.2489 [M+H]+, found 446.2247. 
 
 
70b  
N-(R*)-(((1R*, 2R*)-2-Butylcyclopropyl)-(4’-hydroxy-2-fluoro-4-(phenyl)phenyl)methyl)-
benzamide (70b).  Benzyl ether deprotection. General procedure I: According to the 
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literature procedure81 with some modifications, biphenyl C-cyclopropylalkylamide 69b (0.04 g, 
0.07 mmol) was dissolved, under N2 atmosphere at r.t. in a round bottom flask (25 mL), in 1:1 
mixture of absolute MeOH and freshly distilled THF (5mL).  The flask was evacuated three 
times and fitted with a balloon of H2 gas (1 atm).  Pd(OH)2 (20% w/w) on carbon (0.03 g) was 
added as solid.  The reaction mixture was left to stir under a continuous H2 atmosphere at r.t. for 
16h.  The mixture was concentrated and loaded directly onto a SiO2 column (1:1 
EtOAc/hexanes) to afford 70b (20 mg, 69%) as a colorless solid: m.p. 184-186 oC 
(EtOAc/hexanes);  IR (KBr) 3398, 2923, 1686, 1611, 1527, 1491, 1279, 1174, 708 cm-1; 1H 
NMR (400MHz, CDCl3)  (mixture of diastereomers 6:1, major diastereomer is presented) δ 8.25 
(d, 1 H, J = 5.1 Hz), 7.97 (d, 2 H, J = 5.1 Hz), 7.68 (app t, 1 H, J = 5.4 Hz), 7.64 – 7.59 (m, 3 H), 
7.40 (app t, 1 H, J = 6 Hz), 7.34 (d, 2 H, J = 6.3 Hz), 7.24 – 7.23 (m, 1 H), 7.07 (d, 1 H, J = 5.7 
Hz), 6.77 (d, 2 H, J = 6.6 Hz), 4.82 (t, 1 H, J = 6.3 Hz), 1.53 – 1.45 (m, 6H), 1.36 – 1.32 (m, 2 
H), 1.28 – 1.25 (m, 2 H), 1.02 (t, 3 H, J = 5.7 Hz), 0.76 (dt, 1 H, J = 6.6, 3.3 Hz), 0.52 (dt, 1 H, J 
= 6.3, 4.2 Hz); 13C NMR (100 MHz, CDCl3) δ 167.4, 161.2 (d, J = 244.8 Hz), 142.4 (d, J = 8.4 
Hz), 134.2, 133.9, 132.1, 131.2, 130.4, 129.2, 128.8, 128.2, 127.2, 126.4 (d, J = 12.3 Hz), 122.4, 
116.0, 113.9 (d, J = 22.1 Hz), 55.3, 33.5, 32.1, 23.9, 22.7, 18.8, 14.3, 11.0; MS (API-ES) 440 
([M+Na]+, 53), 418 ([M+H]+, 25), 297 (100), 227 (15), 201 (43); HRMS (MALDI) calcd for 
C27H29FNO2 418.2182 [M+H]+, found 418.2062. 
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70c 
N-(R*)-(((1R*,2R*)-2-Butylcyclopropyl)-(4’hydroxy-4-(phenyl)phenyl)methyl)-benzamide 
(70c).  According to the general procedure I, 70c (5 mg, 92%) was obtained from 69d as a 
colorless solid: m.p. 162.0-164.0 oC (EtOAc/hexanes);  IR (KBr) 3269, 2954, 2923, 2853, 1611, 
1572, 1527, 1500, 1491, 1274, 1209, 1175, 813, 717 cm-1; 1H NMR (400MHz, CDCl3) δ 7.82 (d, 
2 H, J = 8.0 Hz),  7.52 (app d, 2 H, J = 7.6 Hz), 7.48 – 7.41 (m 7H), 7.35 (d, 2 H, J = 8.0 Hz), 
6.77 (d, 2 H, J = 8.0 Hz), 6.59 (app d, 1 H, J = 7.6 Hz), 4.65 (t, 1 H, J = 8.4 Hz), 1.37 – 1.30 (m, 
5H), 1.03 – 0.98 (m, 2 H), 0.86 (t, 3 H, J = 7.2 Hz), 0.64 (dt, 1 H, J = 9.2, 4.8 Hz), 0.47 (dt, 1 H, 
J = 8.4, 5.2 Hz); 13C NMR (100MHz, CDCl3) 166.9, 155.4, 140.2, 139.9, 134.5, 133.3, 133.2,  
131.6, 128.7, 128.2, 127.7, 126.9, 126.8, 115.6, 58.0, 33.4, 31.9, 24.5, 22.5, 18.0, 14.1, 11.3; MS 
(APCI) 400 ([M+H] •+, 100); (MALDI) calcd for C27H29NO2 400.2271 [M+H]+, found 400.1815. 
 
70d  
N-(R*)-(((1R*,2R*)-2-Butylcyclopropyl)-(4’-hydroxy-2-fluoro-4-(phenyl)phenyl)methyl)-
acetamide (70d).  According to the general procedure I, 70d (15 mg, 94%) was obtained from 
69d as a colorless solid: m.p. 196.0-198.0 oC (EtOAc/hexanes);  IR (KBr) 2955, 2927, 2850, 
1706, 1679, 1518, 1448, 1205, 1117, 1089, 905, 822, 795 cm-1; 1H NMR (300MHz, CDCl3) δ 
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8.59 (s, 1 H), 7.66 (d, 1 H, J = 8.0 Hz), 7.50 (dd, 4H, J = 8.5, 2.8 Hz), 7.36 (d, 1 H,  8.1 Hz),   
6.91 (d, 1 H, J = 8.6 Hz), 4.74 (t, 1 H, J = 8.4 Hz), 2.87 (s, 3 H), 1.39 – 1.27 (m, 5H), 1.25-1.15 
(m, 2 H), 1.05 – 0.95 (m, 2 H), 0.88 (t, 3 H, J = 6.8 Hz), 0.50 (dt, 1 H, J = 8.8, 4.6 Hz), 0.25 (dt, 
1 H, J =  8.4, 4.9 Hz); 13C NMR (75MHz, CDCl3) δ 170.0, 161.8 (d, J = 350.3 Hz), 159.4, 143.7, 
132.6, 130.8 (d, J = 6.2 Hz), 129.8, 123.7, 117.6, 114.7 (d, J = 22.4 Hz), 52.7, 35.1, 33.3, 25.8, 
24.0, 23.9, 19.7, 15.4, 11.7; MS (APCI) 356 ([M+H]+, 100); HRMS (MALDI) calcd for 
C22H26FNO2Na 378.1845 [M+Na]+, found 378.2202. 
 
 71  
N-(R*)-(((1R*,2R*)-2-Butylcyclopropyl)-(4’-hydroxy-2-fluoro-4-(phenyl)phenyl)methyl)-
P,P-diphenylphosphinamide (71). According to the general procedure I, 71 (40 mg, 0.08 mmol, 
80%) was obtained from C-cyclopropylalkyl diphenylphosphinamide 68b (0.1 g, 0.1 mmol) as a 
colorless solid: m. p.  134.0-136.0 oC (EtOAc/hexanes);  1H NMR (300MHz, CDCl3) δ 8.00 – 
7.89 (m, 4H), 7.57 – 7.46 (m, 6H), (d, 2 H, J = 8.6 Hz), 7.10 (app dd, 1 H, J = 7.8, 1.8 Hz), 7.06 
(d, 1 H, J = 1.5 Hz), 6.98 (app dd, 1 H, J = 7.8, 1.5 Hz), 6.67 (app d, 2 H, J = 8.7 Hz), 3.87 (dd, 1 
H, J = 10.5, 6.9 Hz), 3.63 (dd, 1 H, J = 18.2, 8.5 Hz), 1.47-1.30 (m, 5H), 1.27 – 1.18 (m, 1 H), 
1.16 – 1.08 (m, 2 H), 0.95 (t, 3 H, J = 6.9 Hz), 0.62 – 0.56 (m, 1 H), 0.33 (app dt, 1 H, J = 9.6, 
6.6 Hz), 0.23 (app dt, 1 H, J = 8.4, 5.1); 13C NMR (75MHz, CDCl3) δ 160.6 (d, J = 242.9 Hz), 
162.2, 158.9, 157.7, 142.1, 133.4, 132.7 (d, J = 9.3 Hz), 132.1, 131.9, 131.8, 130.1 (d, J = 19.0 
Hz), 128.7, 128.5, 127.8, 127.6, 121.9, 115.9, 113.2 (d, J = 22.6 Hz), 55.9, 33.4, 32.0, 26.1, 22.6, 
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19.2, 14.1, 10.4; MS (EI) 513 (M•+, 40), 470 (10), 456 (18), 442 (32), 429 (26), 416 (59), 312 
(21), 256 (25), 201 (100); HRMS (EI) calcd for C32H33FNO2P 513.2233 found 513.2219. 
 
 
72  
N-(R*)-(((1R*,2R*)-2-Butylcyclopropyl)-(4’-hydroxy-2-fluoro-4-
(phenyl)phenyl)methyl)amine hydrochloride (72), (8 mg, 43%) was obtained following the 
literature procedure52 for removal of diphenylphosphine protecting group and recrystalization as 
chloride salt from EtOH/ether, as a colorless solid: m.p. 147.5-149.0 oC (EtOH/diethyl ether); IR 
(KBr)  3432, 2927, 2365, 2346, 1499, 1265, 1208, 1036, 824, 731, 562 cm-1; 1H NMR (300MHz, 
CD3OD) δ 7.49 – 7.44 (m, 3 H), 7.42 (app s, 1 H), 7.37 (app s, 1 H), 7.33 (app s, 1 H), 6.81 (d, 2 
H, J = 8.7 Hz), 3.84 (app d, 1 H, J = 9.9 Hz), 1.51 – 1.33 (m, 6H), 1.28 – 1.20 (m, 2 H), 1.17 – 
1.11 (m, 2 H), 0.88 (t, 3 H, J = 6.9 Hz), 0.52 (dt, 1 H, J = 9.3, 4.8 Hz), 0.41 (dt, 1 H, J =  9.3, 5.1 
Hz); 13C NMR (75MHz, CD3OD) δ 161.8 (d, J = 244.1 Hz), 159.0, 145.7 (d, J = 7.4 Hz),  133.7, 
131.1, 129.8, 129.0, 123.7, 122.5 (d, J = 14.6 Hz), 116.8, 114.4 (d, J = 22.7), 55.2, 34.0, 32.4, 
23.5, 22.3, 20.4, 14.2, 11.3; (MALDI) calcd for C20H25FNO 314.1914 [M+H]+, found 314.1841. 
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74 
N-[4-(Phenyl)phenylmethylidene]-P,P-diphenylphosphinamide (74).52 According to the 
general procedure H,  TiCl4 (0.2 mL, 1.6 mmol), biphenyl-4-carbaldehyde (0.4 g, 2.0 mmol), 
diphenylphosphinamide (0.4 g, 2.0 mmol) and Et3N (1.7 mL, 12 mmol) afforded 74 (430 mg, 
56%) as a colorless solid: 1H NMR (300MHz) δ 9.37 (d, 1 H, J = 31.9 Hz), 8.10 (d, 2 H, J = 8.3 
Hz), 8.01-7.93 (m, 4H), 7.74 (d, 2 H, J = 8.3 Hz), 7.68-7.63 (m, 2 H), 7.69-7.61 (m, 9H).  
 
75 
N-(R*)-(((1R*,2R*)-2-Butylcyclopropyl)-(4-(phenyl)phenyl]methyl))-P,P-
diphenylphosphinamide (75).52  According to the general procedure H, Cp2ZrHCl (0.3 g, 1.2 
mmol), 1-hexyne (0.1 mL, 1.2 mmol), Me2Zn (2 M in toluene, 0.6 mL, 1.2 mmol), aldimine 74 
(0.2 g, 0.4 mmol) and diiodomethane (0.3 mL, 4.0 mmol), afforded 75 (70 mg, 36%) as a 
colorless solid: 1H NMR (300MHz) δ 7.94 – 7.88 (m, 2 H), 7.78 – 7.72 (m, 2 H),  7.57 (d, 2 H, J 
= 7.8 Hz), 7.50 – 7.41 (m, 8H), 7.37 (app d, 2 H, J = 6Hz), 7.31 (d, 2 H, J = 8.1 Hz),  3.62 (dd, 1 
H, J = 18.0, 9.9 Hz), 3.39 – 3.35 (m, 1 H), 1.31 – 1.26 (m, 4 H), 1.21 (t, 3 H, J = 6.9 Hz), 1.11 – 
0.97 (m, 2 H), 0.88 – 0.81 (m, 2 H), 0.77 – 0.71 (m, 1 H), 0.41 (app dt, 1 H, J = 8.4, 4.8 Hz), 
0.25 (app dt, 1 H, J = 9.6, 5.1).  
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5.2. Biology 
 
5.2.1. Plasmids and Transient Transfection Assays 
 
The CMV-ERα, ERE-tk-Luc, and CMV-β-gal plasmids were provided by Dr. Ron Evans at the 
Salk Institute. HEK293 cells were plated in 48-well plates with DMEM medium containing 10% 
FBS and allowed to attach and grow for 48h. They were then transfected with the plasmids 
entrained in N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP) 
(Roche) at a density of 10,000 cells per well.15,23 The liposomes contained 1.0µg of reporter 
plasmid (ERE-tk-Luc), 0.5µg of CMV-ERα, and 0.5µg of the transfection control (CMV-β-gal) 
per well. Plasmids were premixed in PBS and mixed with DOTAP. Cells were treated with 
transfection mixture in serum- and phenol red-free DMEM. After 4h, the medium was replaced 
with DMEM containing 10% FBS. Twenty-four hours later, the medium was changed to DMEM 
containing 10% dextran-coated charcoal-stripped FBS and test chemicals were added. After 24h 
in the presence of test agent, cells were lysed and assayed for luciferase and β-galactosidase 
activities. Transfections were performed in triplicate, and each experiment was repeated at least 
twice. 
 
5.2.2. Luciferase Assay 
 
The medium was removed and cell monolayers were frozen at –80oC. After 30 min, 150µL of 
cell culture lysis reagent was added to each well and incubated at 4 oC for an additional 30 min. 
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Luciferase assay reagents were prepared as described previously.53,54  Cell extracts were clarified 
by centrifugation for 3 min at 3000 rpm at room temperature and supernatants were transferred 
to 96-well assay plates. For each assay, 50µL of supernatant was mixed with 50µL of luciferase 
assay buffer. Luminescence was read using a Victor luminometer. Luciferase activity was 
normalized to β-galactosidase activity and data was calculated as fold of induction as compared 
to vehicle control (DMSO, 0.1% final volume). 
 
5.2.3. Antagonism 
 
Antagonism in the luciferase assay was calculated using the following formula 
   % Inhibition = [100 – ((L + E2) / (E2)] x 100  
where L+E2 represents normalized luciferase activity (using β-Gal as the internal control) in 
cells treated simultaneously with E2 and the test compounds, and E2 the normalized luciferase 
activity in cells treated with E2 alone. GraphPad Prism 4 software was used for constructing 
dose-response curves and calculating IC50s. IC50s were estimated from dose-dependence curves 
that best fit the data obtained as an average from at least two transfections performed in 
triplicate. 
 
5.2.4. Antiproliferative Assays 
 
MCF-7 ERα positive breast cancer cells were plated in 96-well plates at 4000 cells/well in 
phenol red-free RPMI-1640 containing 10% dextran-coated charcoal-stripped FBS and 1nM E2, 
and allowed to attach for 24h. The cells were incubated in the presence of test compounds (at 
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concentrations ranging from 25pM to 50µM) and 1nM E2 for 6 days. Cell density was 
determined by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) dye reduction assay using phenazine methanesulfonate as the electron 
acceptor as described previously. Absorbance was measured at 490nm minus that at 630nm 2h 
after incubation with the reagents. Data represents the average of at least two independent 
experiments done in quadruplicate. E2-stimulated growth of MCF-7 cells at day 6 was set to 
100% growth.  
 
MDA-MB231 ERα negative cells were plated in 96-well plates at 1000 cells/well and allowed to 
attach to the plastic for 72 h in phenol red-free RPMI-1640 containing 10% FBS. Test agents and 
control compounds (colchicine and TAM) were added over the range of 3.2nM–50μM and cells 
were incubated for 72h. Cell density was determined with the MTS assay. GraphPad Prism 4 
software was used for constructing dose-response curves and calculating GI50 values. GI50 
values were estimated from dose-dependence curves that best fit the data. 
 
5.2.5. ER Competitor Assays 
 
The ERα and ERβ competitor assays were performed according to manufacturer’s 
recommendations (Panvera™) with some modifications. The assay was performed in 384-well, 
nonbinding, square, black-bottom black plates (Costar) in a total volume of 40 μL per well. 
Fluorescence polarization was measured using an Analyst™ AD & HT Assay Detection Systems 
(Molecular Devices) fluorescence plate reader. The instrumental set up was validated using serial 
dilutions (100nM to 1pM) of methylfluorescein (Sigma) in the assay buffer. The G value, a 
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correction factor that accounts for differences in the instrument optical system geometry and 
plate well size and geometry, was calcd and found to be 1 for the 384-well plates and 
fluorescence polarization used. The "Z" height for detection was empirically determined to be 
optimally 1.25 mm for 40 μL total volume per well in 384-well plates. Fluorescence was 
measured in the perpendicular and horizontal dimensions with 485 nm excitation and 530 nm 
emission interference filters with the appropriate FL505 dichroic mirror. Recombinant human 
estrogen receptor (ER) was used at the recommended concentration of 15 nM, and Fluormone™ 
ES2 was used at 1 nM in the final mixture. The needed volume of 2X concentration of ERα 
complexed with Fluormone™ ES2 (ER/ES2) was prepared on ice and distributed in 20 μL/well. 
The 70 library members and controls (raloxifene and tamoxifen) were prepared at three 
concentrations (10, 2 and 0.4 μM) in the assay buffer. The dilutions of test compounds were 
added to the plate in 20 μL/well. Final concentrations of the test compounds were 5, 1 and 0.2 
μM. Each compound concentration was tested in duplicate. 17β–Estradiol at 1 μM served as a 
positive control. Fluorescence polarization was was calcd after background subtraction from 
perpendicular and horizontal fluorescence measurements with the Analyst™ AD & HT Assay 
Detection Systems integrated software. Fluorescence polarization is described in dimensionless 
mP values that are calcd using the following formula: mP = 1000x (S-GxP)/(S+GxP), where S = 
fluorescence counts after background subtraction measured in the parallel plane, P = 
fluorescence counts after background subtraction measured perpendicular plane, G = calibrated 
correction value. Average mP values for duplicate measurements were used to calculate percent 
competition for test compounds as compared to mP value of 1 μM 17β–estradiol. The percent 
competition was calcd by the following formula: % I = [(mP0 – mP)/(mP0 – mP100)] x 100, 
where mP0 is mP value for 0% competition as referred to high polarization of fluorescently 
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labeled estradiol complexed to ERα (ER/ES2 complex); mP100 is mP value for 100% 
competition, as referred to low polarization in presence of 1 μM E2; and mP is fluorescence 
polarization in the presence of test compound. Percent competition was calcd for each compound 
in three concentrations. Compounds that showed 50% or higher competition at 0.2 μM and also 
showed concentration dependence in their effects were identified as competitors and were 
considered positive hits in the screening of the library. 
 
5.2.6. Docking in CAChe 
 
When the protein-ligand crystal structure of interest is downloaded from the PDB Databank it 
needs to be processed before any docking studies.  The detailed protocol for this process follows 
the guidance of the software manufacturer with some details highlighted in the example of the 
GEN-ERβ-LBD crystal structure.  The 1QKM crystal structure GEN-ERβ-LBD was uploaded 
using BioMedCAChe and atoms were locked at their crystallographic positions in space.  The 
bonding in the HET groups was checked and corrected by displaying the protein chain, ERβ-
LBD, and the ligand in different colors.  Genistein (GEN) was selected and bonding and charge 
were examined to check the accuracy of the genistein structure.  The tool “beautify valence” was 
used to assign adequate hydrogen atoms, electrons and the atom hybridization.  The next step is 
to balance the charge in the protein. Depending upon its environment in a protein crystal, the 
histidine residue can be neutral or protonated.  When CAChe reads a PDB file, the histidine is 
assumed to be neutral unless a charge has been specified in the PDB file.  Therefore, the 
histidines need to be protonated.82  ND1 (nitrogen atoms) atoms are found and changed to the +1 
charge. After the entire protein molecule is selected and the “beautify valence” tool is applied, 
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hydrogen atoms, electrons and hybridization are added to the protein and water molecules.  The 
total number of atoms changes.  After this step, the H-bonds are subjected to “beautify H-bonds”. 
Hydrogen atoms in hydroxyl groups and water molecules are rotated to maximize hydrogen 
bonding.  Only the geometry of the hydrogen atoms are changed with these “beautify” 
commands.  When the “analyze sequence” tool is used, the ligand can be selected, and then, by 
using the “select neighbor” tool, the pocket around the ligand is defined.  Usually the selection is 
5Å.  The following amino acid residues in 1QKM were selected by this tool: M295, L298, T299, 
L301, A302, E305, W335, M336, L339, M340, L343, R346, F356, I373, I376, F377, L380, 
G472, H475, L476, L477, M479, V484, V487.  Once the pocket was defined and noted, the 
ligand GEN was selected and deleted from this structure, and the ERβ-LBD was saved.  Docking 
in BioMedCAChe used the “FastDock” algorithm.  In the present work the ligand was allowed to 
be flexible and protein was kept rigid. The scoring function was PMF and the genetic algorithm 
parameters used for each run were as follows: population size = 1000 and maximal generations 
between 10000 and 25000.  Docking scores of compared ligands were obtained under identical 
conditions.  It is worth noting that these numbers can serve only for comparison between ligands 
docked under same conditions into the same binding site and should be taken as relative 
measure.  Before newly synthesized or otherwise interesting compounds were docked, as a 
standard the original ligand from the crystal structure, like GEN in the presented case above, was 
minimized by MM3 and then re-docked back into the pocket.  The same orientation and 
hydrogen bonding to key residues were reproduced as compared to the crystal structure.  Usually 
this procedure was repeated multiple times to assure reproducibility.  Then the test ligand was 
superimposed to GEN and this was the starting point for docking.  GEN was removed and the 
test ligand docked into GEN pocket. 
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6. Appendix  
1H and 13C NMR data for the key intermediates and biologically active final compounds. 
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